I'm John, and I write about AI, sentience and the spread of conscious life beyond Earth at Sentient Horizons. This is the fourth of a family of sites built the same way: The Belt Equation tracks the odds of leaving Earth, The Quiet Galaxy asks why the sky is quiet, and The Upgrade Tree counts how much of a person can be changed on purpose today. Here the question is whether, and when, medicine starts giving back more than a year of healthy life for each year that passes. I wanted a place where that argument is laid out piece by piece, every number carries its source, and a new result moves the answer in public.
Why the name?
Because the question is a race between two rates. Ageing takes about a year from a middle-aged person's remaining years every year, and medicine gives a little back. The site asks when the second overtakes the first, so that someone who keeps up with the best available care finds their remaining years holding steady or rising. Advocates of longevity science call that crossing longevity escape velocity, a phrase coined in 2004. The site does not assume it is coming, and works out from the record how far off it looks.
The year at the top of the site is never typed in. It is worked out from the treatments and tools on the tree, each carrying a range for the year it reaches the clinic with the reasoning beside it, by a method anyone can run from the public repository.
What the computation does
Every treatment and tool supplies a year it reaches the clinic. One already there supplies the year it happened: what has happened is not drawn. One below the clinic draws a year from its estimate, a range with three numbers, no earlier than, most likely, and no later than, written on its page with the reasoning. The draw makes the likely year the most probable and the two ends possible but rare, with the chance falling off in a straight line towards each end; statisticians call this a triangular distribution.
Every branch is counted in the year its second treatment reaches the clinic. The branch's years are sorted and the second is taken. So a branch's slow treatments never set its year, only its two fastest; a branch with two treatments in the clinic already is counted in a known year and cannot hold the year back. Being counted is a low bar: it means two treatments exist, not that the damage has been dealt with.
The run's answer is the latest of those years across the eight branches, plus a lag for treatments to spread from the clinic to ordinary people, drawn once per run from a range of 3 to 15 years, most likely 8. The year is meant to be when a person who keeps up with the best available care actually gets the gain, not when the paper came out.
Many thousands of runs, each with fresh draws, give a spread of years. Three numbers are read off it: the middle year, which is the year at the top; the share of runs before 2050; and the share after 2100, shown on the site as "not this century". The middle nine tenths of the runs are reported as the spread.
Two things to be clear about from the start. The combination rule, that every branch must have two treatments in the clinic and then a lag added, is the project's judgment, and the strongest alternative, a weighted sum in which some branches count for more, is recorded below with why it was not chosen. And the ranges are the project's reading of the evidence, revised only with a dated reason and a source, never because a number looked wrong.
The numbers as they stand
Computed on 9 November 2026 from 200,000 runs over 45 treatments and tools, 6 of them already in the clinic: the middle year is 2058, with nine runs in ten between 2050 and 2069; the chance before 2050 is 4.3%; and the share of runs not this century is 0%. A quarter of the runs land by 2054 and three quarters by 2062. 1 estimate the year draws from is still a first pass, so these numbers are the shape of the first reading of the evidence and not a settled forecast; the outside review of the ranges is the next step, and every change it brings is dated on each treatment's page.
The spread of runs shows how far chance moves the answer inside my ranges. It cannot show whether the ranges themselves are right, so two more years are worked out with no random draw at all. If everything went right, with every treatment at the earliest year I think possible and a delay of 3 years, the answer would be 2035. If everything went wrong, with every treatment at its latest and a delay of 15 years, it would be 2095. In both cases damaged DNA is the branch that comes last. Neither end is a likely future, because it would take every one of my guesses leaning the same way at once. They are there to show how much of the year rests on my judgment rather than on the record.
The spread of escape years, by five-year spanShare of 200,000 runs landing in each span. The middle year, 2058, is marked.
Source: the computed result in the public repository, 9 November 2026, also served from this site at /data/headline.json. Each bar is labelled with the years it covers, so the bar marked 2045–49 holds the runs landing from 2045 to 2049; any runs past 2100 get a last bar of their own.
One run, written out
Every treatment and tool is taken at its most likely year (or the year it reached the clinic, where it already has), and the lag at its most likely value, so this is one readable run and not a random draw. Every treatment under a branch is listed with its year; the branch is counted at its second; the latest branch to be counted, the cell's settings, sets the year; and the lag is added.
This one run lands earlier than the middle of all the runs, 2058, and that is expected: the real runs draw a year for every treatment at once, and the latest of eight drawn years is usually later than the latest of eight likely years, because any one of the eight can come in late. That is what the combination rule does, and why the spread across all the runs is wider than any one run suggests.
By branch, the middle year each has two treatments in the clinic across all the runs: worn-out cells 2043, damaged DNA 2044, the cell's settings 2044, broken proteins and waste 2023, energy and fuel sensing 2028, replacing lost cells and parts 2032, inflammation and the body's messaging 2026, measuring ageing 2040. The tree shows each one.
The settings, each with its reason and its strongest alternative
Ten choices, proposed on 16 October 2026 with a confidence level each and adopted the same day. The lag went to the outside review of 17 October 2026 because its three numbers are a first guess with no source behind them; the review produced no published figure either, so the numbers stay until one is found.
The draw for a treatment below the clinic is a triangle over its no-earlier-than, most-likely and no-later-than years. Moderate confidence: three numbers are what a person can argue about in public, and the triangle is the simplest shape that uses all three and nothing else. Alternative: a bell curve centred on the likely year. Smoother, but it never says "no earlier than", and the earliest year on a treatment with no human result is a real floor.
The lag from the clinic to ordinary people is a triangle over 3, 8 and 15 years, drawn once per run and shared by every branch. Low confidence on the numbers, moderate on the shape. Put to the outside review of 17 October 2026, which could name no published figure for the time from approval to wide use; one of its four answers proposed 5, 10 and 20 years, declined by me the same day for want of a source. Alternative: a lag per branch, drawn separately. More honest about the difference between a pill and a transplant, at the cost of eight more guesses; the review proposed four versions of it (for example 8, 15 and 25 years for replacing parts, and 1, 3 and 5 for measuring ageing), none with a source for any year, and I declined it for now on 17 October 2026. Or no lag at all, which would count the year a drug is approved as the year everyone has it.
All required branches must have two treatments in the clinic, and the latest of those years is taken. Moderate confidence: it says in the model what the published science says in prose, that ageing is many kinds of damage and outrunning it means dealing with each. Alternative: a weighted sum, in which the branches with the most deaths behind them count for more and a branch could be skipped. It would pull the year in and would need eight weights nobody has published; a weight is a second judgment on top of the ranges, and the ranges are already the arguable part.
The fixed dates are 2050 and 2100. High confidence: the loudest promises on the claims log land before 2050, most readers under fifty expect to see it, and 2100 is the century's end. Both are project constants, changed only at a yearly review and logged. Alternative: the reader's own life expectancy, as The Belt Equation frames its question; deferred to a later version.
200,000 runs. High confidence: the percentages then wobble by about a tenth of a point from one random start to another, far below any rounding the site shows, and the run takes under a second. Alternative: a million runs for a twentieth of a point, or twenty thousand for noise that would show in the published file.
A fixed starting point for the random draws (2004, the year the phrase "longevity escape velocity" became known). High confidence that it is fixed: the published numbers then reproduce exactly on any machine, and the result changes only when a record changes, so every change to the year is a visible change with a changelog line. Alternative: none, so the numbers wobble on every run and every build produces a change.
Independent draws: every treatment's year and the lag are drawn with no link between them. Moderate confidence: nothing published gives a rule for how a breakthrough in one branch speeds another, and a rule invented here would be a third judgment. The outside review of 17 October 2026 asked, in all four of its answers, for the measuring branch to be linked to the treatment branches, since a regulator accepting a marker of ageing would shorten every trial; the two sources it named argue that and do not measure it, and I ruled the same day that the argument goes on the record and no link is drawn until it has a size with a source. Alternative: linked draws, a shared "the field is going well" factor. More realistic, since the branches share money, regulators and tools, and it would widen the spread; it needs a number with no source.
The computation refuses to run until every branch has at least two treatments to draw from, naming the branches short of it. High confidence: without them a branch could never be counted and every run would say "never", which would reflect a gap in the record and not the state of the science. Alternative: treat a short branch as counted at its last treatment's year, or skip it. Either hides the gap.
The result is written to a file and committed with the records, and the site reads that file. Moderate confidence: a change to the year is then a reviewable change beside the record that caused it. Alternative: compute at build time with no file. Nothing to commit, but the year could change without a changelog line.
Years past 2300 are refused in a record; a drawn year past 2100 counts as "not this century" and is otherwise left as it is in the spread. Moderate confidence: "never" has to be expressible, and a far year is how a three-number estimate says it. Alternative: a separate "chance it never happens" number per treatment. Cleaner in meaning, one more number to argue about, and it needs a rule for combining with the years.
Where the ranges come from
The ranges are the least certain part of the method, and the rest of the method exists to correct them over time. Each treatment's page shows its range with the reasoning in plain words, naming the evidence it rests on, and the papers behind its stage. The range is set by hand from that evidence, not computed from it, because the judgment about what to lean on is the arguable part and it should be visible and arguable. Every range starts life marked as a first pass. Before it is called settled it goes through an outside review, in which the ranges and their reasons are put to other readers, including other AI models, with a fixed brief to argue each one up or down, and I rule on every disagreement. Until that has happened the site says so. Each range was first drafted by Claude, the AI I build this project with, from the published record, and is accepted or moved by me; every change since is a dated revision on the treatment's page with the old numbers, the new ones and the reason.
What counts as a record
A treatment moves up its ladder only on a public record of the kind its own page names: a peer-reviewed report with a measured result, a regulator's approval record, a trial registry. A press release, a funding round, a target date or a first dose with no measured result settles nothing, on any rung. A claim on the claims log needs a primary source, the book and page or the recording and its minute, and news coverage of a remark is coverage, not a source.
What sits beside the year and never moves it
Two records sit beside the tree and never touch it. The claims log is what named people and companies have said about when, each dated and sourced, with a verdict as the dates pass; a claim moves nothing, and nothing on the tree makes a claim true. The self-experiments are what people have tried on themselves in public, with what the public record actually shows; a claim about one person is a story, not a record, and it moves nothing on the tree. Neither kind of record has any place to put a stage or an estimate, and the site will not build if one is added, so neither can move the year even by mistake.
Who does what
I rule on what goes on the tree, on every test, on every range and on every verdict. Claude, an AI assistant, drafts the records, proposes the ranges, checks the papers, runs the weekly reading, and built this site. Nothing goes in without a source.
The working documents, as written
The documents below are the project's own working record, published as they are written because rewriting them would change the record. Each is written for the project rather than for a visitor, uses the project's own words, and may be out of date where this page is current; this page is the plain account.
The ten settings of the computation (the shape of each draw, the lag from the clinic to ordinary people, the rule that every required branch must have two treatments in the clinic, the two fixed dates, the number of runs, the fixed seed, independent draws, when the computation refuses to run, where its result is written, and how a far year is read), each with a confidence level and the strongest alternative, proposed and adopted on 16 October 2026 with the lag flagged for an outside review. It is for anyone who wants to know why the numbers are what they are.
It defines the six kinds of record (a branch, a treatment or tool, a claim, a self-experiment, a publication, and a weekly reading), every field each may carry, the stage ladder, how a treatment’s state feeds the year, the five rules for judging and sourcing a claim, and the rules the checking script enforces. It is for anyone adding or correcting a record.
The plan the project started from on 16 October 2026: the question, the headline number, the eight branches, what a treatment is, the six kinds of record, the name, and how the site is built. It is kept as the record of where the project began, and it is not updated.
The code that checks every record against the layout and refuses to continue on any failure, and that plays the tree out many thousands of times to produce the numbers. It is for anyone who wants to reproduce a figure; with the fixed seed, the published numbers reproduce exactly on any machine.
What the computation wrote: the date, the settings, the three numbers, the spread, and for each branch the year its second treatment reaches the clinic and what each treatment supplied. It is committed with the records it is computed from, so every change to the year is a visible change with a line in the changelog. The same file is served from this site at /data/headline.json, so anyone can fetch the numbers without the repository.
Every change to a record, the method or the site, with its date.
Cite as: Fredrickson, J. A. (2026). Outrunning Ageing [dataset]. Version of 2026-11-21. https://outrunningageing.com. The records are free to reuse with credit, and the code is under the MIT licence. As the site stands the chance before 2050 is 4.3 per cent.
The story so far
What has been read, and what it moved
Everything that bears on the year at the top of the site is logged here with the date it was read, which treatments and branches it touches, and one plain question answered: did it settle a stage or move an estimate? Most do neither, and saying so is the point.
The log is only ever added to. An entry is never edited except to fix an error, with a line in the changelog saying so. The founding papers were logged on 16 October 2026; from the site's launch, each new paper is logged as it is read, and the weekly reading of the treatments against the news adds its moves here. The year was last computed on 9 November 2026.
What changed, day by day
One line for each day the records changed, newest first, made from the records themselves: the year at the top moving, a treatment moving up a rung, a range of years revised, a treatment, claim or self-experiment added, papers logged, a weekly reading run. A day whose only changes were to the wording says so. Each line links to the change it names.
appeared 28 October 2026Read; moved nothingBroken proteins and wasteRevenue of LEQEMBI (Preliminary Basis)Eisai
The maker gives worldwide sales of the amyloid antibody lecanemab of 61.5 billion yen for 2026-04-01 to 2026-09-30, before audit, against 41.1 billion yen a year earlier. The earlier figure included a one-off stockpile by distributors in China. By country: 32.5 billion yen in the United States (19.3 billion a year earlier), 13.0 billion in Japan (11.7 billion) and 9.7 billion in China (7.9 billion). The release gives no count of people treated.
Eisai Co., Ltd.. Company release (2026-10-28). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Read on the maker's own page on 2026-11-21, after the weekly reading of 2026-11-15 pointed to it.
appeared 3 September 2026Read; moved nothingBroken proteins and wasteLEQEMBI (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in ChinaEisai and Biogen
The makers say China's medicines regulator approved the under-the-skin autoinjector form of the amyloid antibody lecanemab as a starting treatment for early Alzheimer's disease on 2026-09-03. It is given at home once a week, as two injections, in place of an infusion every two weeks in a hospital. The makers plan to launch it in China by 2027-03-31, so it was not yet on sale when the release was written.
Eisai Co., Ltd., Biogen Inc.. Company release (2026-09-03). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Read on the maker's own page on 2026-11-21, after the weekly reading of 2026-11-15 pointed to it.
appeared 1 September 2026Read; moved nothingBroken proteins and wasteCanada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI (lecanemab) for Early Alzheimer's DiseaseEisai and Biogen
The makers say Canada's drug agency issued a final recommendation, on reconsideration, that public drug plans pay for the amyloid antibody lecanemab for eligible people with early Alzheimer's disease. A recommendation is not payment: the next steps are a price negotiation between the makers and Canada's public plans together, and then a decision by each province and territory.
Eisai Co., Ltd., Biogen Inc.. Company release (2026-09-01). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Read on the maker's own page on 2026-11-21, after the weekly reading of 2026-11-15 pointed to it.
The first sentence still said the under-the-skin form was approved for the later doses only; it now also gives the approval of 2026-07-13, which the note of 2026-10-17 had recorded. A note dated 2026-11-21 records four newer facts about the drug's reach (the pen on sale in Japan, China's approval of the starting dose, Canada's recommendation of public payment, and the half-year sales) and says why the years stay: none of them counts the people treated. No year changed. Source: Eisai and Biogen, 13 November 2026.
The estimate now names the makers' releases its reasoning rests on, so that each one is linked from the treatment's page. No year changed.
Logged 15 November 2026
appeared 10 November 2026Read; moved nothingMeasuring ageingBeyond organ age gaps: comparing plasma proteomic metrics of organ biology in relation to brain structure and neurodegenerative diseaseZendehel and 10 others
Three ways of scoring 15 organs from the proteins in blood were compared in 52,667 people of the UK Biobank. The three were related but not interchangeable. The gap between an organ's age and the person's age was the score most consistently linked to later brain and blood-vessel diagnoses, but adding the scores to a model of basic personal details improved prediction only modestly, the most for Alzheimer's disease.
R. Zendehel, L. An, L. Chauveau, H. S. Oh, G. Vilkaite, I. Hristovska, V. Warrier, J. Seidlitz, R. A. Bethlehem, A. Pichet-Binette, J. W. Vogel. bioRxiv (preprint, 2026-11-10). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database. A preprint, not yet peer reviewed.
Using population counts and life tables for Japan, Sweden, France, Italy and South Korea, a single author finds that the number of people aged 100 and over is growing because more people reach 100, while the model's measure of the far end of the lifespan shows no comparable long-term rise and sits at about 117 to 122 years. The author says this does not imply a fixed biological maximum.
Byung Mook Weon. Research Square (preprint, 2026-11-13). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database. A preprint, not yet peer reviewed. It bears on the question of a limit to human lifespan as a whole and on no one branch, so it is listed against all eight.
appeared 12 November 2026Read; moved nothingThe cell's settingsPartial reprogramming reveals lineage-specific uncoupling of rejuvenation, function, and recoverability in human cellsWashizu and 4 others
Three kinds of human cell were briefly reset in a dish with the four resetting genes and then left to recover. Skin cells kept a lower age reading from the marks on their DNA but did not fully recover their growth; immune T cells recovered only from a shallow reset; cells that line blood vessels recovered quickly, stayed younger by the same reading and worked better. The authors, Shinya Yamanaka among them, conclude that the balance between making cells younger and letting them recover has to be set one kind of cell at a time.
K. Washizu, X. Wang, J. M. Draper, S. Yamanaka, A. Kunitomi. bioRxiv (preprint, 2026-11-12). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database. A preprint, not yet peer reviewed.
appeared 24 September 2026Read; moved nothingDamaged DNAA Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular DiseaseVerve Therapeutics
A mid-stage (phase 2) trial of a gene editor given into the body to lower LDL cholesterol for good, in 175 adults who have heart and artery disease or are at high risk of it. The entry shows it recruiting in the United States since 2026-09-24, with its main results expected in August 2028 and none posted.
Verve Therapeutics, Inc.. ClinicalTrials.gov, registry entry NCT07839936 (first posted 2026-09-24, last updated 2026-11-10). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the registry's data interface. First posted before the week the reading covered; the entry was updated inside it.
appeared 13 November 2026Read; moved nothingThe cell's settingsEngineered compact TnpB epigenetic editors prevent choroidal neovascularization via Vegfa repressionTian and 9 others
A Chinese group built smaller tools for switching a gene up or down by changing the marks on it, small enough to be carried by a single virus shell. Given once to mice, one of them switched down a gene that drives blood-vessel growth in the eye and markedly reduced the abnormal vessels of a model of the wet form of age-related macular degeneration, with no sign of DNA damage. It is mouse work.
X. Tian, J. Sun, Y. Huo, C. Ge, W. Liu, K. Li, W. Sun, G. Xiang, Y. Tao, H. Wang. Protein & Cell, pwag077 (online 2026-11-13). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database; the journal's own page was not read.
appeared 30 October 2026Read; moved nothingReplacing lost cells and partsFinancial results presentation for the second quarter of the year to March 2027, with research and development updateSumitomo Pharma
The maker of the Parkinson's cell product approved conditionally in Japan on 2026-03-06, nerve cells grown from reprogrammed donor cells, says the first patient in the study it must run after approval was treated at Kyoto University Hospital in October 2026. It plans about 1 or 2 patients in the year to March 2027, about 10 in the next year and 10 to 20 in the year after, with patients in that study given priority and other hospitals and a wider group of patients to follow once the study is complete.
Sumitomo Pharma Co., Ltd.. Company presentation (2026-10-30). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the company's own document; the title is a description, since the presentation's cover page was not read. Published before the week the reading covered.
appeared 28 October 2026Read; moved nothingWorn-out cellsA Bi-Adjuvant Senolytic Nanovaccine Modulating Dendritic Cell Senescence Ameliorates Aging-Related Metabolic DysfunctionSong and 5 others
A vaccine that trains the immune system against aged cells carrying a surface protein called Gpnmb cleared such cells from the fat of old mice, improved their handling of sugar and fat, and, the abstract says, lengthened their lives. A news report of 2026-10-30 on the paper gives the lifespan figure: a median life 12 per cent longer in female mice vaccinated at 75 weeks, with ten mice to a group and untreated mice that were short-lived for their strain. It is small mouse work and no person has been given the vaccine.
Q. Song, X. Du, W. Dong, Y. Wang, X. Wang, Q. Yin. Advanced Science, e78545 (online 2026-10-28). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database; the full paper was not read, and the lifespan figures are from the report on lifespan.io of 2026-10-30. Published eleven days before the week the reading covered.
appeared 11 November 2026Read; moved nothingInflammation and the body's messagingColchicine use was associated with reduced all-cause mortality in patients with diabetic gout without prior coronary artery disease: A propensity-matched nationwide cohort studyShin and 8 others
In Korean national insurance records, 17,337 matched pairs of people with diabetes and gout and no earlier coronary disease were compared by whether they took colchicine. Fewer of the colchicine users died (8.01 against 11.07 per cent), but they had no fewer heart attacks (hazard ratio 1.15, 0.96 to 1.37) or strokes (0.91, 0.81 to 1.01). It is a comparison from records, not a trial.
Y. Shin, J. J. Cha, J. H. Kim, H. J. Joo, J. H. Park, C. W. Yu, M. Park, Y. Lee, S. J. Hong. PLoS One 21, e0362218 (2026-11-11). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database; the journal's own page was not read.
appeared 12 November 2026Read; moved nothingThe cell's settingsScribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate HighlightsScribe Therapeutics
The company says its first trial in people of a one-dose treatment that switches off a cholesterol gene by changing the marks on it, without cutting the DNA, began in mid 2026 and is under way, with first results from people expected in the first half of 2027. In monkeys, it says, one dose kept LDL cholesterol down by more than half for two years.
Scribe Therapeutics, Inc.. Company release, as filed with the United States Securities and Exchange Commission (2026-11-12). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the copy filed with the United States securities regulator. The trial's registry entry (NCT07428473) shows it recruiting in Australia and New Zealand, 64 people planned.
appeared July 2026Read; moved nothingMeasuring ageingAffecting the Aging Trajectory: Public Meeting SummaryReagan-Udall Foundation for the FDA
The summary of a public meeting on treatments for ageing, held by the foundation that Congress created to support the United States regulator, with funding from the government agency ARPA-H and the XPRIZE Foundation. It says no approved route now exists for a drug whose stated use is ageing, that there is no validated marker of ageing and no accepted regulatory measure, and that no marker of ageing has reached the standing of a validated or reasonably likely stand-in for a trial's outcome. Speakers pointed to the routes that exist, among them meetings on a company's own trial plan, the marker qualification programme and approvals disease by disease.
Reagan-Udall Foundation for the FDA. Reagan-Udall Foundation for the FDA, summary of the public meeting of 2026-05-27 (July 2026). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the foundation's own document. Published well before the week the reading covered.
appeared November 2026Read; moved nothingDamaged DNAAbstract 5183: Cardiac Outcomes Following a Single Dose of Nexiguran Ziclumeran in Patients with Transthyretin Amyloidosis with Cardiomyopathy or Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Phase 1 AnalysisRazvi and 13 others
In the 72 people of the first trial of a one-time gene edit made inside the body for transthyretin amyloidosis, the level of the protein in blood was about 89 per cent lower a month after the single dose and stayed there at two years. In the 36 with advanced heart disease, heart measures held steady or improved, and 86 per cent were in the same or a better class of heart failure at 18 months. There was no comparison group, and it is a meeting abstract, not a full paper.
Yousuf Razvi, Scott Solomon, Jorg Taubel, Ed Gane, Björn Pilebro, Andoni Echaniz-Laguna, Jessica Kachadourian, Michael Sopko, Derek Smith, Joy Olbertz, David Gutstein, Liron Walsh, Marianna Fontana, Julian Gillmore. Circulation 154 (supplement 1), abstract 5183 (meeting abstract, 2026). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract's text in the Crossref record, because the journal's page refused; the record was created on 2026-11-08 and the issue's exact date was not confirmed.
appeared 9 November 2026Read; moved nothingBroken proteins and wasteMyocardial Responses to Eplontersen in Transthyretin Amyloid Cardiomyopathy: The CARDIO-TTRansform CMR studyRazvi and 12 others
In 120 people scanned by magnetic resonance inside the large placebo-controlled trial of eplontersen, a drug that switches off the liver's production of the protein transthyretin, the scan measure of amyloid in the heart muscle was 6.7 percentage points lower on the drug than on placebo at week 140 (8.7 to 4.7 lower), with better heart structure and pumping. Most of those scanned were not taking a protein-steadying drug. The authors call it randomised evidence that lowering the protein changes the disease in the heart muscle; the trial as a whole did not significantly reduce heart deaths and repeat heart events.
Y. Razvi, S. D. Solomon, S. A. M. Cuddy, L. Venneri, A. Martinez-Naharro, F. Cappelli, A. Cipriani, P. Garcia-Pavia, A. Masri, A. Sheikh, N. Ramos-Lopez, P. Sekar, and 14 others, the last M. Fontana. Circulation (online 2026-11-09). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database; the journal's own page was not read.
appeared 28 July 2026Read; moved nothingEnergy and fuel sensingA Randomized Clinical Trial of Metformin to Reduce Frailty in Older Adults with Glucose IntoleranceMusi and 13 others
A two-year placebo-controlled trial of metformin in 145 adults of about 72 with raised blood sugar short of diabetes, in San Antonio. On its first frailty score metformin showed no benefit once the weight loss it causes was set aside. On a second score that counts 95 health deficits it gave a small, significant slowing, and two clocks read from the marks on DNA in blood ran slightly slower (by 0.40 and 0.33 years a year). The trial measured frailty, not the time to a first age-related disease.
N. Musi, C. Wang, D. MacCarthy, Z. Feng, J. T. Holmes, M. Suda, T. Pirtskhalava, A. Aslamy, J. Wanagat, R. Brooke, T. Tchkonia, J. L. Kirkland, S. Horvath, S. E. Espinoza. medRxiv (preprint, 2026-07-28). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database. A preprint, not yet peer reviewed. The trial's registry entry (NCT02570672) is marked completed, with results posted on 2025-08-06 and 141 people enrolled. Posted before the week the reading covered.
appeared 11 November 2026Read; moved nothingMeasuring ageingThe cell's settingsReversal of Heart Age in Adults with Obesity After Initiation of Semaglutide Detected by Serial ElectrocardiographyMurugadoss and 2 others
A computer model trained on about a million routine heart tracings estimates a person's age from a tracing. In hospital records, that reading fell relative to calendar age after people with obesity started the weight-loss drug semaglutide, by 0.73 years at 12 months and 1.23 years at 15 months, and did not change after weight-loss surgery, although surgery patients lost far more weight (25.6 per cent against 4.8 per cent). It compares matched patients who chose their treatment, so it cannot show the drug caused the fall, and the reading is not one made from the marks on DNA.
K. Murugadoss, A. Venkatakrishnan, V. Soundararajan. Preprints.org (preprint, 2026-11-11). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database. A preprint, not yet peer reviewed.
appeared 11 November 2026Read; moved nothingWorn-out cellsMiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell TherapiesMiNK Therapeutics
The company says that, in laboratory work with Imperial College London shown at a cancer immunotherapy meeting, two of its off-the-shelf immune-cell products, one of them engineered, cleared the aged cells that chemotherapy and radiation leave behind; it calls them "living senolytics". No person has been treated for this purpose: the company says it will finish its randomised trial in severe lung injury first and take aged cells and scarring into the clinic after that.
MiNK Therapeutics, Inc.. Company release, as filed with the United States Securities and Exchange Commission (2026-11-11). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the copy filed with the United States securities regulator.
appeared 11 November 2026Read; moved nothingEnergy and fuel sensingFirst and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical TrialMarx and 12 others
In the placebo-controlled trial of semaglutide taken by mouth in 9,650 people with type 2 diabetes and heart, artery or kidney disease, followed for about four years, counting every heart attack, stroke and heart death and not only each person's first gave 683 events on the drug against 791 on placebo (ratio 0.86, 0.76 to 0.97). The people in it all had diabetes.
N. Marx, J. E. Deanfield, S. L. Mulvagh, A. Videmark, T. van Bemmel, J. B. Buse, Z. Davicevic-Elez, M. D. M. Engelmann, M. Haluzik, G. K. Hovingh, S. E. Inzucchi, J. F. E. Mann, and 10 others, for the SOUL Study Group. JAMA Cardiology (online 2026-11-11). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database; the journal's own page was not read.
appeared 12 November 2026Read; moved nothingReplacing lost cells and partsMeasuring ageingLongeveron Announces 2026 Third Quarter Financial Results and Provides Business UpdateLongeveron
The company, which makes a donor-cell therapy it is testing against frailty and Alzheimer's disease and is one of the ten finalists of the XPRIZE Healthspan competition, says its trial in 40 infants with a rare heart defect did not meet its main measure. It has 7.2 million dollars in cash, enough to last into the first quarter of 2027, has cut spending and has hired an adviser to look at a partnership, a sale or a merger. It says its chance at the competition's grand prize depends on completing the required trial and finding the money for it.
Longeveron Inc.. Company release, as filed with the United States Securities and Exchange Commission (2026-11-12). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the copy filed with the United States securities regulator.
appeared 9 November 2026Read; moved nothingMeasuring ageingBeyond accelerated aging: Multi-organ aging imbalance predicts adverse health outcomesLi and 9 others
In 221,599 people of the UK Biobank, how unevenly a person's six organ systems had aged went with a higher risk of death beyond their overall biological age (11 per cent higher for each step, 1.09 to 1.13 times), and the link with death held in five other cohorts. The main organ ages here are not all read from blood proteins; the abstract says similar findings were seen with 11 organ ages that are.
Y. Li, X. Xu, X. He, Y. Zheng, C. Suo, Z. Liu, Z. Yuan, Y. Jiang, K. Xu, X. Chen. Research Square (preprint, 2026-11-09). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database. A preprint, not yet peer reviewed.
appeared 12 November 2026Read; moved nothingInflammation and the body's messagingYouthful circulation reshapes age-associated DNA methylation across blood and liverKovalchuk and Kovalchuk
A fresh analysis of 78 blood and liver samples from an experiment already published, in which old mice were joined to a young mouse's circulation for a long period. The age-related marks on DNA were pushed back in both tissues, at many of the same sites, and much of the change was still there two months after the animals were separated. It is a re-analysis, not a new experiment.
I. Kovalchuk, O. Kovalchuk. The Journals of Gerontology, Series A, glag258 (online 2026-11-12). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database; the journal's own page was not read.
appeared 9 November 2026Read; moved nothingBroken proteins and wasteEffects of Eplontersen on Cardiac Structure and Function in Patients With Transthyretin Amyloidosis With Cardiomyopathy: Insights from the CARDIO-TTRansform TrialJering and 12 others
In 1,426 people with transthyretin amyloid in the heart followed by ultrasound in the trial of eplontersen, the drug modestly slowed the thickening of the heart wall and the decline in the heart's filling and pumping over 140 weeks. The benefit was almost all in people not already taking a protein-steadying drug, and none was seen in those who were. The paper repeats that the trial did not significantly reduce its main outcome, heart deaths and repeat heart events.
K. S. Jering, H. Skali, B. Claggett, N. Prasad, J. Chen, E. Gonzalez-Lopez, C. Morbach, S. A. M. Cuddy, M. K. Davis, F. Fernandes, J. D. Mitchell, N. Sarswat, and 6 others, the last S. D. Solomon. Circulation (online 2026-11-09). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database; the journal's own page was not read.
appeared 13 May 2025Read; moved nothingReplacing lost cells and partsJapan Tissue Engineering Announces Approval for Expanded Indication of Autologous Cultured Cartilage "JACC" for OsteoarthritisJapan Tissue Engineering
The company says Japan approved on 2025-05-13 the use of its cultured cartilage, grown from the patient's own knee cartilage cells and sold since 2013 for injuries, for osteoarthritis of the knee, in people with a cartilage defect larger than 2 square centimetres whom medicines and exercise have not helped. It ran its trial for this from April 2019 and applied in June 2024; the product had been used in more than 1,900 cases for its earlier uses. The release gives no trial figures.
Japan Tissue Engineering Co., Ltd.. Company release (2025-05-13). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the company's own release, in English. Published well before the week the reading covered.
appeared 12 November 2026Read; moved nothingInflammation and the body's messagingSide Effects of Low-Dose Colchicine in Chronic Coronary Disease: A Post Hoc Analysis of the LoDoCo2 TrialJannink and 12 others
A later analysis of the 2020 trial of low-dose colchicine in long-standing coronary disease. In the first month, when everyone took the drug, 618 of 6,519 people (9.5 per cent) reported side effects. Among those who then went on to the drug or placebo for about two and a half years, 4.2 per cent on colchicine and 4.4 per cent on placebo stopped for side effects, no difference.
J. Jannink, J. van der Veen, N. Mohammadnia, M. F. van der Bijl, E. Boersma, A. van Broekhoven, C. A. Budgeon, J. H. Cornel, J. W. Eikelboom, S. El Messaoudi, S. M. Nidorf, T. S. J. Opstal, and 8 others, the last A. T. L. Fiolet. Journal of the American Heart Association, e049844 (2026-11-12). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database; the journal's own page was not read.
appeared 13 November 2026Read; moved nothingMeasuring ageingDisease aging clocks in the plasma proteome stratify risk and track preclinical progressionHe and 9 others
The Stanford group that built the organ clocks built blood-protein clocks for 31 age-related diseases in 44,526 people of the UK Biobank. Among people of the same age the clocks separated ten-year risk up to twentyfold; each extra year on a clock raised the hazard of type 2 diabetes by 24 per cent, chronic kidney disease by 21 per cent and Alzheimer's disease by 17 per cent, and 56 per cent of what the clocks measure was not captured by calendar age or the organ clocks. The Alzheimer's clock held, without refitting, in 501 people at a second centre.
Z. He, J. Park, J. Tan, R. Wen, J. Wang, K. Ying, Y. L. Guen, E. Mormino, V. Henderson, T. Wyss-Coray. Research Square (preprint, 2026-11-13). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database. A preprint, not yet peer reviewed.
appeared 13 November 2026Read; moved nothingBroken proteins and wasteLEQEMBI Pen (Subcutaneous Formulation of LEQEMBI) Now Available in Japan for Patients with Early Alzheimer's DiseaseEisai and Biogen
The makers say the under-the-skin pen form of the amyloid antibody lecanemab went on sale in Japan on 2026-11-13, the day it was listed in the national health insurance price list, after its approval there on 2026-09-16. Japan is the second country after the United States where a course can be given at home, once a week by the patient or a carer, in place of an infusion every two weeks at a hospital. Brain scans before and during treatment are still required.
Eisai Co., Ltd., Biogen Inc.. Company release (2026-11-13). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the maker's own page.
appeared 9 November 2026Read; moved nothingDamaged DNAEditas Medicine Announces Third Quarter 2026 Results and Business UpdatesEditas Medicine
The company says it has ethics approval and has completed the notification to Australia's medicines regulator needed to start a first trial in people of its gene editor given into the body to lower LDL cholesterol, in people with an inherited form of high cholesterol, and that it remains on track to treat its first patient in 2026. The trial registry lists the trial as planned for 56 people in Australia and not yet recruiting.
Editas Medicine, Inc.. Company release, as filed with the United States Securities and Exchange Commission (2026-11-09). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the copy filed with the United States securities regulator. The registry entry (NCT07894887, first posted 2026-10-26) was read through the registry's data interface.
appeared 11 November 2026Read; moved nothingEnergy and fuel sensingBody weight modifies the efficacy of lifespan-extending interventions in ad libitum-fed miceBouvet and Partridge
A reanalysis of body weight and survival for 33,780 mice in the United States programme that tests drugs for longer life. In males, the gain in median lifespan rose from 6.2 per cent in the lightest quarter of mice to 20.2 per cent in the heaviest, mainly because heavy untreated mice died sooner; the pattern held for 13 of 14 compounds and was weak in females. The authors conclude that much of the gain is relief from the harm of excess weight in freely fed mice, and that the drugs may do less in healthier mice or in people.
P. Bouvet, L. Partridge. bioRxiv (preprint, 2026-11-11). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database. A preprint, not yet peer reviewed.
appeared 10 November 2026Read; moved nothingEnergy and fuel sensingCardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial EmulationAubrac and 5 others
A study of United States insurance records comparing people with heart and artery disease, overweight or obesity and no diabetes who started semaglutide or the newer drug tirzepatide. It found no significant difference between the two in a combined count of heart attacks, strokes, heart admissions, artery procedures and deaths (hazard ratio 1.21, 0.99 to 1.51). It is a comparison from records, not a trial.
G. Aubrac, R. V. Raquib, M. T. Le, M. Webster-Clark, R. W. Platt, A. C. Stokes. Diabetes, Obesity and Metabolism (online 2026-11-10). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-15 from the abstract in the Europe PMC paper database; the journal's own page was not read.
Logged 9 November 2026
appeared 6 November 2026Read; moved nothingBroken proteins and wasteDonanemab bei früher symptomatischer Alzheimer-Krankheit: Zulassung und Zusatznutzenbewertung (AMNOG) im Spannungsfeld unterschiedlicher EvidenzanforderungenZschocke and 9 others
An account of why Germany's bodies that judge a new drug's added benefit, whose finding informs its price, recognised no added benefit for donanemab, the second amyloid-clearing antibody, in either group of patients with early Alzheimer's disease, although the European regulator approved it for both. The German assessment asked for separate comparisons by stage of disease against the usual care.
Juergen Zschocke, Jonathan Vöglein, Sascha Dichter, Thomas Heisser, Pia Maurer, Martin Doerr, Marion Scharf, Jens Opalka, Robert Perneczky, Oezguer A. Onur. Fortschritte der Neurologie · Psychiatrie (online 2026-11-06), DOI 10.1055/a-2989-2517. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the English abstract in the Europe PMC literature database, with the date and authors confirmed in the Crossref record. The paper is in German and its full text was not read.
appeared 5 November 2026Read; moved nothingThe cell's settingsDurable and reversible epigenetic programming of human hematopoietic stem cells as a platform for modulation of platelet functionYe and 21 others
Tools that edit the chemical marks on DNA, delivered briefly as RNA, switched off a platelet gene in human blood stem cells. The switching-off survived the cells' division and maturing, could be partly undone by a second edit, and was still in place 4 months after the cells were transplanted into mice. The work is in cells and mice, not in a person.
Ye T, Xu W, Barrachina MN, Lyu P, Antoszewski M, Della Volpe L, Guo CJ, Lee AJ, Villalpando E, Johnson IA, Theardy MS, Shelton SD, Wahlster L, Caulier A, Messa L, Poeschla M, Agarwal G, Mitra R, Schmaier AA, Weissman JS, Machlus KR, Sankaran VG. Cell Stem Cell (online 2026-11-05), DOI 10.1016/j.stem.2026.10.009. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 from the abstract and record in the Europe PMC literature database. The journal's own page was not opened. It is peer-reviewed work on the same kind of tool the treatment's test names, but it is not a person, so it does not meet the test.
appeared 6 November 2026Read; moved nothingWorn-out cellsAltered protein cysteine reactivity in senescent cells is a vulnerability for senolysis to ameliorate agingWu and 15 others
The authors report that vanadyl sulfate, a mineral compound taken by mouth, kills aged cells by pushing their proteins to misfold. In male mice it cleared aged cells, improved features of ageing and several age-related disorders, and lengthened lifespan. The abstract gives no lifespan figures, and the work is in mice only.
Wu R, Yang F, Li J, Wu T, Lyu R, Xiang J, Gao X, Zhang R, Fan H, Yin C, Tu J, Xie Z, Cai C, Zhang FQ, Xue K, Najarro J and colleagues. Nature Aging (online 2026-11-06), DOI 10.1038/s43587-026-01253-5. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 from the abstract and record in the Europe PMC literature database, dated there 2026-11-06. The journal's own page was not opened, so the figures in the full paper are unread. It adds a second kind of drug to the animal evidence and does not change what the treatment's test asks for, which is a result in people.
appeared 2 November 2026Read; moved nothingReplacing lost cells and partsVertex Reports Third Quarter 2026 Financial ResultsVertex Pharmaceuticals
The company says it "has decided to focus on accelerating the development of" a second version of its insulin-making cells grown from stem cells, meant for people of any blood type and now in an early trial, which it expects to take into a late-stage trial in 2027. It describes its first version, zimislecel, as designed for people with blood types A or AB only, and gives no date for filing it for approval.
Vertex Pharmaceuticals. Company release, as filed with the United States Securities and Exchange Commission (2026-11-02). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the copy filed with the United States securities regulator. The title is as the release is usually headed; the filed exhibit was read for the passage on the cell therapy.
appeared 5 November 2026Read; moved nothingReplacing lost cells and partsVericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial GuidanceCorporation
The maker of the approved knee cartilage product grown from a person's own cells reports that its sales for July to September 2026 rose 21 per cent to 67.4 million dollars, with record numbers of surgeons using it, and that it remains on track for a possible launch in the United Kingdom in 2027. The release says nothing about worn joints in older people.
Vericel Corporation. Company release, as filed with the United States Securities and Exchange Commission (2026-11-05). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the copy filed with the United States securities regulator.
appeared 6 November 2026Read; moved nothingEnergy and fuel sensingMeasuring ageingValidation & Intervention Testing for Aging, Longevity and Healthspan (VITAL-H)The University of Texas Health Science Center at San Antonio
A registry entry for a phase 2, placebo-controlled trial of two approved drugs, dapagliflozin and semaglutide taken as a tablet, in 1,200 adults, with the United States Department of Health and Human Services named as collaborator. The conditions named are "Aging" and "Functional Decline", and the main measure is a score of physical performance (balance, walking speed and rising from a chair). It is not yet recruiting: the start is estimated for January 2027 and the main result for December 2030. No result exists.
The University of Texas Health Science Center at San Antonio. ClinicalTrials.gov, NCT07923630 (first posted 2026-11-06). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the registry entry, read through the registry's data interface. The university's announcement of 2026-03-04 described three drugs including rapamycin and 726 people; the registered design has two drugs and 1,200 people.
appeared 31 March 2026Read; moved nothingEnergy and fuel sensingU of A launches rapamycin clinical trial with philanthropic support of alumnus Ken CoitUniversity of Arizona Foundation
The university says its researchers will begin a double-blind, randomised phase 3 trial of low-dose rapamycin in people of 65 and over, paid for by a gift of 12 million dollars, to measure whether it maintains or improves physical and immune function. Participants take the drug or a placebo for two years with a further year of follow-up; the trial awaited final approval from the United States regulator and is expected to take six years.
University of Arizona Foundation. University of Arizona announcement (2026-03-31). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the university's own page. No entry for the trial was found on the trial registry.
appeared 4 November 2026Read; moved nothingReplacing lost cells and partsQuarterly report for the quarter ended 30 September 2026United Therapeutics Corporation
The company reports that the first transplant in its first pig kidney trial took place in the last quarter of 2025 and the trial continues; that the United States regulator cleared a second kidney trial, of a kidney transplanted with the pig's thymus tissue, in August 2025; and that in May 2026 the regulator cleared a first trial of its pig heart, to begin with up to two adults with advanced heart failure.
United Therapeutics Corporation. Form 10-Q, filed with the United States Securities and Exchange Commission (2026-11-04). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the report as filed with the United States securities regulator.
appeared 14 July 2026Read; moved nothingBroken proteins and wasteReversal of protein chemical aging by enzymatic deglycationTrabosh and 7 others
The authors report an engineered enzyme that undoes one kind of sugar damage to proteins, called CML, restoring the protein's original building block. It worked on model proteins in a dish and in tissue samples from elderly donors. The damage it reverses is a single-protein modification, not a cross-link between proteins, and the work was not done in a living animal or a person.
Trabosh N, Smith J, Hsu MY, Panja S, Nagaraj R, Olsson N, McAllister FE, Cravens A. Nature Communications 17, 5926 (2026). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the abstract in the Europe PMC literature database. The journal's own page did not load for the final check, so the full paper is unread.
appeared 6 March 2026Read; moved nothingReplacing lost cells and partsAnnouncement of conditional and time-limited approval in Japan for the iPS cell-derived dopaminergic neural progenitor cell product AMCHEPRY (raguneprocel)Sumitomo Pharma and RACTHERA
The companies announce that on 2026-03-06 Japan granted conditional and time-limited approval to make and sell dopamine-making nerve cells grown from reprogrammed donor cells, to improve movement in people with Parkinson's disease who do not respond well enough to existing drugs. The approval rests on a study run by Kyoto University Hospital, and the company must run a further study after launch. The Japanese regulator's list of review reports shows the product as approved in March 2026.
Sumitomo Pharma Co., Ltd., RACTHERA Co., Ltd.. Company announcement (2026-03-06). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the company's own page; the regulator's list of review reports was opened and shows the product, but the review report itself was not read. The title is a short description of the announcement, not its exact heading.
appeared 5 November 2026Read; moved nothingEnergy and fuel sensingRapamycin and human longevity among kidney transplant recipients surviving the first yearStewart and Fitzsimmons
Using the United States transplant registry, the authors compared 4,885 kidney transplant recipients prescribed rapamycin with 6,589 who were not, followed for a median of 11 years, during which 6,443 died. After adjusting for age, body weight, diabetes and 15 other factors, the age to which half of each group survived was 64.6 years with rapamycin and 64.3 without, a difference the authors call statistically similar (the 95 per cent range for the difference runs from 1.6 years shorter to 2.0 years longer). It is a study of records, not a randomised trial, in transplant patients who take the drug at transplant doses alongside other drugs.
Darren E. Stewart, William E. Fitzsimmons. GeroScience (online 2026-11-05), DOI 10.1007/s11357-026-02643-8. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the abstract in the Europe PMC literature database, with the date and authors confirmed in the Crossref record. The journal's own page refused to open, so the full paper is unread.
appeared 5 November 2026Read; moved nothingWorn-out cellsEvaluation of Fisetin to Reduce Systemic SenescenceSteadman Philippon Research Institute
The registry lists a finished randomised trial of fisetin, a plant compound some researchers use to clear aged cells, in 82 people. It compares two fisetin schedules, 100 mg a day for 60 days against a larger dose over two days, with no placebo group. Its main measure is the change in aged immune cells in blood; it ran from 2023-05-24 to 2024-01-30 and no results are posted.
Steadman Philippon Research Institute (sponsor). ClinicalTrials.gov registry entry NCT07918261, first posted 2026-11-05. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09. The entry was first posted on 2026-11-05, long after the trial finished, so results may follow. With no placebo group it cannot meet the test for the next step; it is logged because a posted or published result would bear on the treatment.
appeared 25 March 2021Read; moved nothingWorn-out cellsThe Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for OsteoarthritisSteadman Philippon Research Institute
A registry entry for a placebo-controlled trial in knee osteoarthritis, planned for 100 people, that gives fisetin or losartan alongside a person's own bone marrow cells. Its main measure is safety. It started on 2021-05-18; the registry now shows its status as unknown, and no results are posted.
Steadman Philippon Research Institute. ClinicalTrials.gov, NCT04815902 (first posted 2021-03-25, last updated 2024-04-16). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the registry entry, read through the registry's data interface.
appeared 1 May 2023Read; moved nothingDamaged DNAMyocardial Telomere Recapping Study for Dilated CardiomyopathyHospital
A registry entry for an early study in which 12 people with heart failure were to receive a gene therapy carrying a modified telomerase gene, with a company as collaborator. Its main measures are safety. The registry now shows its status as unknown, and no results are posted.
Shanghai East Hospital. ClinicalTrials.gov, NCT05837143 (first posted 2023-05-01, last updated 2024-07-16). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the registry entry, read through the registry's data interface. A 2026 paper from the same group describes the modified gene as protecting chromosome ends while lacking the activity that lengthens them.
appeared 4 November 2026Read; moved nothingEnergy and fuel sensingWhole-blood NAD levels track cardiovascular disease but not chronological ageRomenskaja-Avgul and 10 others
From 1,340 measurements in 1,068 adults, the authors found that the amount of NAD in whole blood does not fall with age in healthy people: it stays level in men and rises in women. It was lower in people with cardiovascular disease and high blood pressure. The authors say the study was not designed to show cause and gives no direct evidence that raising NAD would treat those diseases.
Diana Romenskaja-Avgul, Deimantė Stakelytė, Audrius Laurynėnas, Eimantas Ramonas, Rūta Zabitaitė, Simona Cibulskė, Sigita Danilevičienė, Rapolas Danilevičius, Kristina Ratautė, Marius Dagys, Dalius Ratautas. Nature Metabolism (online 2026-11-04), DOI 10.1038/s42255-026-01660-3. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the abstract in the Europe PMC literature database, with the date and authors confirmed in the Crossref record.
appeared 5 November 2026Read; moved nothingEnergy and fuel sensingA Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular DiseaseRoche
A registry entry for a phase 3, placebo-controlled trial of enicepatide, a newer drug of the weight-loss family, in an estimated 8,200 people with excess weight and cardiovascular disease. Its main measure is the time to a first major heart or circulation event. It is due to start in January 2027 and reach its main result in March 2031.
Hoffmann-La Roche. ClinicalTrials.gov, NCT07918846 (first posted 2026-11-05). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the registry entry, read through the registry's data interface.
appeared 7 November 2026Moved an estimateInflammation and the body's messagingInterleukin-6 Inhibition with Ziltivekimab for Atherosclerotic DiseaseRidker and 32 others
The full report of the ZEUS trial. In 6,376 people with hardened arteries, chronic kidney disease and raised inflammation, mean age 69, given a monthly injection of ziltivekimab, an antibody against the inflammatory messenger interleukin-6, or a placebo, and followed for a median of 33 months, heart attack, stroke or death from heart disease happened to 17.6 per cent on the drug and 17.7 per cent on placebo (561 people against 565), no meaningful difference. The drug lowered the inflammation markers it was meant to lower, there was no effect on deaths from any cause, and infections rose slightly. The authors suggest the people enrolled, about ten years older and sicker than in the 2017 canakinumab trial, may have had disease too far along to change; the lead author added, in his hospital's release, that low-dose colchicine, already shown to work and approved, is under-used.
Paul M. Ridker, A. Michael Lincoff, Nikolaus Marx, Ann Marie Navar, Naveed Sattar, Katherine R. Tuttle, Matthew Budoff, Morten Böttcher, Matthew A. Cavender, Robin P. Choudhury, Jan H. Cornel, Grzegorz Gajos, Issei Komuro, K.M.K. Reddy Parvathareddy, Roberto Pontremoli, José Francisco Kerr Saraiva, Iana I. Simova, Lance A. Sloan, Alejandro López-Suárez, Yi-Da Tang, Lale Tokgözoğlu, Nqoba Tsabedze, Konstantinos Tsioufis, Subodh Verma, Mathias Vrolix, Andreas Andersen, Florian M.M. Baeres, Kathrine Ekström, Mads D.M. Engelmann, Sofia Gerward, G. Kees Hovingh, Anders Hvelplund, Vlado Perkovic. New England Journal of Medicine, 2026, published online 2026-11-07, presented the same day at the American Heart Association's Scientific Sessions 2026. Read it.
What it moved: the notes for A drug that acts only on inflammation is approved to prevent heart attacks changed, on 9 November 2026: The peer-reviewed report of the ZEUS trial replaces the company's announcement as the source for the result, so the notes say so.; the earliest year to reach wide use for A drug that acts only on inflammation is approved to prevent heart attacks, 2027 to 2028, on 9 November 2026: The estimate moves later because the ZEUS trial failed: its full report (Ridker and colleagues, New England Journal of Medicine, 2026-11-07) found no fewer heart attacks, strokes or heart deaths on ziltivekimab. The earliest year had allowed for a second drug helping colchicine into routine use; with ziltivekimab's remaining trials not due to report until 2027, it now rests on colchicine alone.; the likely year to reach wide use for A drug that acts only on inflammation is approved to prevent heart attacks, 2032 to 2035, on 9 November 2026: The estimate moves later because the ZEUS trial failed. Two large trials of drugs acting on inflammation have now come back against (the 2025 colchicine trial after a heart attack, and ZEUS), and the trial's lead author said on 2026-11-07 that colchicine is still under-used, so the most likely year for wide use moves three years later.; the latest year to reach wide use for A drug that acts only on inflammation is approved to prevent heart attacks, 2050 to 2055, on 9 November 2026: The estimate moves later because the ZEUS trial failed. The latest year had allowed for one negative trial keeping the treatment a niche choice; with a second, it allows longer, until a different drug acting further up the chain of inflammation proves itself.; the reasoning behind the estimate for A drug that acts only on inflammation is approved to prevent heart attacks changed, on 9 November 2026: Rewritten on 2026-11-09 to give the reason for the later years: the ZEUS trial's full report, and what it leaves wide use resting on.
The peer-reviewed report of the result the company announced on 2026-07-31 (Novo Nordisk, its announcement of that date, also in this log). The weekly reading of 2026-11-09 found it and left it for me, because it bears on the estimate of when a drug acting only on inflammation is in wide use to prevent heart attacks. The estimate moved later on 2026-11-09, because the trial found no fewer heart attacks, strokes or heart deaths.
The journal's page did not open on 2026-11-09: it showed a check for automated visitors, which was not got round. So the figures were read from two pages opened in full that day. The release by Mass General Brigham, the hospital group of the lead author (Heart researchers unpack neutral findings from ZEUS, an anti-inflammatory clinical trial, 2026-11-07, https://www.eurekalert.org/news-releases/1150801), gives 561 against 565 events, the reassuring safety with a small rise in infections and no effect on deaths from any cause, the older and sicker population, and Ridker's remark that low-dose colchicine is under-used. The American College of Cardiology's report of the presentation (2026-11-07, https://www.acc.org/latest-in-cardiology/articles/2026/11/06/14/37/sat-935am-zeus-aha-2026) gives the 6,376 people, the dose, the mean age of 69, the median follow-up of 33 months, and 17.6 per cent against 17.7 per cent. The paper's title, its date of 2026-11-07 and its 33 named authors were read from the record the journal filed with the DOI registry. The hazard ratio of 0.99 is the company's own figure, from its announcement of 2026-07-31.
appeared 2 July 2026Read; moved nothingEnergy and fuel sensingAntecedent Metabolic Health and Metformin Aging StudyOklahoma Medical Research Foundation
A completed placebo-controlled trial of metformin in 166 people free of chronic disease, with the National Institute on Aging among its collaborators. The results posted on the registry show no significant effect of metformin on either main measure, insulin sensitivity (P = 0.576 and 0.488 in the two groups of participants) or the working of the muscle's mitochondria (P = 0.88 and 0.932). It measured short-term biology, not time to disease, and no peer-reviewed report of it was found.
Oklahoma Medical Research Foundation. ClinicalTrials.gov, NCT04264897 (results first posted 2026-07-02, entry updated 2026-11-05). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the registry entry, read through the registry's data interface.
The company reports that the phase 3 trials ZEUS and HERMES of ziltivekimab "did not meet the primary endpoint", that it stopped study treatment and closed HERMES, in heart failure, on its data monitoring committee's recommendation, and that it took an impairment charge of 4.6 billion Danish kroner on the drug. It also says it provides treatment to 5.6 million people living with obesity and that Wegovy has been launched in around 70 countries.
Novo Nordisk A/S. Company announcement, as filed with the United States Securities and Exchange Commission (2026-11-04). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the copy filed with the United States securities regulator. A company's own account of its trials and sales, not a peer-reviewed report.
appeared 4 November 2026Read; moved nothingEnergy and fuel sensingNiagen Bioscience third quarter 2026 financial resultsNiagen Bioscience
The largest seller of the supplement nicotinamide riboside says it has signed an agreement with the Mass General Brigham hospital group to begin planning what it calls the largest trial of its supplement so far, and that it is advancing an experimental drug of its own aimed at rare genetic diseases and disorders of ageing. The release names no condition, size or date for either.
Niagen Bioscience, Inc.. Company release, as filed with the United States Securities and Exchange Commission (2026-11-04). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the copy filed with the United States securities regulator. The title is a short description of the release, not its exact heading.
appeared 27 October 2026Read; moved nothingDamaged DNALow-Dose Danazol for the Treatment of Telomere Related DiseasesNational Heart
The registry entry shows the trial terminated, "stopped due to poor accrual", after 18 people, with results posted on 2026-10-27. The main measure was how many people's telomeres were shortening more slowly after six months: 5 of 8 on the lower dose and 5 of 10 on the higher, with no difference between the doses (P = 0.664) and no untreated group. That is slower shortening, not lengthening.
National Heart, Lung, and Blood Institute (NHLBI). ClinicalTrials.gov, NCT03312400 (results first posted 2026-10-27). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the registry entry, read through the registry's data interface.
appeared 2 November 2026Read; moved nothingBroken proteins and wasteEarly real-world use of acoramidis for transthyretin amyloid cardiomyopathy in Germany: results from StarTTRMorbach and 9 others
From a database covering 82 per cent of reimbursed prescriptions in Germany, the authors found 289 people dispensed acoramidis, the second protein-steadying drug for this heart disease, between April and September 2025. Their median age was 82, 15 per cent were women and 86 per cent had not had such a treatment before; most were started in hospital outpatient departments.
Caroline Morbach, Christoph Ohlmeier, Teresa Trenkwalder, Fabian aus dem Siepen, Silvia Kruppert, Gereon Keuken, Thomas Evers, Roman Pfister, Stefan Herrmann, Stefan Störk. Clinical Research in Cardiology (online 2026-11-02), DOI 10.1007/s00392-026-03023-0. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the abstract in the Europe PMC literature database, with the date and authors confirmed in the Crossref record.
appeared 6 November 2026Read; moved nothingDamaged DNAIn Vivo CRISPR Base Editing of ANGPTL3 for Durable Lipid LoweringMizoguchi and 12 others
The authors describe a single infusion that changes one letter of a liver gene, ANGPTL3, which raises LDL cholesterol and triglycerides. In monkeys it was well tolerated and cut the protein the gene makes by more than 90 per cent on average, with the effect lasting; in human liver cells no editing was found at about 3,000 other candidate sites. It is animal and cell work, not a trial in people.
Taiji Mizoguchi, Jamie E. DeNizio, Alexandra C. Chadwick, Anne Marie Mazzola, Maxwell P. Brown, Shashank Mishra, Manashree Damle, Yuri Matsumoto, Victoria Neang, Ryan Garrity, Manini Mantri, Joy Oshoname Olorife, and 27 more. Nature (online 2026-11-06), DOI 10.1038/s41586-026-11233-9. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the abstract in the Europe PMC literature database, with the date and authors confirmed in the Crossref record.
appeared 2 November 2026Read; moved nothingWorn-out cellsFatty acid desaturation controls cellular fate decisions between senescence and ferroptosisKuehnemann and 12 others
The authors report that aged cells run low on one fatty acid, and that giving it back makes them die. Fed to old mice, it lowered the markers of aged cells and improved measures of function. The abstract reports no effect on length of life.
Chisaka Kuehnemann, Samantha T. Jezak, Bronwyn A. Mogck, Niharika Kura, Rushmeen Tariq, Yuheng Che, Maija Vaittinen, Ioannis Siokas, Sharvari Deshpande, Carlyn Guthrie, Xuejuan Tan, Eliezer Aimontche, and 21 more. Cell (online 2026-11-02), DOI 10.1016/j.cell.2026.09.036. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the abstract in the Europe PMC literature database, with the date and authors confirmed in the Crossref record.
appeared 2 August 2024Read; moved nothingBroken proteins and wasteSubgroup Analysis from a Phase 1/2 Randomized Clinical Trial of 2.6% EDTA Ophthalmic Solution in Patients with Age-Related CataractKuboi and 5 others
A subgroup analysis of a randomised, double-blinded, placebo-controlled early-stage trial of an eye drop, called C-KAD, in people with early age-related cataract. In 41 eyes whose contrast vision was already reduced, it reports better contrast vision than placebo, with lens density analysed in a smaller group. The drop is a different one from the lanosterol drop, and the university's news page says three of the authors are employees of the company that makes it.
Tatsuya Kuboi, Roy S. Chuck, Roberto Pineda, Rajiv Bhushan, Amit Goswamy, Randall J. Olson. American Journal of Ophthalmology 268, 155-164 (2024). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the abstract in the Europe PMC literature database, dated there 2024-08-02, with the journal details confirmed in the Crossref record. The paper's own page was not opened, so the figures in the full paper are unread.
appeared 5 November 2026Read; moved nothingDamaged DNAIntellia Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesIntellia Therapeutics
The company says that during the third quarter it finished enrolling its phase 3 trial of a one-time gene edit in the liver for the nerve form of transthyretin amyloidosis, past its target of 60 people, and that the larger trial in the heart form is still enrolling. It also says that in September the United States regulator accepted its licence application for a different in-body gene editor, for hereditary angioedema, with priority review and a decision date of 2027-03-10.
Intellia Therapeutics, Inc.. Company release, as filed with the United States Securities and Exchange Commission (2026-11-05). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the copy filed with the United States securities regulator. The registry entry for the nerve trial, updated 2026-11-05, shows 67 people enrolled and main results expected in July 2027.
appeared 2 November 2026Read; moved nothingWorn-out cellsFirst Human Administration of Senolytic Immunotherapy to Fight Cellular Aging Announced by Immorta BioImmorta Bio
The company announces that a first person has been given its treatment meant to prompt the immune system to find and remove aged cells. The release gives no trial registry number and no measurement of aged cells, and the treatment is not made of engineered immune cells.
Immorta Bio, Inc.. Company release on PR Newswire (2026-11-02). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the release on the wire service's own page. A company's claim with no registry entry or paper behind it.
appeared 3 November 2026Read; moved nothingInflammation and the body's messagingFecal Microbiota Transplantation (FMT) to Slow Biological AgingHuman Biome
The registry lists a planned randomised, double-blind, placebo-controlled trial of gut-microbe capsules to slow biological ageing, in 68 adults aged 45 to 80. It has not started recruiting; the estimated start is December 2026 and the estimated end December 2027. The main measure is a response on the DunedinPACE ageing-pace clock or on inflammation markers.
Human Biome S.A. (sponsor). ClinicalTrials.gov registry entry NCT07912164, first posted 2026-11-03. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09. A registration with no result, so it moves nothing.
appeared 3 November 2026Read; moved nothingBroken proteins and wasteLong-Term Impact of Vutrisiran in Patients With TTR Amyloidosis With Cardiomyopathy: 1-Year Efficacy and Safety Outcomes From the HELIOS-B Open-Label ExtensionGarcia-Pavia and 19 others
Of 654 people in the original heart trial, 466 entered the open-label extension. Through month 48, those on vutrisiran throughout had a 37 per cent lower risk of death or a first heart event than those who started it after placebo (hazard ratio 0.63, 95 per cent confidence interval 0.51 to 0.79), and the same for death alone (0.63, 0.46 to 0.84). Health-status scores and heart-failure class were better, and no new safety signals appeared.
Garcia-Pavia P, Witteles R, Morbach C, Delgado D, Kitaoka H, Maurer MS, van der Meer P, Yilmaz A, Algalarrondo V, Solomon SD, Cappelli F, Azevedo O, Tang WHW, Lairez O, Boyle KL, Eraly SA, Bao Y, Bender S, Vest J, Fontana M. Circulation (online 2026-11-03), DOI 10.1161/circulationaha.126.080735. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 from the abstract and record in the Europe PMC literature database. The journal's own page was not opened. It follows up a drug that is already approved for this use, so the treatment's stage does not change.
appeared 6 November 2026Read; moved nothingBroken proteins and wasteEffectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective StudyFudan University
A registry entry for a look back at the records of an estimated 3,000 people with Alzheimer's disease given disease-modifying treatment in ordinary care in China, measuring safety and how well the treatment worked. It began on 2026-10-26 and is due to finish its main part in June 2027. No result exists.
Fudan University. ClinicalTrials.gov, NCT07923812 (first posted 2026-11-06). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the registry entry, read through the registry's data interface.
appeared 9 November 2026Read; moved nothingEnergy and fuel sensingFDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye ConditionUnited States Food and Drug Administration
The United States regulator requires the labels of the drugs of the weight-loss and diabetes family to warn of a possible raised risk of a rare, sudden loss of sight in one eye. Its pooling of 126 randomised trials in 134,253 people found 15 probable cases, 10 on these drugs and 5 on placebo: 6.4 against 3.8 cases for every 100,000 people treated for a year.
United States Food and Drug Administration. FDA Drug Safety Communication (2026-11-09). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the regulator's own page.
appeared 6 March 2026Read; moved nothingReplacing lost cells and partsWorld's First iPSC-Derived Cardiomyocyte Therapy for Heart Failure Receives Conditional Approval in JapanCuorips
The company announces that Japan's Ministry of Health, Labour and Welfare granted conditional and time-limited marketing approval for its sheets of heart muscle cells grown from reprogrammed donor cells, for people with severe heart failure after heart attacks. A second notice from the company, dated 2026-10-01, says the product came under public health insurance on 2026-09-01 and was first used under that cover on 2026-09-29 at a hospital in Osaka. The Japanese regulator's list of review reports shows the product as approved in March 2026.
Cuorips Inc.. Company release (2026-03-06). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the company's own two notices; the regulator's list of review reports was opened and shows the product, but the review report itself was not read.
appeared 2 November 2026Read; moved nothingDamaged DNACRISPR Therapeutics third quarter 2026 financial results and business updateCRISPR Therapeutics
The company says the United States regulator has granted its in-body gene editor CTX310, which switches off a liver gene that raises blood fats, two Regenerative Medicine Advanced Therapy designations: for severe high triglycerides and for raised LDL cholesterol. The designations bring early meetings with the regulator and possible priority review; they are not an approval, and the editor is still in its first trial.
CRISPR Therapeutics. Company release, as filed with the United States Securities and Exchange Commission (2026-11-02). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the copy filed with the United States securities regulator. The title is a short description of the release, not its exact heading.
appeared 4 November 2026Read; moved nothingBroken proteins and wasteLecanemab in Singapore: Appropriate use recommendations for early Alzheimer's diseaseChen and 8 others
National recommendations for Singapore's doctors on which patients with early Alzheimer's disease should be given lecanemab, the first of the amyloid-clearing antibodies, and how they should be watched with brain scans and gene tests. The paper states that the antibody is approved in Singapore. It gives no figure for how many people there receive it.
Christopher Li-Hsian Chen, Nagaendran Kandiah, Sumeet Kumar, Kim En Lee, Tan Ming Liew, Adeline Su Lyn Ng, Kok Pin Ng, Laura Bee Gek Tay, Simon Kang Seng Ting. Annals of the Academy of Medicine, Singapore 55 (online 2026-11-04), DOI 10.47102/annals-acadmedsg.2026185. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the abstract in the Europe PMC literature database, with the date and authors confirmed in the Crossref record.
appeared 30 October 2026Read; moved nothingThe cell's settingsMeasuring ageingTirzepatide and Organ-Specific Biological Aging: A Parallel-Design Feasibility Study Using Proteomic Organ Clocks in a Preventive Brain Health CohortAtria Research and Global Health Institute
A registry entry for a study of the weight-loss and diabetes drug tirzepatide in an estimated 22 people, whose main measure is the change after six months in a brain age read from blood proteins. A company that sells organ-age tests is named as collaborator. It is enrolling by invitation and has no result.
Atria Research and Global Health Institute (ARGHI). ClinicalTrials.gov, NCT07906041 (first posted 2026-10-30, updated 2026-11-02). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the registry entry, read through the registry's data interface.
appeared 18 May 2026Read; moved nothingMeasuring ageingIntrinsic Capacity Framework for Geroscience and Healthspan Trials: A ConsensusGroup
A working group convened by the United States health research agency gives the regulator its agreed recommendations on measuring a person's physical and mental capacity in five parts and using it as an outcome in trials of treatments for ageing. The document says it "does not claim" that the measure is a validated stand-in for death or disability, or that a single combined score is ready to be the main measure for approving a drug.
ARPA-H Convened Working Group. Consensus statement to the United States Food and Drug Administration, published by the Advanced Research Projects Agency for Health (2026-05-18). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the document on the agency's own site; its opening pages were read, not all 46.
A registry entry from the maker of the supplement urolithin A for a study in an estimated 24 healthy adults of how two forms of it are taken up into the blood. It is not yet recruiting and measures no function of ageing.
Amazentis SA. ClinicalTrials.gov, NCT07925853 (first posted 2026-11-09). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-09 (its second run that day) from the registry entry, read through the registry's data interface.
The peer-reviewed report of the ZEUS trial replaces the company's announcement as the source for the result, so the notes say so. Source: Ridker and 32 others, 7 November 2026.
The estimate moves later because the ZEUS trial failed: its full report (Ridker and colleagues, New England Journal of Medicine, 2026-11-07) found no fewer heart attacks, strokes or heart deaths on ziltivekimab. The earliest year had allowed for a second drug helping colchicine into routine use; with ziltivekimab's remaining trials not due to report until 2027, it now rests on colchicine alone. Source: Ridker and 32 others, 7 November 2026.
The estimate moves later because the ZEUS trial failed. Two large trials of drugs acting on inflammation have now come back against (the 2025 colchicine trial after a heart attack, and ZEUS), and the trial's lead author said on 2026-11-07 that colchicine is still under-used, so the most likely year for wide use moves three years later. Source: Ridker and 32 others, 7 November 2026.
The estimate moves later because the ZEUS trial failed. The latest year had allowed for one negative trial keeping the treatment a niche choice; with a second, it allows longer, until a different drug acting further up the chain of inflammation proves itself. Source: Ridker and 32 others, 7 November 2026.
Rewritten on 2026-11-09 to give the reason for the later years: the ZEUS trial's full report, and what it leaves wide use resting on. Source: Ridker and 32 others, 7 November 2026.
The estimate was set again on 2026-11-09, when the ZEUS trial's full report moved it later.
Logged 1 November 2026
appeared 29 October 2026Read; moved nothingBroken proteins and wasteAlnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period ProgressAlnylam Pharmaceuticals
The company reports sales of its heart-amyloid drug vutrisiran (Amvuttra) of $1,130 million in the third quarter of 2026, and $1,150 million with its older drug patisiran, 59 per cent more than a year earlier for the two drugs together. It also raises the target enrolment of its pivotal trial of the next drug, nucresiran, in transthyretin amyloid heart disease to 2,250 people, and says it still expects a launch for that disease by 2030. The release gives revenue, not the number or share of eligible patients treated.
Alnylam Pharmaceuticals, Inc.. Company results release, 2026-10-29, filed as an exhibit to a Form 8-K with the US Securities and Exchange Commission. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged by the weekly reading of 2026-11-01. This is the company's own results release, read in full on 2026-11-01 from the copy filed with the US Securities and Exchange Commission; the figures are the company's statements.
The Amsterdam liver trial report was read in full on 2026-10-20. Its sequencing compares each group's end with its own start, not the treated group with the placebo group, and it replaced the planned count of aged cells with gene patterns read from pooled biopsies. The stage and the years are unchanged. Source: Koning and 34 others, 1 October 2026.
The Amsterdam liver trial report, earlier read from its abstract, was read in full on 2026-10-20. Its main figures match the abstract; the full text adds how the dropouts were counted, how much the result depends on that, and a difference between the groups at the start, which this entry now says. The stage and the years are unchanged. Source: Koning and 34 others, 1 October 2026.
The COSMOS clock paper, read in full on 2026-10-19, reports that the cocoa extract slowed no clock but that PCPhenoAge rose slightly faster with it than with placebo; the paper's own record was corrected that day and this note, written from the abstract, is brought into line on 2026-10-20. The stage and the years are unchanged. Source: Li and 9 others, 9 March 2026.
The 2023 Stanford report was read in full on 2026-10-20. Its fifteen-year follow-up is for heart failure; its brain result is a higher risk of dementia worsening within five years. The stage, its date and the years are unchanged.
The 2023 Stanford report and its 2025 follow-up, earlier read from their abstracts, were read in full on 2026-10-20, which answers part of the open question in this entry's notes about calendar age. The stage, its date and the years are unchanged.
After the COSMOS clock paper was read in full on 2026-10-19: the stage is now dated to that paper's publication, because its authors state the clock study was planned before the trial's data were unlocked, which the 2023 CALERIE paper's analysis was not. The stage itself, first human, does not change. He was told that the paper gives no dated plan, does not show the reworked clocks were named in advance, and made no correction for testing five clocks, and the description says so. Source: Li and 9 others, 9 March 2026.
Because its clock study was planned before the trial's data were unlocked, the COSMOS clock paper in Nature Medicine replaces the 2023 CALERIE paper as the record of this entry's stage; the CALERIE paper stays on the record as an earlier report that does not settle it. Source: Li and 9 others, 9 March 2026.
So that the description tells a reader plainly that the authors state the plan came first but give no dated plan, that the reworked clocks were not shown to be named in advance, and that there was no correction for testing five clocks. The old wording also called the CALERIE analysis pre-planned, which its paper does not: the paper calls it post hoc, decided on after the fact. Source: Li and 9 others, 9 March 2026.
The stage record moved on 2026-10-19 to the COSMOS clock paper, so the notes say so. Source: Li and 9 others, 9 March 2026.
Logged 18 October 2026
appeared 26 November 2025Read; moved nothingMeasuring ageingOrgan-specific proteomic aging clocks predict disease and longevity across diverse populationsWang and 24 others
Using blood-plasma proteins and machine learning, the authors built an organismal and ten organ-specific ageing clocks in 43,616 UK Biobank people and validated them in cohorts from China (3,977 people) and the United States (800 people; cross-cohort correlations 0.98 and 0.93). Accelerated organ ageing predicted disease onset, progression and death beyond clinical and genetic risk factors, with brain ageing the most strongly linked to death; a brain clock also stratified Alzheimer's disease risk across APOE gene types.
Wang Y, Xiao S, Liu B, Jiang R, Liu Y, Hang Y, Chen L, Chen R, Vitiello MV, Bennett D, Wang B, Lv J, and 13 others (25 in all). Nature Aging (2026), pages 162-180; published online 2025-11-26. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added in the change to the records on 2026-10-18, on the audit's point about two more organ-clock papers (the audit, on 2026-10-18, of the first scheduled weekly reading). Checked 2026-10-18: the open full text at PubMed Central (PMC12823432) was read through its XML text; the date is the first publication date in the Europe PMC record. The clocks are the authors' own, built from a different protein platform (Olink) than the Stanford group's; the American validation cohort of 800 is below the thousand that the test for the treatment "An age for each organ is read from the proteins in a person's blood" asks for, the Chinese cohort of 3,977 is above it.
appeared 19 September 2024Read; moved nothingWorn-out cellsSenolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial (registry entry with results posted)Steadman Philippon Research Institute
A phase 1 and 2, randomised, quadruple-masked, placebo-controlled trial of fisetin (100 mg capsules, about 20 mg per kilogram a day, on two consecutive days, 28 days off, then two more days) in knee osteoarthritis. 74 people started (34 on fisetin, 40 on placebo; the entry's enrolment count is 75). The main measure was safety: 28 people on fisetin and 33 on placebo had at least one adverse event (p above 0.9). None of the secondary measures differed between the groups at the 0.05 level: knee pain and function questionnaires (p 0.44 to above 0.99), walking and strength tests, cartilage on MRI (p above 0.99) and blood markers (the lowest p was 0.0829, for one marker at six months).
Steadman Philippon Research Institute (sponsor); principal investigator Thomas A. Evans, MD, The Steadman Clinic. ClinicalTrials.gov, registry number NCT04210986; results first posted 2024-09-19; status verified 2024-09, completed 2023-02-01. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added in the change to the records on 2026-10-18, on the audit's point about a fisetin trial in knee arthritis (the audit, on 2026-10-18, of the first scheduled weekly reading). Checked 2026-10-18 through the registry's data interface (https://clinicaltrials.gov/api/v2/studies/NCT04210986), which returns the full entry; the study page itself is an empty shell to a page reader. A conference abstract titled 'Results: from a randomized clinical trial evaluating the senolytic fisetin for treating knee osteoarthritis' (Tashman, Philippon, Dornan and Huard; Osteoarthritis and Cartilage 33, April 2025, page S456; https://doi.org/10.1016/j.joca.2025.02.667; details from the Crossref record) exists; its text was not read (the page is an empty shell) and which trial it reports was not checked, so this record rests on the registry entry alone. The scheduled weekly reading of 2026-10-18 gave the registry number NCT04770064 (a trial called ROPE) for a null fisetin result with 74 people; that entry is withdrawn ('Funding was not awarded', enrolment 0, never run).
appeared 29 May 2024Read; moved nothingWorn-out cellsEnergy and fuel sensingA randomized, controlled clinical trial demonstrates improved owner-assessed cognitive function in senior dogs receiving a senolytic and NAD+ precursor combinationSimon and 9 others
In a randomised, placebo-controlled trial of 70 dogs aged ten or more with mild to moderate cognitive impairment (23 on placebo, 23 on a low dose and 21 on a full dose of a combined NAD-raising and aged-cell-clearing supplement for three months), the owner-rated cognition score changed differently between groups (p = 0.02, the largest improvement in the full-dose group). Activity monitors, the in-clinic cognitive tests, frailty (p = 0.32) and owner-rated happiness (p = 0.34) did not differ between groups; all groups improved, which the authors say suggests a placebo effect and the benefits of taking part; and the cognition gain was not kept at six months. By the abstract's count 59 dogs completed the three-month check (the results text says 62).
Katherine E. Simon, Katharine Russell, Alejandra Mondino, Chin-Chieh Yang, Beth C. Case, Zachary Anderson, Christine Whitley, Emily Griffith, Margaret E. Gruen, Natasha J. Olby. Scientific Reports 14, article 12399 (2024); received 2024-02-17, accepted 2024-05-23. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added in the change to the records on 2026-10-18, on the audit's point about the peer-reviewed paper behind David Sinclair's dog-supplement claim (the audit, on 2026-10-18, of the first scheduled weekly reading). Checked 2026-10-18: the open copy at PubMed Central (https://pmc.ncbi.nlm.nih.gov/articles/PMC11137034) was read in full, through its XML text. The paper says the trial was funded by 'Animal Bioscience, Boston MA', which 'played no role in data acquisition, analysis or presentation', and the authors declare no competing interests. It bears on David Sinclair's claim of 2024-02-29 about a dog supplement, which is a claim, not a treatment, and so is named here only in these notes.
appeared 29 June 2026Read; moved nothingMeasuring ageingAssociations of proteomic age clocks with lifestyle risk factors, incident chronic diseases and mortality in two European cohortsRobinson and 27 others
In 17,473 participants of the European Prospective Investigation into Cancer and Nutrition followed for up to 28 years (with the mortality results replicated in 6,240 people in the Whitehall II study), blood-protein ageing clocks, including organ-specific clocks, were linked to smoking, alcohol, inactivity and a higher risk of death, cardiovascular disease, dementia and cancers of the liver, upper airways and digestive tract, lung and kidney. Lung, kidney and stomach cancers were more strongly linked to the related organ's age gap (the kidney age gap and kidney cancer, hazard ratio 1.63, 95 per cent confidence interval 1.36 to 1.94). The authors say that before this only the organ clocks of Oh and colleagues had been independently tested for disease onset across disease classes in a longitudinal setting.
Robinson O, Xiao H, Homann J, Viallon V, Ferrari P, Frank P, Huerta JM, Jiménez Zabala A, Kaaks R, Katzke VA, Kivimaki M, Langenberg C, and 16 others (28 in all). Nature Aging (2026), pages 1437-1451; published online 2026-06-29. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added in the change to the records on 2026-10-18, on the audit's point about two more organ-clock papers (the audit, on 2026-10-18, of the first scheduled weekly reading). Checked 2026-10-18: the open full text at PubMed Central (PMC13375651) was read through its XML text. The organ-specific clocks tested here use the weights of Oh and colleagues (the Stanford group's), so this is an independent test of those clocks, in a different cohort; the paper also uses five earlier whole-body clocks for comparison. Its mortality comparison sets a model of calendar age and sex (concordance index 0.71) against the combined Global age gap (0.73), not each organ clock against calendar age.
appeared 26 October 2021Read; moved nothingMeasuring ageingMitochondrial phenotypes in purified human immune cell subtypes and cell mixturesRausser and 11 others
In 21 healthy adults aged 20 to 59, platelets stuck to a blood sample made its mitochondrial measures read 9 to 22 per cent high, and platelet count fell about 6 per cent per decade of life, which could account for the fall in blood mitochondrial DNA with age seen in earlier studies. In sorted white-cell types the count per cell rose with age, a difference hidden in mixed cells. The authors say larger studies are needed.
Shannon Rausser, Caroline Trumpff, Marlon A. McGill, Alex Junker, Wei Wang, Siu-Hong Ho, Anika Mitchell, Kalpita R. Karan, Catherine Monk, Suzanne C. Segerstrom, Rebecca G. Reed, Martin Picard. eLife 10, e70899 (2021). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
appeared 19 June 2021Read; moved nothingMeasuring ageingBlood mitochondrial DNA copy number: What are we counting?Picard
A review arguing that the count of mitochondrial DNA in blood is set mostly by which kinds of white cells and how many platelets a sample holds, is not a measure of how well mitochondria work, and can signal trouble when high or low; it asks studies to record platelets and white-cell types or to use purified cells.
Martin Picard. Mitochondrion 60, 1–11 (2021). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
appeared 9 March 2026Settled a stageMeasuring ageingEffects of daily multivitamin-multimineral and cocoa extract supplementation on epigenetic aging clocks in the COSMOS randomized clinical trialLi and 9 others
A prespecified ancillary study of the COSMOS randomised, placebo-controlled trial, in 958 people (482 women, 476 men) given a daily multivitamin-multimineral tablet (Centrum Silver) or cocoa extract for two years, measured five DNA-methylation clocks (PCHannum, PCHorvath, PCPhenoAge, PCGrimAge and DunedinPACE). The multivitamin slowed the yearly rise of PCGrimAge by 0.113 years (95 per cent confidence interval 0.020 to 0.205; P = 0.017) and of PCPhenoAge by 0.214 years (0.019 to 0.410; P = 0.032), and slowed PCGrimAge more in people with faster-than-expected ageing at the start. The cocoa extract slowed none of the five clocks; on one, PCPhenoAge, the yearly rise was slightly faster with cocoa than with placebo (0.202 years; P = 0.044), which the authors think may partly reflect chance differences between the groups at the start. The authors call the effects small and say more studies are needed to know whether they matter clinically.
Li S, Hamaya R, Zhu H, Chen BH, Pereira AC, Ivey KL, Rist PM, Manson JE, Dong Y, Sesso HD. Nature Medicine (2026), pages 1012-1022; published online 2026-03-09. Read it.
Added in the change to the records on 2026-10-18, on the audit's point about the COSMOS multivitamin paper (the audit, on 2026-10-18, of the first scheduled weekly reading). Checked 2026-10-18: the journal's own page needs a sign-in for a page reader, so this record states what the abstract says, read in the Europe PMC record of the paper (PubMed number 41803341); the first sentence of the abstract calls it a prespecified ancillary study. Harvard's news report of 2026-03-09 says all five clocks slowed with two significant; the abstract names the two and says nothing of the other three. The paper is not marked as having settled a stage: whether it should replace the 2023 CALERIE paper as the record of the stage of the treatment "A treatment slows a biological age clock in a controlled trial" is mine to rule (see the treatment's notes).
Checked 2026-10-19, on my agreement of that day to make this paper the stage record if its methods showed the clock analysis was planned before the data were unblinded and the clocks were named in advance. The full text still needs a sign-in, and the paper is not in PubMed Central, so the methods themselves were not read. Four open sources were read instead. (1) The journal's reporting summary, which the authors last updated on 2026-01-05 (https://media.springernature.com/original/springer-static/esm/art%3A10.1038%2Fs41591-026-04239-3/MediaObjects/41591_2026_4239_MOESM2_ESM.pdf): it gives two trial registrations, the main COSMOS trial (https://clinicaltrials.gov/study/NCT02422745) and this clock study (https://clinicaltrials.gov/study/NCT05510375); it says the treatments ran until 2020-12-31, that participants, investigators and the people analysing the data were kept unaware of who took what, that the study was first planned for 600 people on one grant, and that the paper uses re-computed, steadier versions of the Horvath, Hannum, PhenoAge and GrimAge clocks (the method of Higgins-Chen and colleagues) and DunedinPACE. It does not say when the analysis plan was fixed. (2) The clock study's registration was first submitted on 2021-09-15, after the treatments had ended, and first posted on 2022-08-22; it names its main measure only as "epigenetic age acceleration", with no clock named. (3) The grant that paid for it (National Institutes of Health, R01HL157665, awarded 2021-07-15, https://reporter.nih.gov/project-details/10185971) names the clocks as the original Horvath, Hannum, GrimAge and PhenoAge clocks and a blood measure of the length of the chromosome tips (telomeres), for 600 people, and states its main hypothesis about the cocoa extract; the multivitamin is to be looked at in parallel. (4) The main trial's protocol, in its version of 2024-04-01 (https://cdn.clinicaltrials.gov/large-docs/45/NCT02422745/Prot_000.pdf), lists the same clocks in the same words. So: a clock study of this trial was planned and paid for before its results, and GrimAge and PhenoAge, the two clocks the multivitamin slowed, were named in advance. But no open source shows the plan was fixed before the data were unblinded (the earliest dated plan, the grant of 2021-07-15, comes after the treatments ended), the paper reports re-computed versions of those clocks rather than the ones named, adds DunedinPACE and drops the telomere measure, and the hypothesis named in advance was about the cocoa extract, which moved no clock. The condition was not met from open sources, so this paper is still not marked as settling the stage, and the question goes back to me.
Read in full on 2026-10-19, in the published paper (Nature Medicine, volume 32, pages 1012 to 1022, March 2026, with its online Methods and nine extended-data items; the separate supplementary file, with Supplementary Tables 1 and 2 and Supplementary Figure 1, is referred to but was not part of the copy read). On the four points my condition turns on: (1) Planned before unblinding. The Methods say the clock study "was prespecified before the data unlock and completion of the parent COSMOS trial", and the results section says the authors prespecified clock measures read from blood DNA as the main outcomes. No date is given for that plan, and the paper names no analysis plan beyond its trial registration, which was first submitted on 2021-09-15. So the paper states the plan came first but does not show when. (2) The clocks named in advance. The paper says what was prespecified only as "epigenetic aging measures"; it does not say the five clocks were named in advance. It says the authors "focused on" five clocks and used the re-computed, steadier versions of the first four (the method of Higgins-Chen and colleagues, published in Nature Aging in 2022) because they are more reliable, without saying that choice was made before the results were seen. The grant of 2021 named the original versions and a telomere measure, not the re-computed versions or DunedinPACE, so the two results the paper rests on, on PCGrimAge and PCPhenoAge, are on versions of the clocks that no dated plan names. (3) The main comparison. The paper states one main hypothesis for both supplements together, that they could slow biological ageing; it does not make either the main comparison, and the grant's main hypothesis was about the cocoa extract. The cocoa extract slowed no clock, though PCPhenoAge rose slightly faster with it; the earlier lines here that said it had no effect on any clock are corrected in the finding above. (4) Testing five clocks. The paper made no correction for testing five clocks on two supplements, because the clocks are closely related (the two-year changes on PCGrimAge and PCPhenoAge move together, with a correlation of 0.80), and its list of limits says "false positives are likely to occur". With the simplest correction for five clocks (a threshold of 0.01 in place of 0.05), neither of the multivitamin's two results would count as significant; that is this record's arithmetic, not the authors'. So the condition is met only in part: the paper says the clock study was planned before the data were unlocked, but gives no date, and does not show that the clock versions its result rests on were named in advance. The paper is still not marked as settling the stage, and the question goes back to me.
On 2026-10-19 this paper became the record of the stage of the treatment "A treatment slows a biological age clock in a controlled trial", because its authors state the clock study was planned before the trial's data were unlocked, so it is now marked as settling that stage (first human, dated 2026-03-09), and the treatment's description says what the paper does not show.
appeared 6 August 2026Read; moved nothingDamaged DNAIntellia Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesIntellia Therapeutics
The company says that a genomic analysis of more than 600 patient samples from its trials of the in-body gene editor nexiguran ziclumeran (nex-z), done with its partner Regeneron and outside experts, found the highest liver-enzyme (transaminase) rises in patients carrying one specific immune-gene variant (an HLA allele, which the release does not name). It says it is engaging the United States regulator and other health authorities about the finding, will give genotyping results to the doctors and patients in the two ongoing late-stage trials, and restarted enrolment in them in the second quarter. It also says it expects the regulator to accept its licence application for a different editor, lonvo-z, for hereditary angioedema in the second half of 2026.
Intellia Therapeutics, Inc.. Company press release, Cambridge, Massachusetts, 2026-08-06, distributed by GlobeNewswire. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added in the change to the records on 2026-10-18, on the audit's point about gene editing inside a person (the audit, on 2026-10-18, of the first scheduled weekly reading). Checked 2026-10-18: the release was read as the wire text carried by BioSpace (https://www.biospace.com/press-releases/intellia-therapeutics-announces-second-quarter-2026-financial-results-and-business-updates), with the dateline 'Aug. 06, 2026 (GLOBE NEWSWIRE)'. The company's own page refused the page reader used for this check (access denied); the scheduled weekly reading of 2026-10-18 had opened it there. The figures and the sentence about the allele are the release's own words in substance; the allele is not named.
appeared 20 August 2026Read; moved nothingInflammation and the body's messagingResolution of the Federal Joint Committee on an Amendment of the Pharmaceuticals Directive: Annex XII, Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V: Colchicine (known active ingredient with new data protection: for the prevention of ischaemic cardiovascular events in patients with atherosclerotic CHD following a myocardial infarction)Federal Joint Committee
Germany's Federal Joint Committee, which rules on the added benefit of medicines, resolved on 2026-08-20 that colchicine added to optimised standard therapy, in adults with coronary heart disease and a recent heart attack, has a hint of a minor additional benefit over standard therapy alone, on the evidence of the COLCOT trial. The resolution gives the German marketing authorisation as of 2025-08-02, for the prevention of ischaemic cardiovascular events in those adults.
Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA), Germany. Regulator's resolution of 2026-08-20, in force the same day (courtesy English translation; only the German version is legally binding). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added in the change to the records on 2026-10-18, on the audit's point about colchicine in Germany (the audit, on 2026-10-18, of the first scheduled weekly reading). Checked 2026-10-18: the resolution's PDF was opened and its text read (the tool that fetched it returned it as compressed binary data, so it was read with the computer's own PDF reader): the date of the resolution, the date of the marketing authorisation, the indication, the sentence 'Hint of a minor additional benefit' and the named trial are all on its first three pages. The press statement that the drug has been on the German market since 2026-03-01 is not in the notice and is not used here.
appeared 1 November 2017Read; moved nothingMeasuring ageingAssociation of mitochondrial DNA copy number with cardiovascular diseaseAshar and 13 others
In 21,870 people in three studies followed for 13.5 years on average, a one-standard-deviation lower count of mitochondrial DNA in blood went with a 23 per cent higher risk of heart disease or stroke (hazard ratio 1.23, 95% interval 1.19 to 1.26), unchanged after allowing for the usual risk factors, and adding the count to a standard risk equation improved how people were sorted into risk groups.
Foram N. Ashar, Yiyi Zhang, Ryan J. Longchamps, John Lane, Anna Moes, Megan L. Grove, Josyf C. Mychaleckyj, Kent D. Taylor, Josef Coresh, Jerome I. Rotter, Eric Boerwinkle, Nathan Pankratz, Eliseo Guallar, Dan E. Arking. JAMA Cardiology 2(11), 1247–1255 (2017). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
appeared 4 December 2014Settled a stageMeasuring ageingAssociation of mitochondrial DNA levels with frailty and all-cause mortalityAshar and 11 others
In 16,401 people in two long-running studies, a lower count of mitochondrial DNA copies in blood went with dying sooner: the lowest fifth had a 47 per cent higher chance of death than the highest fifth (hazard ratio 1.47, 95% interval 1.33 to 1.62), after allowing for age and sex. The count fell with age, and a lower count went with frailty in one group.
Foram N. Ashar, Anna Moes, Ann Z. Moore, Megan L. Grove, Paulo H. M. Chaves, Josef Coresh, Anne B. Newman, Amy M. Matteini, Karen Bandeen-Roche, Eric Boerwinkle, Jeremy D. Walston, Dan E. Arking. Journal of Molecular Medicine 93(2), 177–186 (2015). Read it.
The weekly reading of 2026-10-18 reported a second fisetin trial, and the audit of that reading the same day asked for a reading of the full source; it was done through the registry's data interface on 2026-10-18. What the reading reported (a second fisetin trial, ROPE, with a null result) is not supported: ROPE was withdrawn. What the registry does support is that the trial already named here has reported, with no benefit on its secondary measures; that is what is applied. The estimate is untouched. Source: Steadman Philippon Research Institute, 19 September 2024.
The weekly reading of 2026-10-18 added the company's own account of the liver-enzyme finding, which the description of 2026-10-17 did not carry. An audit of that reading, on 2026-10-18, proposed two changes to this entry, and the first change only was made, in the change to the records on 2026-10-18. The second (a note that an approval of the editor lonvo-z for hereditary angioedema would not reach the clinic rung under this test) waits until the company's own release on the regulator's acceptance has been opened. The company's report of 2026-08-06 was read as carried by BioSpace. The stage and the years are unchanged. Source: Intellia Therapeutics, 6 August 2026.
Wording corrected on 2026-10-18: "records studies" meant studies of medical records, such as the UK general-practice records study by Bannister and colleagues, 2014; the reasoning behind the estimate had the same slip ("records evidence") and is corrected the same way. No fact changed. Source: Bannister and 7 others, 31 July 2014.
An audit on 2026-10-18 of the weekly reading of that date asked whether the highest-dose group was 12 or 16 people. The abstract (read through Europe PMC on 2026-10-18) says 16 patients were treated with the safe maximal dose and 12 of them completed the prespecified 3-month interim follow-up; the German centre's release of 2026-05-29 says the first 16 given the highest safe dose were analysed. Both numbers are right, and the description had run them together. The date needed no change: the publication record gives online 2026-05-27 and the issue dated 2026-05-28. Applied on 2026-10-18; the stage and the years are unchanged. Source: Zimmermann and 34 others, 27 May 2026.
Found by the weekly reading of 2026-10-18 and applied in the change to the records on 2026-10-18, on the audit of that reading: the resolution's PDF was opened and read (date, authorisation date, indication, the sentence on added benefit). The press statement that the drug has been on the German market since 2026-03-01 is not in the notice and is left out. Source: Federal Joint Committee, 20 August 2026.
Corrected on 2026-10-18, under the rule that each possible error found in the wording pass is checked against its source: the start in 2021 comes only from the supplier's release (Grifols, 2026-03-12, which calls the centre's programme operational since 2021); the centre's own announcement of 2026-04-27, read again on 2026-10-18, does not give the year. No stage or date changed. Source: Grifols, 12 March 2026.
The weekly reading of 2026-10-18 found the paper, and the audit of that reading the same day asked for a reading of the full source; the abstract was read through Europe PMC on 2026-10-18 and the paper logged. Applied as a note only on 2026-10-18; the record cited for the stage and its date are not changed, and whether it should change is still open. The estimate is untouched. Source: Li and 9 others, 9 March 2026.
The weekly reading of 2026-10-18 reported both papers, and the audit of that reading the same day asked for a reading of the full sources; both papers' open copies at PubMed Central were read on 2026-10-18 and the papers logged. The kidney figure the reading gave (1.6) is in the text as 1.63. Applied on 2026-10-18; the stage, the years and the open question are unchanged. Source: Robinson and 27 others, 29 June 2026.
Logged 17 October 2026
appeared 27 May 2026Read; moved nothingReplacing lost cells and partsStem-Cell-Derived Biologic Ventricular Assist Tissue in Heart FailureZimmermann and 34 others
In an open-label phase 1-2 study with no comparison group, 20 people with heart failure (ejection fraction 35 per cent or less) were given patches of engineered heart muscle made from donor stem cells, with drugs to prevent rejection. Three died during the study (one each of vasoplegia, covid-19 and aortic dissection) and one had a heart transplant. Of the 16 given the highest dose, 12 had reached the 3-month interim follow-up: the treated wall was 4.5 mm thicker, the heart's ejection fraction was 3.9 percentage points higher (P = 0.04) and a quality-of-life score 6.7 points higher (P = 0.06). Every patient had at least one adverse event.
Wolfram-Hubertus Zimmermann, Stephan Ensminger, Ingo Kutschka, Christina Paitazoglou, Tim Seidler, Soren Brandenburg, Stefan D. Anker, and 28 others (35 in all), for the BioVAT-HF Investigators. New England Journal of Medicine 394(20), 1991-2001 (2026), published online 2026-05-27, issue dated 2026-05-28; trial registered as NCT04396899. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added during the weekly reading of 2026-10-17. The treatment "Heart muscle grown from stem cells is grafted onto a person's failing heart" was already at first human on the 2025 single-case report in Nature (that report is still the record of its stage); this paper is a larger human result of the same kind and is the sort of evidence the next stage needs only in the sense that a regulator would look at it. Because it is an interim, uncontrolled analysis and the next stage is an approval, no stage moves. The paper is not named as the record of the treatment's stage, so it is not marked as having settled a stage.
Checked 2026-10-17: the journal's full text is behind a payment page and has no open copy, so this record states only what the published abstract says (read through the PubMed and Europe PMC records), and every figure above is in that abstract. The registry entry (NCT04396899) was read: a single-group, open-label phase 1-2 study with no masking, an estimated 53 people, still recruiting when last updated on 2026-02-20, primary completion estimated for 2027-12, and a target population described as heart failure with an ejection fraction of 35 per cent or less. The range of follow-up that press releases mention (6 to 52 months) is in neither the abstract nor the registry entry, so it is not recorded here. The abstract also says the drugs that prevent rejection were stopped in four people (two who received a mechanical pump, one with kidney failure and one with a cancer of the urinary tract).
appeared 7 September 2026Read; moved nothingMeasuring ageingIntegration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessmentZhavoronkov and 18 others
The authors applied six published blood-protein ageing clocks to stored blood samples from 42 people with a lung-scarring disease (idiopathic pulmonary fibrosis) in an earlier 12-week, placebo-controlled phase 2a trial of the drug rentosertib, and found that all six predicted a lower biological age in the treated groups than in the placebo group. Of 54 comparisons (six clocks, three time points and three dose regimens, each against placebo), 21 were statistically significant at the authors' adjusted threshold (Q value below 0.10), mostly at week 4. They call the findings exploratory and say the clocks alone cannot tell slower ageing from an improved diseased lung; the strongest effect was in the 30 mg twice-daily group.
Alex Zhavoronkov, Fedor Galkin, Shan Chen, Feng Ren, Alex Aliper, Mikhail Durymanov, Denis Sidorenko, Hui Cui, Jing-Dong J. Han, Hao Xu, Xiaodong Liu, Zuojun Xu, and 7 others, ending with Mahdi Moqri, Alexander Tyshkovskiy and Vadim N. Gladyshev (19 in all). Nature Biotechnology (2026), online 2026-09-07, pages 1 to 13. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added during the weekly reading of 2026-10-17. It is not the record that settles the stage of the treatment "A treatment slows a biological age clock in a controlled trial": the clock analysis was run on samples already collected in a trial that had been published, and the authors call it exploratory, so it was not planned before the data were unblinded, which that treatment's test asks for (the same reason I gave on 2026-10-17 for the 2023 CALERIE paper). The first author is the founder and chief executive of the company that makes the drug.
Checked 2026-10-17 against the full text on the journal's page, which is open to read: the cohort was 42 people from the trial of 71, the 21 of 54 comparisons and the Q value below 0.10 are as the paper states them in its results, and the dose regimen with the most significant comparisons was 30 mg twice daily (nine), ahead of 60 mg once daily (seven) and 30 mg once daily (five). The paper's competing-interests statement names the first author as founder and chief executive of Insilico Medicine.
appeared 20 November 2020Moved an estimateDamaged DNAThe TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary FibrosisThe University of Queensland
The registry lists a phase 2, multi-centre, randomised, placebo-controlled trial in Australia of danazol added to standard care in pulmonary fibrosis (lung scarring) linked to short telomeres, aimed at slowing telomere shortening, started 2021-09-07 with 29 people enrolled. Its status is terminated: the data safety monitoring board recommended stopping for futility, with a primary completion date of 2025-01-16. On 2026-10-17 the registry held five trials of danazol in telomere disease in all: this one; a withdrawn phase 1/2 trial after lung transplant (NCT04807309); a phase 1/2 trial in Paris of unknown status (NCT03710356); and the two completed National Institutes of Health phase 1/2 studies (NCT01441037, the 2016 trial that settled this treatment's stage at first human, and NCT03312400, low-dose danazol). None is a phase 3, and none names a sponsor carrying danazol to an approval.
The University of Queensland (sponsor). ClinicalTrials.gov registry entry NCT04638517, first posted 2020-11-20, last updated 2025-08-05. Read it.
What it moved: the earliest year to reach clinical use for A drug lengthens the ends of chromosomes in a person, 2030 to 2038, on 17 October 2026: Accepted from an outside review's proposal of 2026-10-17 for this range: the earliest had assumed a filing on existing data within four years, and the record's own long-term follow-up (Lee and colleagues, Blood Advances 10, 208 to 212, 2026, https://doi.org/10.1182/bloodadvances.2025017860) found no significant lengthening in the few patients re-measured, so no filing for a lengthening claim can rest on the data in hand; the trial registry shows no sponsor carrying danazol towards an approval (its entry for the TELO-SCOPE trial).; the likely year to reach clinical use for A drug lengthens the ends of chromosomes in a person, 2036 to 2048, on 17 October 2026: Accepted from an outside review's proposal of 2026-10-17 for this range: the likely year had assumed an approval of danazol or a relative around 2034 after a confirmatory trial; the registry shows the one phase 2 trial aimed at telomere attrition (TELO-SCOPE, NCT04638517) stopped for futility, no phase 3 and no sponsor, so a new treatment would have to go through every trial phase.; the latest year to reach clinical use for A drug lengthens the ends of chromosomes in a person, 2070 to 2085, on 17 October 2026: Accepted from an outside review's proposal of 2026-10-17 for this range: with no sponsor in sight, the record's own latest-year clause (no sponsor ever taking a generic drug through the process) looks like the likely case, and the latest moves out with the rest of the range.; the reasoning behind the estimate for A drug lengthens the ends of chromosomes in a person changed, on 17 October 2026: Accepted from an outside review's proposal of 2026-10-17 for this range: the reasoning is rewritten to say which premises failed, on which sources, and what the new years assume. The reviewer overstated one thing, recorded here: the 2016 trial did measure lengthening by its own method, so a confirmatory trial could still do so; the follow-up's finding is in a few samples by a different method.
Logged as the added source behind the change of 2026-10-17 on the outside review's case for the treatment "A drug lengthens the ends of chromosomes in a person": the likely year in the treatment's estimate had assumed a confirmatory trial and an approval of danazol or a relative for a telomere disease around 2034, and the registry shows the one phase 2 trial aimed at telomere attrition stopped for futility and no sponsor in sight. The futility finding is the registry's own stated reason for stopping and was not in the write-up of the review and the decisions on it, which recorded the trial as terminated.
appeared 21 August 2026Read; moved nothingThe cell's settingsMeasuring ageingResponsiveness of epigenetic aging biomarkers to longevity interventions in humansSehgal and 12 others
The authors assembled 51 public and private studies in which people were measured before and after a treatment, and read 16 widely used clocks (estimates of biological age from the chemical marks on DNA) and 94 other DNA-mark measures on every sample. Across the 16 clocks, 19 of the 50 treatments significantly lowered the clocks' readings (13 after correction for multiple testing), 5 raised them and 26 had no significant effect; clocks built to predict death or the pace of ageing responded most, drugs and lifestyle changes drove the strongest responses, and drugs that block the inflammatory messenger TNF moved nearly all of the newer clocks by similar amounts in patients with arthritis or inflammatory bowel disease. It is a reanalysis of existing trial samples, not a trial of its own.
Raghav Sehgal, Daniel Borrus, Jenel F. Armstrong, John Gonzalez, Jessica Kasamoto, Yaroslav Markov, Ahana Priyanka, Ryan Smith, Natàlia Carreras-Gallo, Jessica Lasky-Su, Varun B. Dwaraka, Michael J. Corley, Albert Higgins-Chen. Nature Medicine 32, 3477–3490 (2026), online 2026-08-21, in the issue of 2026-09. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged because the outside review of 2026-10-17 pointed to it (in its part on cells and the cell's settings), alongside the change of the same day on the review's case for the treatment "A person's biological age, read from the marks on their DNA, falls after a treatment". It is the largest published test of whether clocks respond to treatments, which is why it is logged against both that treatment and the treatment "A treatment slows a biological age clock in a controlled trial" on the measuring ageing branch. It moves no stage and no year: it reanalyses other studies' samples, so it is not itself a controlled trial with a pre-planned clock analysis, and it is not a clinic's publication of its practice. The reviewer's reading of it, that it supports an earlier likely year for the biological-age-reading treatment to reach clinical use, was declined, for this reason: the test asks for a treatment given on the strength of a clock, which this paper is not.
appeared 9 July 2026Read; moved nothingEnergy and fuel sensingChanges in Semaglutide Fills Following Expanded FDA and Medicare PoliciesScannell and 4 others
Using national prescription counts from September 2023 to September 2024, the authors found that monthly Wegovy fills rose 136.4 per cent (from 367,371 in February 2024 to 868,301 in September 2024), and that the March 2024 approval to reduce heart events, together with Medicare Part D coverage of it, was associated with an estimated 592,624 additional fills by September 2024 (95 per cent confidence interval 464,446 to 720,803) beyond what earlier trends predicted. Medicare Part D fills of Wegovy rose from 4,689 in February 2024 to 32,732 in September 2024, six months after coverage began; the authors say that is under 1 per cent of an estimated 3.6 million eligible beneficiaries.
Christopher Scannell, John A. Romley, Rebecca Myerson, Dana Goldman, Dima Mazen Qato. The American Journal of Managed Care 32(7), 392-395 (2026), published 2026-07-09. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added during the weekly reading of 2026-10-17. It is the first published uptake figure for the heart-prevention purpose of the weight-loss drug in the treatment "A weight-loss drug is approved to prevent heart attacks and strokes in people without diabetes", and it covers one country and one payer, ending in September 2024. It points the other way from the earliest year for wide use in that treatment's estimate as it stood then, 2027, which I may want to weigh; no year was changed by the reading. Later on 2026-10-17, on an outside review's proposal, the earliest year for wide use moved from 2027 to 2030 and the likely year from 2029 to 2033.
Checked 2026-10-17 against the full text on the journal's page (https://www.ajmc.com/view/changes-in-semaglutide-fills-following-expanded-fda-and-medicare-policies). The figure of 3.6 million eligible beneficiaries is the authors' estimate, taken from a Kaiser Family Foundation brief of 2024-04-24 that they cite. The figures of 4,689 and 32,732 are monthly Part D fills, not a running total. The table of the extra fills by payer was not separately read; the text gives the overall figure.
appeared 9 February 2026Read; moved nothingBroken proteins and wasteA Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related CataractOcusun Ophthalmic Pharmaceutical
The registry lists a phase 2 pilot in the United States of an investigational eye drop, 0.4 per cent ZOC2017217, against a drops-with-no-active-ingredient control, twice a day for 24 weeks in about 40 people aged 50 or over with age-related cataract, quadruple-masked and randomised. Its start date is 2026-02-10, the entry shows 8 people enrolled, and its primary completion is estimated for 2027-02; outcomes include best-corrected vision, contrast sensitivity and lens opacity at weeks 4, 12 and 24.
Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd. (sponsor). ClinicalTrials.gov registry entry NCT07395986, first posted 2026-02-09, last updated 2026-08-11. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added during the weekly reading of 2026-10-17. The registry's status was read from the registry's own data; the reading had described the trial as active but not recruiting. It is a registered controlled human trial of a lanosterol-derived drop, which the estimate for the treatment "Eye drops dissolve the clouded protein of a cataract" said did not exist; it has not reported, so the treatment stays at shown in animals.
The registry entry does not name lanosterol. That the drop is derived from lanosterol, and the exploratory study in China in which 50.0 to 86.4 per cent of participants reached 20/40 vision 12 to 24 weeks after treatment, are the company's own account, in the joint release of 2026-07-14 by the sponsor (Ocusun) and its research organisation (Lexitas Pharma Services), opened and read on 2026-10-17: https://www.biospace.com/press-releases/lexitas-pharma-services-and-ocusun-enroll-first-patient-in-a-pilot-study-for-an-upcoming-phase-iii-clinical-trial-evaluating-investigational-eye-drop-for-age-related-cataract . The release cites no paper for that study, and a search of the Europe PMC literature database on 2026-10-17 found no published report of it, so those figures are the company's statement, not a peer-reviewed result. The release calls this trial a pilot for an upcoming phase 3 trial and says its first patient was enrolled on 2026-07-14, while the registry gives a start date of 2026-02-10.
appeared 31 July 2026Read; moved nothingInflammation and the body's messagingNovo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammationNovo Nordisk
The company says its ZEUS trial of ziltivekimab, a monthly antibody against the inflammatory messenger interleukin-6, in over 6,300 people with hardened arteries, chronic kidney disease and raised inflammation, lowered the expected inflammation markers but did not lower heart attacks, strokes or cardiovascular deaths against placebo (hazard ratio 0.99, 95 per cent confidence interval 0.88 to 1.11). Overall rates of side effects were similar, serious infections were more frequent on the drug, and deaths from any cause did not differ. Full results are to be presented at a scientific meeting later in 2026; two further trials in heart failure and after a heart attack are expected to read out in the first half of 2027.
Novo Nordisk A/S. Company announcement, 2026-07-31 (reference PR260731-ZEUS); the trial is registered as NCT05021835. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added during the weekly reading of 2026-10-17. The largest test since the 2017 canakinumab trial of a drug that acts on inflammation alone, and it found no benefit on heart events; the notes on the treatment "A drug that acts only on inflammation is approved to prevent heart attacks" now carry it beside the 2025 colchicine trial. The years in that treatment's estimate were not changed.
This is a company announcement of top-line results, not a peer-reviewed report, and every figure above is the company's own statement in the release, opened and read in full on 2026-10-17; the full results had not been presented. The trial's registry entry (NCT05021835, "ZEUS", sponsor Novo Nordisk, completed, 6,385 people enrolled, primary completion 2026-06-09) was read on 2026-10-17 and agrees on the design.
appeared 7 July 2025Moved an estimateThe cell's settingsDo you really know your age? How chronological and biological age stack up at Northwestern Medicine's new Longevity ClinicNorthwestern Medicine
The hospital system says its Human Longevity Clinic opened to the public on 2025-07-07, offering tests that were previously reserved for research studies to measure the difference between a person's age in years and their biological age. The tests listed include heart, lung, muscle, balance and memory assessments, retinal imaging and "lab work including molecular clocks that can be used to measure your biological age directly"; patients then meet a longevity physician for lifestyle recommendations, and selected tests are repeated six months later. The page does not name a clock, does not say "epigenetic", and names no published report of the clinic's practice.
Northwestern Medicine. Northwestern Medicine news release, Chicago, 2025-07-07. Read it.
What it moved: the earliest year to reach clinical use for A person's biological age, read from the marks on their DNA, falls after a treatment, 2032 to 2028, on 17 October 2026: An outside review's proposal of 2026-10-17 for this range was accepted in part: the earliest year only. Northwestern Medicine's own release of 2025-07-07 says its Human Longevity Clinic measures molecular clocks of biological age in routine care and repeats selected tests at six months, so a named clinic's publication of a clock-monitored practice, which the test's clinic rung allows, could come within a few years rather than the six the old earliest assumed. The reviewer's proposed likely year (2035) and latest (2070) were declined: the test asks for a treatment given on the strength of a clock result, which no clinic has published, and the likely year is tied to the regulator's acceptance of a clock around 2040.; the reasoning behind the estimate for A person's biological age, read from the marks on their DNA, falls after a treatment changed, on 17 October 2026: On an outside review's proposal of 2026-10-17 for this range: the reasoning now says why the earliest year moved and why the other two did not, and names the Nature Medicine paper logged against this treatment.
Logged because the outside review of 2026-10-17 pointed to it, in its part on cells and the cell's settings. It is the source behind the change of 2026-10-17 on the review's case for the treatment "A person's biological age, read from the marks on their DNA, falls after a treatment": a named academic clinic has measured molecular clocks in routine care since 2025 and repeats them at six months, so a publication of that practice could come any year, and the treatment's earliest year for reaching clinical use moved from 2032 to 2028. It does not itself put the treatment in clinical use: the test asks for a treatment given in routine care with the clock monitored and that practice published, and this page describes testing and lifestyle advice, with no published report of practice.
appeared 25 February 2025Read; moved nothingDamaged DNAClinical Use of ZSCAN4 for Telomere Elongation in Hematopoietic Stem CellsMyers and 13 others
Four people with a rare inherited disease of very short chromosome ends (a telomere biology disorder) were enrolled; two could have their blood stem cells collected, and these two were given their own stem cells back, treated outside the body with a virus carrying the gene ZSCAN4, which lengthens telomeres, and followed for 24 and 5 months (both still continuing). The telomeres of the treated stem cells were 1.06 to 1.34 times longer in the dish; in one person the telomere length in a subgroup of white blood cells (lymphocytes) changed from 3.6 to 6.7 thousand base pairs, and in both people a count of one kind of white blood cell (neutrophils) rose after treatment. The authors say definitive conclusions cannot be drawn from two treated patients. The abstract reports no rate of cancer.
Kasiani C. Myers, Stella M. Davies, Carolyn Lutzko, Robin Wahle, David D. Grier, Geraldine Aubert, Kevin Norris, Duncan M. Baird, Minako Koga, Akihiro C. Ko, Tomokazu Amano, Misa Amano, Hong Yu, Minoru S. H. Ko. NEJM Evidence 4(3) (2025), published 2025-02-25; trial registered as NCT04211714. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added during the weekly reading of 2026-10-17. On a plain reading it does not meet the test that the treatment "A gene therapy lengthens the ends of chromosomes in an old animal, with no rise in cancer" sets for its next stage, first human: the gene is ZSCAN4, not telomerase; the cells were treated outside the body; there are two patients; and the abstract gives no cancer rate. Whether it counts is for me to decide; the treatment was left at shown in animals.
Checked 2026-10-17: the journal's full text is behind a payment page and the authors' accepted manuscript (held by Cardiff University) could not be opened, so this record states only what the published abstract says (read through the PubMed and Europe PMC records); what the full text says about follow-up beyond the abstract and about cancer monitoring is not recorded. The author list was corrected on 2026-10-17 from the journal's record: it has 14 authors, not 13.
appeared 8 October 2026Read; moved nothingThe cell's settingsLife Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic NeuropathiesLife Biosciences
The company reports interim results from the first three people with open-angle glaucoma given its eye-injected reprogramming therapy ER-100 (first dose level, with a daily antibiotic to switch the genes on for 56 days) in an open-label safety trial: no dose-limiting toxicity and no serious adverse events by day 56, and a safety board's recommendation to move to the second dose level. In two of the three people, at least 28 per cent of tested points in the visual field improved by more than 4 decibels at day 56; the company calls this a preliminary signal in a trial designed to measure safety.
Life Biosciences, Inc.. Company press release, Boston, 2026-10-08, with data presented at the session named 'Eyecelerator @ American Academy of Ophthalmology (AAO) 2026'; trial registered as NCT07290244. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added during the weekly reading of 2026-10-17. An open-label company announcement of a visual-function change in two of three people is not the peer-reviewed report that the treatment "Partially resetting cells reverses ageing in a living animal" asks for at its first human stage, and it measures sight, not a marker of biological age; that treatment stays at shown in animals. The record of the first dose, of 2026-06-09, is the company's announcement of that date.
Checked 2026-10-17 against the company's release (opened on the company's own site), which gives the figures used here: three people with open-angle glaucoma, the first dose level, daily doxycycline by mouth for 56 days, no dose-limiting toxicity and no serious adverse events by day 56, the safety board's recommendation to move to the second dose level, and, in two of the three, at least 28 per cent of visual-field points improving by more than 4 decibels. The release itself does not name the meeting; the company's announcement of 2026-10-01 (https://www.lifebiosciences.com/life-biosciences-to-present-first-in-human-data-from-ongoing-phase-1-trial-evaluating-er-100-in-optic-neuropathies-at-eyecelerator-2026/) says the data would be given in an oral session at that event on 2026-10-08 in New Orleans. No conference abstract or published slides were found, so the figures rest on the company's own release and are the company's.
appeared 1 October 2026Read; moved nothingWorn-out cellsSenolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trialKoning and 34 others
Thirty-one adults with scarred fatty liver disease (median age 56) were randomly given either the two-drug course dasatinib plus quercetin, taken three days a week for three weeks and repeated across three seven-week cycles, or a matching placebo. The pre-stated main measure, at least one stage less scarring on paired liver biopsies without the disease worsening, was met by 47 per cent of treated people against 7 per cent on placebo (P = 0.02); the disease resolved in 53 per cent against 7 per cent. Sequencing of single cells from the biopsies showed fewer signs of aged cells and of scar-forming cells in the treated group. Side effects were more frequent on the drugs (82 per cent against 43 per cent of people), mostly mild or moderate; the authors call them all self-limiting, though their own table lists a few that left minor after-effects or were still going on. Four people did not finish, three of them on the drugs (one left because of side effects), and the main analysis counted all four as not improved. Counted the least favourable way for the drugs, the result was no longer significant (P = 0.068), and the authors call it hypothesis-generating, not confirmatory, pending a larger trial. The aged cells were not counted directly: the planned count was replaced by the sequencing, which found too little of the usual single markers of aged cells to rely on them and so used sets of genes typical of aged cells, in biopsies pooled two or three to a sample. More of the treated group had type 2 diabetes at the start (76.5 per cent against 35.7 per cent). Blood and scan measures of liver scarring did not differ between the groups at 21 weeks.
Mijra Koning, Artemiy Kovynev, Marcos F. Fondevila, Eliza J. M. Ruhe, Michiel C. Mommersteeg, Christian Ramakers, Barbara A. Hutten, Bart Verwer, Marije Vlug, Teaco Kuiper, Maarten van den Berg, Anne Vrieze, and 23 others, ending with Tamar Tchkonia, Bernd Schnabl, James L. Kirkland and Abraham S. Meijnikman (35 in all). Nature Metabolism (2026), online 2026-10-01, pages 1 to 12; trial registered as NCT05506488. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added from the weekly reading of 2026-10-17, as one of the items it flagged, entered by hand. The page read is the journal's own. The trial is a second controlled result for this class of drug on a clinical-type measure, in the liver; the treatment "A drug that clears aged cells beats a sham treatment in a controlled trial" was already at first human on the 2022 eye trial, so it moves no stage. Two authors (Tchkonia, Kirkland) declare patents on drugs that clear aged cells (senolytic drugs) held by the Mayo Clinic, as the paper's competing-interests statement says. The years in the treatment's estimate were not changed.
Checked 2026-10-17. The journal's page and Crossref's record both list 35 authors, with the first twelve and the last four as given here; the journal's page gives the pages as 1 to 12.
Read in full on 2026-10-20, in the authors' accepted manuscript (which does not yet carry page numbers or a publication date), with its methods, extended-data tables and figures; the supplementary file, with the trial protocol and the analysis plan, was not part of the copy read. Every figure in the abstract matches the full text (the main result's P value is 0.021 there), and the manuscript lists the same 35 authors. The full text adds what the abstract left out: the dropouts and how they were counted, the result's sensitivity to that choice, the difference in diabetes between the groups at the start, and that the aged cells were read from gene patterns rather than counted; the finding above was corrected on 2026-10-20 to say so, where it had said only that every side effect passed on its own. None of this moves a stage or a year: the treatment it bears on was already at first human on the 2022 eye trial.
appeared 2 March 2026Read; moved nothingDamaged DNAIntellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CMIntellia Therapeutics
The company says the United States regulator has lifted its stop on the late-stage MAGNITUDE trial of its in-body gene editor nexiguran ziclumeran in people with heart disease caused by the protein transthyretin (about 1,200 people, a single infusion against placebo). The stops on this trial and its sister trial in nerve disease were imposed on 2025-10-29 after one person given the drug had a very large rise in liver enzymes and bilirubin; the sister trial's stop was lifted on 2026-01-27. The release itself does not mention the death of the person who triggered the stops; the company's report to the securities regulator of 2026-01-09 does (see the notes). The changes agreed with the regulator are closer liver-test monitoring, guidance on short steroid treatment, exclusion of people with certain liver abnormalities, and, for this trial, exclusion of people with a recent unstable heart or an ejection fraction under 25 per cent.
Intellia Therapeutics, Inc.. Company press release, Cambridge, Massachusetts, 2026-03-02, filed with the United States securities regulator as exhibit 99.2 to a Form 8-K. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added during the weekly reading of 2026-10-17 as the source for the correction to the description of the treatment "A gene is edited inside a person's body to stop an age-related disease". The restart date in that description (March 2026) matches the release.
Checked 2026-10-17. The release does not mention the patient's death, so the death and its cause are sourced to the company's other written statements. Its report to the United States securities regulator of 2026-01-09 (Form 8-K, item 8.01, https://www.sec.gov/Archives/edgar/data/1652130/000119312526008307/d15047d8k.htm) says the patient, dosed in the heart trial, died on 2025-11-05, that the trial's lead doctor reported death from septic shock after a perforated duodenal ulcer, that the patient's course also included acute liver injury and its treatment with steroids, and that an autopsy supported the clinical diagnoses. The company's annual report filed 2026-02-26 repeats the passage. Its quarterly report filed 2025-11-06 first records that the patient passed away on 2025-11-05 and that an investigation was under way. The patient's age and sex, the early trade reports linking the death to the liver event, and the chief executive's remark at a January 2026 investor conference that the death was not from liver failure rest only on the trade press and were removed from the record on 2026-10-17 for want of a company statement. The trial registry's entry (NCT06128629) was not used for the death.
appeared 12 March 2026Read; moved nothingInflammation and the body's messagingGrifols and Ace Alzheimer Center Barcelona renew their collaboration to promote the AMBAR clinical program and incorporate new centersGrifols
The company says it has renewed its agreement with the Ace Alzheimer Center in Barcelona to keep running its plasma-exchange-with-albumin programme (AMBAR) there, which has operated since 2021; that AMBAR clinic centres are opening in hospitals in Madrid, Mallorca and Alicante; that more than 5,000 plasma exchanges with albumin have been done since the programme began; and that the protocol is included in the medical guidelines of the American Society for Apheresis (the society's 2023 guidelines do list it: plasma exchange for mild or moderate Alzheimer's disease is in Category III, meaning the best role for the treatment is not established and the decision should be made case by case; see the notes). A registry with real-world data is planned. The release describes the 2020 trial as having slowed progression by 61 per cent in some patients, a figure that is the company's own wording.
Grifols, S.A.. Company press release, Barcelona, 2026-03-12. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added during the weekly reading of 2026-10-17. The test that the treatment "Replacing the liquid part of a person's blood slows an age-related disease" sets for in clinical use accepts a named clinical setting that gives the treatment in routine care and publishes that practice; this release may be that for a named centre in Barcelona, but it is the supplier's account. The reading left the treatment at first human, and set out the case for moving it to in clinical use in the treatment's notes for me to decide.
Checked 2026-10-17. The release is the supplier's account, not the Barcelona centre's own publication of its practice. The society's guidelines (Connelly-Smith and others, Journal of Clinical Apheresis 2023, volume 38, pages 77 to 278, https://doi.org/10.1002/jca.22043; the journal's copy is behind a subscription wall, and the page was read in a copy of the full guidelines) list "Alzheimer's disease, mild or moderate, plasma exchange" as Category III with evidence grade 2A (table on page 105). The guidelines define Category III as "Optimum role of apheresis therapy is not established. Decision-making should be individualized." So the claim that the protocol is in the society's guidelines is confirmed, but the placement is the third of the society's four categories, for a treatment whose role is not settled, and not an endorsement as standard care.
appeared 14 February 2025Read; moved nothingInflammation and the body's messagingInfusion of young donor plasma components in older patients modifies the immune and inflammatory response to surgical tissue injury: a randomized clinical trialGaudilliere and 24 others
In a double-blind, placebo-controlled phase 2a trial, 38 older people having a hip or knee replacement were randomly given four infusions of a plasma protein fraction from young donors (GRF6021) or salt water, around the day of surgery; 36 finished. Blood tests showed that the immune and inflammatory response to the surgery differed between the groups. The authors call it a first proof of principle in humans that a young plasma fraction regulates immune and inflammatory responses in older people; it was not designed to show a clinical benefit. The clinical measures over the six weeks after surgery (fatigue, pain, opioid use, leg function) were secondary: the paper reports changes in the treated group's favour for fatigue and pain that were not statistically significant (a median of 12 days to half recovery from fatigue against 16 days on placebo, and 12 days to mild pain against 18 days), and lower opioid use in hospital on the first two days after surgery.
Brice Gaudilliere, Lei Xue, Amy S. Tsai, Xiaoxiao Gao, Tiffany N. McAllister, Martha Tingle, Gladys Porras, Igor Feinstein, Dorien Feyaerts, Franck Verdonk, Maximilian Sabayev, Julien Hedou, and 13 others, ending with Stuart B. Goodman, Nima Aghaeepour and Martin S. Angst (25 in all). Journal of Translational Medicine 23, article 183 (2025), published 2025-02-14; trial registered as NCT03981419. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added during the weekly reading of 2026-10-17. It is the nearest controlled human result to what the treatment "Young blood rejuvenates an old animal" asks for at its next stage, first human, but its measure is the response to surgical injury, not an age-related function, so the treatment stays at shown in animals; whether such a measure could count is for me to decide.
Checked 2026-10-17 against the full text, which is open access (https://pmc.ncbi.nlm.nih.gov/articles/PMC11829456/). The trial randomised 38 people and analysed 36 (one surgery was cancelled and one patient was given a steroid during surgery, a breach of the protocol). The authors say the study was designed to detect differences in blood measures and that the clinical measures were there to show the direction of change. Their statistical check for a link between the clinical outcomes and the immune measures found nothing that survived correction for many comparisons.
appeared 13 July 2026Read; moved nothingBroken proteins and wasteFDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's DiseaseEisai and Biogen
The two companies say the United States regulator has approved an under-the-skin weekly autoinjector form of lecanemab as the starting dose as well as the maintenance dose (500 mg a week as two injections to start; 360 mg a week after 18 months), so that a whole course can be taken at home; a United States launch as a starting dose was planned for late August 2026. The approval rests on exposure matching the drip form in a long-term extension of the main trial, with similar rates of brain swelling and bleeding and some injection-site reactions. The release gives no figure for how many people have been treated.
Eisai Co., Ltd., Biogen Inc.. Company press release, Tokyo and Cambridge, Massachusetts, 2026-07-13, as carried by BioSpace. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added during the weekly reading of 2026-10-17. The entry for the treatment "An antibody clears amyloid from the brain and slows the decline of Alzheimer's disease" names the need for infusions as one condition holding the drug back from wide use; this approval removes that one, but not the brain scans, the price or the missing uptake figures, so the treatment stays at in clinical use. Whether it moves the earliest or likely year in the treatment's estimate for wide use is for me to decide.
Checked 2026-10-17. The regulator's approved prescribing information, as published on the National Library of Medicine's DailyMed site (revised 7/2026, posted 2026-07-27; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d1ff786-e577-410a-a273-c4d7d0e4e975), confirms the regimen: a starting dose of 500 mg a week as two 250 mg injections with the autoinjector, a 360 mg weekly maintenance dose, and the option, after 18 months, of continuing the starting dose or moving to maintenance. The label gives the month of its revision, not the day, and the regulator's own approvals page (Drugs@FDA) had not yet listed the supplement on 2026-10-17, so the approval date of 2026-07-13 is the date of the companies' announcement.
appeared 10 September 2026Read; moved nothingWorn-out cellsBlocking PD-L2 prevents senescent cell accumulation and age-related dysfunctionChaib and 47 others
The authors report that a protein called PD-L2, which immune cells read as a signal not to attack, is higher on aged (senescent) human cells grown in the laboratory and rises during ageing, and that drugs which kill aged cells remove the aged cells that carry the most of it. Old mice bred without PD-L2 held fewer aged cells than ordinary old mice, and had better insulin sensitivity and grip strength; a treatment against PD-L2 restored insulin sensitivity in ordinary old mice. They conclude that PD-L2 helps aged cells escape the immune system and persist.
Selim Chaib, Larissa G. P. Langhi Prata, Masayoshi Suda, and 45 others, ending with Ikeno, Tchkonia and James L. Kirkland (48 in all). Cell Metabolism, online 2026-09-10 (September 2026 issue; the publisher's article number is S1550-4131(26)00339-6; volume and pages were not in the records read). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Added 2026-10-17. This is work in mice and in human cells in the laboratory, not a person given a drug, so it moves no stage and no estimate year. Only the abstract could be read: the journal's page asks for a subscription, and there is no open copy. A statement in trade coverage (GEN), quoting the paper's own highlights, that a form of PD-L2 circulating in the blood rose with age and fell after aged-cell-clearing drugs in people, and so might serve as a blood marker, is not in the abstract; the highlights themselves could not be opened, so that statement is not recorded here. The release of 2026-09-10 from Cedars-Sinai (the senior author's institution) says only that PD-L2 could serve as a blood marker.
appeared 27 April 2026Settled a stageInflammation and the body's messagingAce Alzheimer Center presents pioneering evidence on plasma exchange to slow Alzheimer'sAce Alzheimer Center Barcelona
The centre says its medical team presented, at the 2026 meeting of the American Society for Apheresis, results of therapeutic plasma exchange with albumin in people with Alzheimer's disease given, in its words, "under routine clinical practice conditions in Barcelona" rather than in a clinical trial: 71 patients completed the 15-month programme as outpatients; the observed cognitive decline was lower than what is typically reported for the disease's natural course; 44 per cent of patients were classified as responders with stable cognitive trajectories; and more than 96 per cent of procedures were free of adverse events, all of them mild and transient. The page names no peer-reviewed paper or conference abstract and gives no date for when the service began.
Ace Alzheimer Center Barcelona. The centre's own news page, Barcelona, 2026-04-27. Read it.
What it moved: the stage for Replacing the liquid part of a person's blood slows an age-related disease, first human to in clinical use, on 17 October 2026: On a point raised by an outside review of 2026-10-17, that the clinic rung might already be met: the Ace Alzheimer Center in Barcelona published on its own page on 2026-04-27 that 71 patients completed its plasma-exchange programme under routine clinical practice conditions, and this counts as a named clinical setting publishing that it gives the treatment for that purpose in routine care, which is what the test's clinic rung asks. It settles the question the weekly reading of 2026-10-17 left open. The record is an announcement of a conference presentation, not a peer-reviewed paper, and the apheresis society's guidelines place the treatment in the category whose role is not established; both are noted and were weighed.; the date the stage was reached for Replacing the liquid part of a person's blood slows an age-related disease, 2020-07-27 to 2026-04-27, on 17 October 2026: On the outside review's point of 2026-10-17 about the Barcelona centre: the clinic rung is dated to the centre's own publication of its practice, not to 2021, when the supplier's release says the programme began, because the test asks for the practice to be published and the centre's page is the earliest such publication. The 2020 trial report moves to the list of earlier stages as the first human record.; the record that settles the stage for Replacing the liquid part of a person's blood slows an age-related disease, https://doi.org/10.1002/alz.12137 to https://www.acebarcelona.org/en/plasma-exchange-alzheimers-asfa-2026, on 17 October 2026: On the outside review's point of 2026-10-17 about the Barcelona centre: the stage record is now the centre's announcement of 2026-04-27; the 2020 trial report is kept as the first human record under earlier stages.; the estimate to reach clinical use for Replacing the liquid part of a person's blood slows an age-related disease, earliest 2030, likely 2038, latest 2075 to (removed; the rung was reached on 2026-04-27), on 17 October 2026: On the outside review's point of 2026-10-17 about the Barcelona centre: a rung that has been reached is a matter of record and is no longer estimated. The write-up of the review predicted this move would give a headline of 2057 and a 5.9 per cent chance before 2050; the change to the records on 2026-10-17 says what the re-run gave.; the estimate to reach wide use for Replacing the liquid part of a person's blood slows an age-related disease, (none) to earliest 2032, likely 2045, latest 2090, on 17 October 2026: Written when the change of 2026-10-17 on the outside review's point about the Barcelona centre was applied, as a first estimate, not yet reviewed, for the rung now above the stage; the headline does not draw it. Proposed, not ruled: I have not set these years, and the reasoning says what they assume. Set on 2026-10-17 as a first estimate, not yet reviewed.; the reasoning behind the estimate for Replacing the liquid part of a person's blood slows an age-related disease changed, on 17 October 2026: The reasoning was for the clinic rung, which was reached on 2026-04-27, as recorded on 2026-10-17 on the outside review's point about the Barcelona centre; the new reasoning is for the wide-use rung and says it is a first estimate written on 2026-10-17 and not yet reviewed.; the description for Replacing the liquid part of a person's blood slows an age-related disease changed, on 17 October 2026: On the outside review's point of 2026-10-17 about the Barcelona centre: the description now says how the treatment reached the clinic and on what record.; the notes for Replacing the liquid part of a person's blood slows an age-related disease changed, on 17 October 2026: On the outside review's point of 2026-10-17 about the Barcelona centre: the paragraph the weekly reading left for me now carries the answer and its reason, so a reader can see the question and the answer together.
This page settles whether the plasma-exchange treatment is in clinical use, because it is what the test asks for: a named clinical setting publishing, on its own page, that it gives the treatment for that purpose in routine care. The weekly reading of 2026-10-17 had left the question open because the only source then in the record was the supplier's release (Grifols, 2026-03-12). The centre's page answers that objection; it is still an announcement of a conference presentation and not a peer-reviewed publication of the practice, and the apheresis society's own guidelines (see the notes on the Grifols release) place plasma exchange for Alzheimer's disease in the category whose role is not established. Weighed against the test, the announcement still counts, because it is what the test asks for; the treatment's entry carries the reasoning. The treatment is dated to this page, 2026-04-27, and not to 2021, when the supplier's release says the programme began, because this page is the earliest publication by the clinical setting itself.
The weekly reading of 2026-10-17 found the sentence 'the one company drug to reach a controlled trial on a clinical outcome ... failed in 2020' out of date once the Amsterdam liver trial read out positive on 2026-10-01. The stage is unchanged: the 2019 kidney report stays the record of first human. Source: Koning and 34 others, 1 October 2026.
The weekly reading of 2026-10-17 added a dated note that the estimate's premise that the one controlled trial so far failed no longer holds; no year changed. Source: Koning and 34 others, 1 October 2026.
The weekly reading of 2026-10-17 records the supporting measurement of aged cells in the new liver trial. Source: Koning and 34 others, 1 October 2026.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and proposed moving this range, which I declined on 2026-10-17: the reviewer proposed 2027, 2029, 2038 on the ground that longevity clinics already give the two-drug combination off-label, but named no clinic, report or page a reader can open, and the kind of record this entry names as settling the rung is a regulator's approval record; the range stays 2031, 2038, 2060. Left for the yearly review: this test's clinic rung admits a private clinic's published off-label protocol, which the chromosome-ends treatment's test excludes on purpose. With every point of the review answered, this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say.
The weekly reading of 2026-10-17 added the Amsterdam liver trial (Nature Metabolism, 2026-10-01), a second controlled result for the class that the description of 2026-10-16 did not know. The stage was already first human, so it does not move. Source: Koning and 34 others, 1 October 2026.
The weekly reading of 2026-10-17 replaced 'the first controlled human result in the drug class' with the two controlled results now on record. Source: Koning and 34 others, 1 October 2026.
The weekly reading of 2026-10-17 added a dated note that the premise 'one positive controlled trial exists' is out of date; the years are my and were not changed. Source: Koning and 34 others, 1 October 2026.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
A check against the sources on 2026-10-17: the peer-reviewed long-term follow-up (Blood Advances, 2026, volume 10, page 208) was read. It reports stable telomere length by a second method and no significant lengthening in the few patients with later samples, not a gain that held in some and not in others; its figures differ from the 2024 conference abstract's. The stage does not change.
Accepted from an outside review's proposal of 2026-10-17 for this range: the earliest had assumed a filing on existing data within four years, and the record's own long-term follow-up (Lee and colleagues, Blood Advances 10, 208 to 212, 2026, https://doi.org/10.1182/bloodadvances.2025017860) found no significant lengthening in the few patients re-measured, so no filing for a lengthening claim can rest on the data in hand; the trial registry shows no sponsor carrying danazol towards an approval (its entry for the TELO-SCOPE trial). Source: The University of Queensland, 20 November 2020.
Accepted from an outside review's proposal of 2026-10-17 for this range: the likely year had assumed an approval of danazol or a relative around 2034 after a confirmatory trial; the registry shows the one phase 2 trial aimed at telomere attrition (TELO-SCOPE, NCT04638517) stopped for futility, no phase 3 and no sponsor, so a new treatment would have to go through every trial phase. Source: The University of Queensland, 20 November 2020.
Accepted from an outside review's proposal of 2026-10-17 for this range: with no sponsor in sight, the record's own latest-year clause (no sponsor ever taking a generic drug through the process) looks like the likely case, and the latest moves out with the rest of the range. Source: The University of Queensland, 20 November 2020.
Accepted from an outside review's proposal of 2026-10-17 for this range: the reasoning is rewritten to say which premises failed, on which sources, and what the new years assume. The reviewer overstated one thing, recorded here: the 2016 trial did measure lengthening by its own method, so a confirmatory trial could still do so; the follow-up's finding is in a few samples by a different method. Source: The University of Queensland, 20 November 2020.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and proposed a change to this range, which was accepted the same day: the range moved to 2038, 2048, 2085 (see the revisions above). With every point of the review answered, the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say.
The weekly reading of 2026-10-17 added the death in the heart trial and the two accounts of its cause, which the description of 2026-10-16 left out. The company's release of 2026-03-02 (Intellia's announcement that the regulator had lifted its hold on the late-stage heart trial) confirms the stop of 2025-10-29 and the restart; the death and its cause come from trade reports of the company's own remarks. The stage does not change. Source: Intellia Therapeutics, 2 March 2026.
A check against the sources on 2026-10-17 found the company's own written statement: its report to the United States securities regulator (Form 8-K) of 2026-01-09 (https://www.sec.gov/Archives/edgar/data/1652130/000119312526008307/d15047d8k.htm, item 8.01), repeated in its annual report filed 2026-02-26. The text now says only what the filing says. Removed because the company's filings do not state them: the patient's age and sex (from trade reports), the early trade reports' link to the liver event, and the chief executive's remark, reported by Clinical Trials Arena, that the death was not from liver failure. The filing names a perforated duodenal ulcer, not a bowel perforation as the trade account had it. The stage does not change. Source: Intellia Therapeutics, 2 March 2026.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
The weekly reading of 2026-10-17 added a dated note that the estimate's first sentence ('no registered trial of a telomerase gene therapy in people existed') is wrong as written, and why the ZSCAN4 report does not move the stage; no year changed. Source: Myers and 13 others, 25 February 2025.
A check of the sources on 2026-10-17: the dated note pointed to a list of checks that no longer exists on this entry; it now names the registry entry itself. No year changed.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and proposed moving this range, which I declined on 2026-10-17: the reviewer proposed moving the earliest to 2036 and the likely to 2042 as too fast for a whole-body gene therapy, citing the regulator's long-term follow-up guidance of 2020-01-30 and Zolgensma's five years from first trial (2014-05-05) to approval (2019-05-24); the guidance does not say approval waits for the follow-up, and the record's earliest clinic year sits five years after its earliest first human year, the pace the reviewer's own precedent gives; the range stays 2032, 2038, 2080. With every point of the review answered, this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say.
A check against the sources on 2026-10-17: 'None has been shown to work in a living animal in a peer-reviewed report' was not safe: searches on 2026-10-17 found peer-reviewed 2025 reports of a two-chemical mix in worms and in ageing mice, and a 2026 mouse report with no change in tissue age and toxicity at higher doses. The text now says what each reports. None is counted as the animal rung, so the stage does not change; whether the mouse report counts is left for me.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
The weekly reading of 2026-10-17 noted the interim data of 2026-10-08, which the record of 2026-10-16 did not mention. Source: Life Biosciences, 8 October 2026.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
An outside review's proposal of 2026-10-17 for this range was accepted in part: the earliest year only. Northwestern Medicine's own release of 2025-07-07 says its Human Longevity Clinic measures molecular clocks of biological age in routine care and repeats selected tests at six months, so a named clinic's publication of a clock-monitored practice, which the test's clinic rung allows, could come within a few years rather than the six the old earliest assumed. The reviewer's proposed likely year (2035) and latest (2070) were declined: the test asks for a treatment given on the strength of a clock result, which no clinic has published, and the likely year is tied to the regulator's acceptance of a clock around 2040. Source: Northwestern Medicine, 7 July 2025.
On an outside review's proposal of 2026-10-17 for this range: the reasoning now says why the earliest year moved and why the other two did not, and names the Nature Medicine paper logged against this treatment. Source: Northwestern Medicine, 7 July 2025.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) proposed a change to this range, which was accepted in part the same day: the earliest year moved to 2028 on Northwestern Medicine's release (see the revision above); the likely and latest moves were declined. With every point of the review answered, the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say.
The weekly reading of 2026-10-17 found the sentence 'with no result yet reported' out of date from 2026-10-08. The announcement is a company release of preliminary, uncontrolled data on sight, not the peer-reviewed report of a measured reversal that the first human step asks for, so the stage stays at shown in animals. Source: Life Biosciences, 8 October 2026.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
A check against the sources on 2026-10-17: 'Has been given to people since late 2024' is not stated by the trial registry (https://clinicaltrials.gov/study/NCT06671093), which gives a study start of 2024-11-29, or by the company's releases of 2024-11-14 and 2026-05-30, none of which gives the date of the first person dosed. The text now says what they say: a trial the registry shows as started on 2024-11-29, and markers repressed for up to seventeen months after one dose (company release, 2026-05-30). The stage does not change.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
A check of the sources on 2026-10-17 states why no animal stage is recorded, with the discovery paper as the source, in place of a statement not yet checked against a source; no stage or year changed.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
A check of the trial reports on 2026-10-17 records the two trial results that a statement not yet checked against a source described, with their sources; no stage or year changed.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
The weekly reading of 2026-10-17 found that 'The drug needs infusions' stopped being true on 2026-07-13, when the companies announced the United States approval of the autoinjector as a starting dose. Scans, price and the lack of uptake figures stand, so the stage stays at clinical use. Source: Eisai and Biogen, 13 July 2026.
The weekly reading of 2026-10-17 added a dated note that one of the estimate's stated bars to wide use has been removed; no year changed. Source: Eisai and Biogen, 13 July 2026.
A check of the sources on 2026-10-17 records what the companies' own filings do and do not say about uptake, and the Cochrane overview's abstract, after two statements about uptake and the overview that had not yet been checked against a source were checked; no stage or year changed.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
The weekly reading of 2026-10-17 found that the description said no human trial had been published, which is still true, but left out the registered trial under way. The stage stays at shown in animals: the first human step asks for a peer-reviewed controlled report of clearer lenses in people. Source: Ocusun Ophthalmic Pharmaceutical, 9 February 2026.
The weekly reading of 2026-10-17 added a dated note that the estimate's premise of no registered human trial no longer holds; no year changed. Source: Ocusun Ophthalmic Pharmaceutical, 9 February 2026.
A check of the sources on 2026-10-17: the lanosterol origin and the China figures are the company's account in its release of 2026-07-14 (opened and read), not a registry or journal fact, so they are now attributed to it; the registry's start date is stated as the registry's, since the release says the first patient was enrolled on 2026-07-14. Source: Ocusun Ophthalmic Pharmaceutical, 9 February 2026.
A check of the sources on 2026-10-17, wording only: attributes the lanosterol origin to the makers and the start date to the registry; no year changed. Source: Ocusun Ophthalmic Pharmaceutical, 9 February 2026.
On a point raised by an outside review of 2026-10-17: the estimate's premise, that no human trial was registered, was out of date on the record's own evidence; the registered placebo-controlled phase 2 pilot (ClinicalTrials.gov NCT07395986, start 2026-02-10, primary completion estimated 2027-02; sponsored by Ocusun) gives the fast path of a phase 3 by 2030 and an approval the next year. The weekly reading of 2026-10-17 had flagged the same thing. Source: Ocusun Ophthalmic Pharmaceutical, 9 February 2026.
On the outside review's point of 2026-10-17 about the registered trial: the likely year is the plain reading of the registered trial's dates with time for a phase 3 and a review, while still assuming the 2015 dog result has to replicate in people; the latest of 2120 is left as it is for that reason. Source: Ocusun Ophthalmic Pharmaceutical, 9 February 2026.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and argued that this range rested on there being no registered human trial, which is out of date; That was accepted the same day, and the clinic rung's earliest and likely years moved to 2031 and 2040 (see the revisions above). With every point of the review answered, this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say.
Checked against the regulator's own list and the company's own pages on 2026-10-17; the two statements previously rested on the company's posts and a web search.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
Checked against the source on 2026-10-17: the claim that no one had enrolled rested on trade coverage alone; the sponsor's own page is the primary record and says the trial was still raising funds to launch.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
A check of the sources on 2026-10-17: a search found a peer-reviewed report in old mice of an improved immune response to a vaccine on rapamycin, the same kind of measure as the 2014 trial in people; the stage itself is unchanged.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
The weekly reading of 2026-10-17 recorded the first published uptake figure, which the notes said was still to come. Source: Scannell and 4 others, 9 July 2026.
The weekly reading of 2026-10-17 added a dated note that the first uptake figure undercuts the premise behind the earliest wide-use year; no year changed. Source: Scannell and 4 others, 9 July 2026.
Checked against the paper on 2026-10-17: the median lifespans are as the paper gives them; the gap in the record (no animal rung) is now stated in the notes with its reason.
Accepted from an outside review's proposal of 2026-10-17 for this range: the earliest assumed uptake for the heart-prevention purpose might already count, and the one published figure (Scannell and colleagues, American Journal of Managed Care, 2026-07-09, https://doi.org/10.37765/ajmc.2026.89983) says it does not: under 1 per cent of an estimated 3.6 million eligible Medicare beneficiaries six months after coverage began. The weekly reading of 2026-10-17 had flagged the same thing. Source: Scannell and 4 others, 9 July 2026.
Accepted from an outside review's proposal of 2026-10-17 for this range: a substantial share of eligible people in several countries takes years of payer negotiation and prescribing habit after an approval, and the only uptake figure in the record is far below the bar; the latest of 2040 stays. Source: Scannell and 4 others, 9 July 2026.
Accepted from an outside review's proposal of 2026-10-17 for this range: the reasoning now says what moved and why. Source: Scannell and 4 others, 9 July 2026.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) proposed a change to this range, which was accepted the same day: the wide-use earliest and likely years moved to 2030 and 2033 (see the revisions above). With every point of the review answered, the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say.
A check of the trial registry and the journals on 2026-10-17 records the registry entries and reports that a statement not yet checked against a source described; no stage or year changed.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
Checked against the sources on 2026-10-17: the claim that no one had enrolled rested on web articles that disagree with each other; the sponsor's own page and NPR of 2024-04-22 are primary, and give the cost as 45 to 70 million dollars, not 40 to 70. The 2015 planning date was not in any source opened; the design paper is of 2016.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
A check against the sources on 2026-10-17: 'The oldest approved therapy made from a person's own grown cells' is a priority claim that the regulator's record does not support for MACI: its forerunner Carticel was licensed on 1997-08-22 (FDA Purple Book; label 'Initial U.S. Approval: 1997') on open-label observational studies. The sentence now says that. The clinic date and the stage do not change; whether the 1997 licence reached the clinic rung first is left for me.
Accepted from an outside review's proposal of 2026-10-17 for this range: the earliest assumed use figures might already meet the wide-use bar once counted, but the test's wide-use rung requires use in worn joints in older people, and the trial registry (https://clinicaltrials.gov/search?cond=osteoarthritis&intr=autologous%20chondrocyte, read 2026-10-17) holds no phase 3 trial of cultured cartilage cells in osteoarthritis: two recruiting phase 2 trials in patellofemoral osteoarthritis (NCT06163573, NCT06576583) and two completed post-marketing surveillance studies of a Korean product. A phase 3, a label extension and a roll-out cannot fit before 2033.
Accepted from an outside review's proposal of 2026-10-17 for this range: with no phase 3 in osteoarthritis registered, a trial reading out in the early 2030s and use widening through that decade puts the likely year at 2040; the latest of 2065 stays.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) proposed a change to this range, which was accepted the same day: the wide-use earliest and likely years moved to 2033 and 2040 (see the revisions above). With every point of the review answered, the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
A check of the sources on 2026-10-17: the company's own filings show the late-stage trial had not finished dosing in 2025 and that no filing for approval has been announced; the sentence now says what they say. Stage and years unchanged.
A check of the sources on 2026-10-17 added a dated note that the estimate's premise (dosing finished in 2025, filing due in 2026) no longer matches the company's filings; no year changed.
On a point raised by an outside review of 2026-10-17, that this range assumed a filing for approval in 2026 that has not come; the condition for the change (no filing for approval announced by that day) was checked the same day: Vertex's filings with the United States securities regulator (https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000875320&type=8-K) show nothing after the 8-K of 2026-09-01, an officer appointment, and its release of 2026-08-03 and quarterly filing of 2026-08-04 say only that updated timelines will come later in 2026. With dosing resumed in 2026-05 and the last patients' one-year follow-up running into 2027, a filing, a review and manufacturing scrutiny put approval at 2029 or 2030 at the earliest.
On the outside review's point of 2026-10-17 about the filing: the likely year follows the dates the record cites (dosing paused in 2025, resumed by 2026-05-04, no filing announced) with ordinary time for a filing and a review.
On the outside review's point of 2026-10-17 about the filing: the latest allows for a regulator demanding a larger trial, which the old latest, resting on the Parkinson's therapy's read-out in 2027, only partly covered.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and argued that this range assumed a filing for approval in 2026 that has not come; That was accepted the same day, and the clinic range moved to 2030, 2032, 2046 (see the revisions above). With every point of the review answered, this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say.
The weekly reading of 2026-10-17 found that the description said the trial was under way; it reported on 2026-05-27. The entry was already at first human on the 2025 case, so the stage does not move, and the new paper is an interim, uncontrolled report, not an approval. Source: Zimmermann and 34 others, 27 May 2026.
The weekly reading of 2026-10-17 added a dated note that the estimate's premise about when the first trial reports has been overtaken; no year changed. Source: Zimmermann and 34 others, 27 May 2026.
A check of the sources on 2026-10-17: the woman's age, her sex and the year 2021 came from news coverage; the 2025 paper in Nature, read in full, gives none of them, so they were removed. The ten patches, the 400 million cells and the transplant three months later are in the paper.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and proposed moving this range, which I declined on 2026-10-17: the reviewer proposed 2035, 2043, 2085, reading the three deaths among twenty people in the 2026 New England Journal of Medicine report (https://doi.org/10.1056/NEJMoa2513525) as a severe safety signal; the paper gives the deaths' causes as vasoplegia, COVID-19 and aortic dissection, one each, does not call them treatment-related and does not call its findings a safety signal, so the source does not say what the reviewer read into it; the range stays 2031, 2038, 2070. With every point of the review answered, this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
The weekly reading of 2026-10-17 writes the case for the clinic rung into the notes with its source and leaves it for me to decide, as the reading's rules require; the stage did not move. Source: Grifols, 12 March 2026.
On a point raised by an outside review of 2026-10-17, that the clinic rung might already be met: the Ace Alzheimer Center in Barcelona published on its own page on 2026-04-27 that 71 patients completed its plasma-exchange programme under routine clinical practice conditions, and this counts as a named clinical setting publishing that it gives the treatment for that purpose in routine care, which is what the test's clinic rung asks. It settles the question the weekly reading of 2026-10-17 left open. The record is an announcement of a conference presentation, not a peer-reviewed paper, and the apheresis society's guidelines place the treatment in the category whose role is not established; both are noted and were weighed. Source: Ace Alzheimer Center Barcelona, 27 April 2026.
On the outside review's point of 2026-10-17 about the Barcelona centre: the clinic rung is dated to the centre's own publication of its practice, not to 2021, when the supplier's release says the programme began, because the test asks for the practice to be published and the centre's page is the earliest such publication. The 2020 trial report moves to the list of earlier stages as the first human record. Source: Ace Alzheimer Center Barcelona, 27 April 2026.
On the outside review's point of 2026-10-17 about the Barcelona centre: the stage record is now the centre's announcement of 2026-04-27; the 2020 trial report is kept as the first human record under earlier stages. Source: Ace Alzheimer Center Barcelona, 27 April 2026.
On the outside review's point of 2026-10-17 about the Barcelona centre: a rung that has been reached is a matter of record and is no longer estimated. The write-up of the review predicted this move would give a headline of 2057 and a 5.9 per cent chance before 2050; the change to the records on 2026-10-17 says what the re-run gave. Source: Ace Alzheimer Center Barcelona, 27 April 2026.
Written when the change of 2026-10-17 on the outside review's point about the Barcelona centre was applied, as a first estimate, not yet reviewed, for the rung now above the stage; the headline does not draw it. Proposed, not ruled: I have not set these years, and the reasoning says what they assume. Set on 2026-10-17 as a first estimate, not yet reviewed. Source: Ace Alzheimer Center Barcelona, 27 April 2026.
The reasoning was for the clinic rung, which was reached on 2026-04-27, as recorded on 2026-10-17 on the outside review's point about the Barcelona centre; the new reasoning is for the wide-use rung and says it is a first estimate written on 2026-10-17 and not yet reviewed. Source: Ace Alzheimer Center Barcelona, 27 April 2026.
On the outside review's point of 2026-10-17 about the Barcelona centre: the description now says how the treatment reached the clinic and on what record. Source: Ace Alzheimer Center Barcelona, 27 April 2026.
On the outside review's point of 2026-10-17 about the Barcelona centre: the paragraph the weekly reading left for me now carries the answer and its reason, so a reader can see the question and the answer together. Source: Ace Alzheimer Center Barcelona, 27 April 2026.
The wide-use range of 2032, 2045 and 2090 written when the treatment moved to the clinic was kept on 2026-10-17, so the estimate is marked reviewed like the other 43 estimates; the years and the reasoning are unchanged. The headline does not draw this rung.
The weekly reading of 2026-10-17 found the description's 'no controlled trial has found a benefit' true but narrower than it looked; the nearest controlled human result is now named. The stage stays at shown in animals. Source: Gaudilliere and 24 others, 14 February 2025.
The weekly reading of 2026-10-17 adds the nearest controlled human trial to the notes and leaves the question of whether it counts for me. Source: Gaudilliere and 24 others, 14 February 2025.
An outside review of the year ranges ran on 2026-10-17 (by an AI model from another company, Google's Gemini 3.1 Pro in its preview version, given the treatments in four groups) and left this range as it is, with a line saying why. Every point the review of 2026-10-17 raised has been answered, so this estimate moves from a first estimate, not yet reviewed, to a reviewed one, as the rules for the record and for outside reviews say; no year changed.
A check against the sources on 2026-10-17: the wording 'The first such clock' was a priority claim that no source read settles, and 'better than age' was more than the GrimAge abstract says (it reports prediction of time to death, heart disease and cancer more strongly than earlier clocks, in validation data from thousands of people). The text now says what the Horvath 2013 abstract (https://doi.org/10.1186/gb-2013-14-10-r115) and the GrimAge abstract (https://doi.org/10.18632/aging.101684) say. The stage and its date do not change.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
Checked against the regulator's own list on 2026-10-17; the earlier statement rested on a peer-reviewed count to 2025-07-01 and an August 2026 trade article.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
Checked against the sources on 2026-10-17: the two papers on the trial's design say the regulator was consulted and favoured a disease-based outcome but give no date and no promise to accept; the 2015 meeting and the acceptance had only trade coverage and a paywalled news feature behind them. The sponsor's own page replaces the claim that no one had enrolled.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
The weekly reading of 2026-10-17 added the rentosertib clock paper and noted why it does not settle a rung, for the same reason as the CALERIE paper: its clock analysis was not planned in advance. Source: Zhavoronkov and 18 others, 7 September 2026.
A check against the sources on 2026-10-17: the company statements reported by MIT Technology Review on 2026-10-06 were opened and found to be conference talks, with one unreviewed preprint behind Novo's; a peer-reviewed controlled trial of semaglutide on clocks (Nature Communications, 2026-05-19) was found and, being post hoc, does not settle the rung. No stage or year was changed.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
An outside review of the ranges of years ran on 2026-10-17 (by Google's Gemini 3.1 Pro, an AI model, in its preview version, sent the records in four parts) and left this range as it is, with a line saying why. Every point the outside review of 2026-10-17 raised has been answered, so the estimate moves from a first estimate, not yet reviewed, to reviewed, as the rules for the records and for the review say; no year changed.
Logged 16 October 2026
appeared 22 April 2021Settled a stageEnergy and fuel sensingNicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic womenYoshino and 10 others
Twenty-five overweight or obese post-menopausal women with prediabetes took either 250 mg a day
of nicotinamide mononucleotide (NMN, a building block of the cell's energy-carrying molecule NAD)
or a placebo for ten weeks in a double-blind trial. Muscle insulin sensitivity, measured directly
with an insulin clamp, rose by 25 percent in the NMN group and not at all on placebo; blood sugar,
blood pressure, blood fats, liver insulin sensitivity and liver fat did not change. The first
controlled trial to show an NAD precursor doing anything measurable in people, on one tissue and
one measurement.
Mihoko Yoshino, Jun Yoshino, Brandon D. Kayser, Gary J. Patti, Michael P. Franczyk, Kathryn F. Mills, Miriam Sindelar, Terri Pietka, Bruce W. Patterson, Shin-Ichiro Imai, Samuel Klein. Science 372(6547), 1224–1229 (2021). Read it.
Logged for the treatment planned as an NAD precursor (a substance the body turns into NAD) with a
measured effect in people, on the energy and fuel sensing branch. Thirteen women were randomised
to NMN and twelve to placebo. Online 2021-04-22; the print issue is dated 2021-06-11. Registered
as NCT03151239.
Adult male cynomolgus monkeys, aged 13 to 16 years at the start (about 40 to 50 in human years), were
given metformin daily in their drinking water at 20 milligrams per kilogram of body weight for 40 months
and compared with untreated monkeys of the same age and with younger ones, on several biological age
clocks built from gene activity, DNA marks, blood proteins and metabolites across many tissues. The
clocks ran slower in the treated animals, with the brain reading about six years younger; the authors tie the brain effect partly to
the protective Nrf2 pathway. A controlled animal study on measurements, not on lifespan or
disease, in a small group: in the figures, mostly six treated monkeys and five untreated monkeys of the
same age (one of the untreated animals died of kidney failure during the study), three middle-aged
and six young adult comparison monkeys, with a few analyses using one fewer.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatments planned as a drug makes people live longer in good health (metformin),
on the energy and fuel sensing branch, and a clock validated as a trial measure, on the measuring
ageing branch. Online 2024-09-12; the print issue is dated 2024-10-31.
Checked 2026-10-17 against the full text of the paper (a copy of the journal's proof, held at
https://gwern.net/doc/longevity/metformin/2024-yang.pdf , as the publisher's own page could not be opened
by the checking tools). Corrected on 2026-10-17: the group sizes recorded on 2026-10-16 from a news
report (12 treated, 16 untreated elderly and 18 younger monkeys) do not match the paper, whose figure
legends give six treated, five untreated of the same age, three middle-aged and six young adult monkeys.
The dose of 20 milligrams per kilogram a day, given in drinking water for 1,200 days (40 months), is
stated in the paper's results and methods.
appeared 9 February 2023Read; moved nothingMeasuring ageingEnergy and fuel sensingEffect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trialWaziry and 21 others
The CALERIE trial had randomised 220 healthy adults without obesity to cut their calories by a
quarter or eat as usual for two years; those assigned to restriction managed 11.9 percent on
average. In the 197 with blood samples, a clock that reads the pace of ageing from DNA
methylation (DunedinPACE) ran 2 to 3 percent slower in the restricted group at one and two years,
while two clocks that read accumulated age (PhenoAge and GrimAge) did not move. The first
randomised trial in people to show an intervention slowing a biological age clock, by an amount the
authors call small.
R. Waziry, C. P. Ryan, D. L. Corcoran, K. M. Huffman, M. S. Kobor, M. Kothari, G. H. Graf, V. B. Kraus, W. E. Kraus, D. T. S. Lin, C. F. Pieper, M. E. Ramaker, M. Bhapkar, S. K. Das, L. Ferrucci, W. J. Hastings, M. Kebbe, D. C. Parker, S. B. Racette, I. Shalev, B. Schilling, D. W. Belsky. Nature Aging 3(3), 248–257 (2023). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatment planned as a clock validated to predict outcomes and used as a trial measure,
on the measuring ageing branch; and the energy and fuel sensing branch, since calorie restriction is
the intervention the rapamycin and metformin treatments imitate. A correction appeared on 2023-05-09
(Nature Aging 3(6), 753) and was not read here. Online 2023-02-09; the print issue is March 2023.
This paper does not settle the stage of the treatment "A treatment
slows a biological age clock in a controlled trial", because it calls its own clock analysis post hoc
(decided on after the data were in) and the treatment's test asks for one planned in advance; so it is
not marked as the paper that settles that stage.
appeared 17 August 2020Read; moved nothingWorn-out cellsUNITY Biotechnology Announces 12-week data from UBX0101 Phase 2 Clinical Study in Patients with Painful Osteoarthritis of the KneeUNITY Biotechnology
In a phase 2 trial, 183 people with moderate to severe knee osteoarthritis pain had a single
injection into the knee of placebo or one of three doses of UBX0101, a drug meant to kill
worn-out cells in the joint. At twelve weeks there was no statistically significant difference in
pain between any dose and placebo (p-values 0.52, 0.81 and 0.99 against placebo); the drug was
well tolerated. The company said it would not take the drug into pivotal trials and would narrow
its work to eye and nerve diseases. The first controlled trial of a cell-clearing drug on a
clinical outcome, and it failed.
UNITY Biotechnology, Inc.. Company press release, South San Francisco, 2020-08-17, filed the same day as exhibit 99.1 to a Form 8-K with the US Securities and Exchange Commission. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatment planned as a drug clears aged cells from a person, on the worn-out
cells branch, and now linked to "An aged-cell-clearing drug relieves knee arthritis", whose
description tells of this failure, as does that of "An aged-cell-clearing drug beats a sham in a
controlled trial". (Corrected 2026-10-18: this note had said the description of "A drug clears
aged cells from a person" refers to it; that description no longer does.) The release's own page on
unitybiotechnology.com and the wire copy on GlobeNewswire are no longer served; the wire
address was https://www.globenewswire.com/news-release/2020/08/17/2079116/0/en/. Doses 0.5, 2.0
and 4.0 mg, 45 to 46 people per arm; the primary outcome was change in the WOMAC-A pain score
at week 12.
appeared 29 October 2018Read; moved nothingInflammation and the body's messagingSafety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical TrialSha and 18 others
Eighteen people aged 50 to 90 with mild to moderate Alzheimer's disease were given four weekly
infusions of plasma from male donors aged 18 to 30 at Stanford: nine in a double-blind crossover
against salt water, and nine more in an open-label plasma-only group. The infusions were safe and
well tolerated, with no related serious adverse events. Cognition, measured only as an exploratory
outcome, did not change; caregivers rated day-to-day function better, which the authors treated as
unconfirmed. A safety trial of the young-blood idea in people, not a test of whether it works.
Sharon J. Sha, Gayle K. Deutsch, Lu Tian, Kara Richardson, Maria Coburn, Jennifer L. Gaudioso, Tatiana Marcal, Ethan Solomon, Athanasia Boumis, Anthony Bet, Maarten Mennes, Erik van Oort, Christian F. Beckmann, Steven P. Braithwaite, Sam Jackson, Karoly Nikolich, Darby Stephens, Geoffrey A. Kerchner, Tony Wyss-Coray. JAMA Neurology 76(1), 35–40 (2019). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatment planned as plasma exchange or dilution with a measured effect in
people, on the branch for inflammation and the body's messaging. The trial had no primary
measure of cognition, so "no effect" should not be read as a failed efficacy trial. Online
2018-10-29; the print issue is dated 2019-01-01, which is why this record is filed under 2019.
Registered as NCT02256306.
Using national death records from 1990 to 2019 for the eight longest-lived countries plus Hong Kong
and the United States, the authors show that gains in life expectancy have slowed since 1990:
life expectancy at birth rose 6.5 years on average over the period in Hong Kong and the eight
countries, and in every population but Hong Kong and South Korea the yearly gain has fallen below
0.2 years. If old-age death rates fell over the next three decades as fast as they did from 1990 to
2019, they reckon life expectancy at birth would rise by only about 2.5 years. They conclude that survival
to 100 is unlikely to exceed 15 percent for women and 5 percent for men, and that radical life
extension (defined as three years gained per decade, the twentieth-century pace) is implausible
this century unless biological ageing itself is markedly slowed. The demographers' case against
the headline, and the baseline the headline has to beat.
S. Jay Olshansky, Bradley J. Willcox, Lloyd Demetrius, Hiram Beltrán-Sánchez. Nature Aging 4(11), 1635–1642 (2024). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Bears on the headline question itself rather than any one branch, so listed against all eight. Its
own escape clause, that the trend holds unless ageing is slowed, is exactly what the branches
track. Online 2024-10-07; the print issue is November 2024.
Read in full on 2026-10-20, in the published paper. Every figure above matches it; the 6.5-year average
is for Hong Kong and the eight countries, without the United States, and the finding now says so.
The paper defines radical life extension as a rise in life expectancy at birth of 0.3 years a year,
three years a decade, the pace of the twentieth century, and it names no gain it calls plausible;
it says any number for the effect of treatments not yet developed is hard to justify. It calls
fifteen and five per cent surviving to 100 an optimistic outcome for most countries this century,
a limit that only treatments that slow biological ageing could breach. It does not mention
the bet between Steven Austad and its first author.
appeared 15 December 2016Settled a stageThe cell's settingsIn Vivo Amelioration of Age-Associated Hallmarks by Partial ReprogrammingOcampo and 21 others
Mice were given the four Yamanaka genes that turn an adult cell back into an embryonic-like stem
cell, but switched on for only two days in every seven so that cells reset part of the way without
losing their identity. In mice bred to age fast (the LAKI progeria model) the cycling treatment
reduced the signs of ageing in several tissues and lengthened life; in normally aged mice it
improved the repair of muscle and pancreas after injury. The first demonstration that partial
reprogramming can be done in a living animal without killing it with tumours.
Alejandro Ocampo, Pradeep Reddy, Paloma Martinez-Redondo, Aida Platero-Luengo, Fumiyuki Hatanaka, Tomoaki Hishida, Mo Li, David Lam, Masakazu Kurita, Ergin Beyret, Toshikazu Araoka, Eric Vazquez-Ferrer, David Donoso, Jose Luis Roman, Jinna Xu, Concepcion Rodriguez Esteban, Gabriel Nuñez, Estrella Nuñez Delicado, Josep M. Campistol, Isabel Guillen, Pedro Guillen, Juan Carlos Izpisua Belmonte. Cell 167(7), 1719–1733.e12 (2016). Read it.
Logged for the treatment "Partially resetting cells reverses ageing in a living animal", on the
branch for the cell's settings; one of the five treatments shared with The Upgrade Tree. The paper
itself gives no percentage for the lifespan gain, only
"a dramatic increase in median and maximal lifespan" and a survival curve; the widely quoted figure
of about 30 percent longer comes from the Salk Institute's news release of 2016-12-15, not from the
paper, so the record does not carry it.
appeared 31 August 2023Read; moved nothingMeasuring ageingBiomarkers of aging for the identification and evaluation of longevity interventionsMoqri and 27 others
A position paper from a consortium of ageing researchers setting out what a measure of biological
age would have to do before a trial could use it in place of waiting for disease and death: be
practical to take, track age, predict function and death better than a birth date does, rest on a
mechanism, and move when an intervention works, then pass laboratory and clinical validation. It
states that no such measure has yet been validated as a stand-in outcome for a trial. The
field's own account of how far the measuring branch has to go.
Mahdi Moqri, Chiara Herzog, Jesse R. Poganik, Biomarkers of Aging Consortium, Jamie Justice, Daniel W. Belsky, Albert Higgins-Chen, Alexey Moskalev, Georg Fuellen, Alan A. Cohen, Ivan Bautmans, Martin Widschwendter, Jingzhong Ding, Alexander Fleming, Joan Mannick, Jing-Dong Jackie Han, Alex Zhavoronkov, Nir Barzilai, Matt Kaeberlein, Steven Cummings, Brian K. Kennedy, Luigi Ferrucci, Steve Horvath, Eric Verdin, Andrea B. Maier, Michael P. Snyder, Vittorio Sebastiano, Vadim N. Gladyshev. Cell 186(18), 3758–3775 (2023). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatment "A regulator accepts a marker of ageing as proof that a treatment slowed
it", on the measuring ageing branch; this paper is the criteria such a marker must meet, not an
acceptance. Cell prints the consortium fourth in the author list, as given here; some indexes move
it first or drop it.
appeared 4 April 2025Read; moved nothingEnergy and fuel sensingInfluence of rapamycin on safety and healthspan metrics after one year: PEARL trial resultsMoel and 6 others
The PEARL trial gave healthy adults aged 50 to 85 a weekly 5 mg or 10 mg dose of compounded
rapamycin, or placebo, for 48 weeks in a double-blind trial run remotely; 114 completed (40, 35 and
39 in the three groups) and 11 dropped out. The primary outcome, deep abdominal fat on a body
scan, did not change. Women on the higher dose gained lean mass and reported less pain, and the
lower-dose group reported better emotional well-being and general health; serious adverse events
were 1, 2 and 3 in the three groups. Mid-trial the team found the compounded drug reached about a
third of the blood level of the commercial product, so the real doses were about two-thirds lower
than intended. The first year-long placebo-controlled trial of rapamycin in healthy people, run by
the company that sells it but paid for mainly by a crowdfunding appeal, and it missed its primary outcome.
Mauricio Moel, Girish Harinath, Virginia Lee, Andy Nyquist, Stefanie L. Morgan, Anar Isman, Sajad Zalzala. Aging (Albany NY) 17(4), 908–936 (2025). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatment planned as a drug makes people live longer in good health (rapamycin),
on the energy and fuel sensing branch; a first human result on a measurement, not a healthy-years
result. All seven authors are employees and shareholders of AgelessRx. Registered as NCT04488601
on 2020-07-28. The paper gives no single randomised total in its text; 125 is the completers plus
the dropouts.
appeared 30 May 2020Settled a stageInflammation and the body's messagingRejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albuminMehdipour and 9 others
Half of the blood plasma of old mice was replaced with salt water containing 5 percent albumin,
with no young blood involved. A single exchange matched or exceeded what young blood had done in
earlier work: better muscle repair, less fat and scarring in the liver, and more new neurons in
the memory centre of the brain. In a small human arm, serum taken after one ordinary therapeutic
plasma exchange no longer suppressed the growth of progenitor cells the way old serum does. The
authors' reading is that diluting what accumulates in old blood matters more than adding anything
young; the abstract gives no percentages.
Melod Mehdipour, Colin Skinner, Nathan Wong, Michael Lieb, Chao Liu, Jessy Etienne, Cameron Kato, Dobri Kiprov, Michael J. Conboy, Irina M. Conboy. Aging (Albany NY) 12(10), 8790–8819 (2020). Read it.
Logged for the treatment planned as plasma exchange or dilution with a measured effect in
people, on the branch for inflammation and the body's messaging. The animal founding paper is
the 2005 paper by Conboy and colleagues from the same group; the young-plasma trial in
Alzheimer's is the report by Sha and colleagues (2019).
appeared 29 March 2018Read; moved nothingEnergy and fuel sensingChronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adultsMartens and 7 others
Thirty healthy adults aged 55 to 79 were enrolled, and 24 completed, a crossover in which each
took 1,000 mg a day of nicotinamide riboside (a form of vitamin B3 that the body turns into NAD)
and a placebo for six weeks each. Levels of NAD in white blood cells rose by about 60 percent on
the supplement; blood pressure trended lower by about 4 points but not significantly after
correction for multiple comparisons; no serious side effects. The first trial to show the
supplement raises NAD in older people, with no effect on any health outcome tested.
Christopher R. Martens, Blair A. Denman, Melissa R. Mazzo, Michael L. Armstrong, Nichole Reisdorph, Matthew B. McQueen, Michel Chonchol, Douglas R. Seals. Nature Communications 9, 1286 (2018). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatment planned as an NAD precursor (a substance the body turns into NAD) with
a measured effect in people, on the energy and fuel sensing branch. The NAD rise was measured in
blood mononuclear cells; the paper says the molecules are not detectable in plasma, so "blood
NAD" would overstate it.
Volunteers aged 65 and over took RAD001 (everolimus, a relative of rapamycin that damps the cell's
main fuel-sensing pathway) or a placebo for six weeks, then had a flu vaccine. At doses that were
reasonably well tolerated, the antibody response to the vaccine was about 20 percent stronger, and
fewer of their T cells carried the exhaustion marker PD-1. The first controlled trial in people to
show that a drug acting on the ageing pathways found in animals improves an age-related function,
here the immune system's.
Joan B. Mannick, Giuseppe Del Giudice, Maria Lattanzi, Nicholas M. Valiante, Jens Praestgaard, Baisong Huang, Michael A. Lonetto, Holden T. Maecker, John Kovarik, Simon Carson, David J. Glass, Lloyd B. Klickstein. Science Translational Medicine 6(268), 268ra179 (2014). Read it.
Logged for the treatments planned as immune rejuvenation with a measured effect in people, on the
branch for inflammation and the body's messaging, and a drug makes people live longer in good
health (rapamycin and relatives), on the energy and fuel sensing branch. The same group's 2018
follow-up (not logged here) reported fewer infections in older people on a related drug.
appeared 16 March 2017Read; moved nothingReplacing lost cells and partsAutologous Induced Stem-Cell–Derived Retinal Cells for Macular DegenerationMandai and 38 others
A 77-year-old Japanese woman with a wet form of age-related macular degeneration had skin cells
turned back into stem cells, grown into a sheet of the retina's supporting layer 1.3 by 3 millimetres
across, and transplanted under her retina on 2014-09-12. A year later the sheet was intact, her
sight was unchanged rather than worse, and there was no rejection and no serious complication
without any immune-suppressing drugs. The first person to receive tissue made from their own
reprogrammed cells; a second patient was not treated because of DNA changes found in his cells.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatment planned as a stem cell therapy restores a lost function in a controlled
trial, on the branch for replacing lost cells and parts; this is a safety record from the first
person treated, not a restored function or a controlled trial. Thirty-nine authors; Mandai,
Watanabe and Kurimoto contributed equally. Registered as UMIN000011929.
appeared 2 December 2020Read; moved nothingThe cell's settingsReprogramming to recover youthful epigenetic information and restore visionLu and 28 others
Three of the four Yamanaka reprogramming genes (Oct4, Sox2 and Klf4, leaving out the cancer-linked
c-Myc) were delivered by a gene-therapy virus into the eyes of mice and switched on with an
antibiotic. The treatment made crushed optic nerves regrow, restored sight lost to a glaucoma model
and to ordinary ageing in twelve-month-old mice, and turned back a DNA-methylation measure of the
cells' age; the effect needed two enzymes that strip methylation marks, and switching the genes on
for up to fifteen months caused no tumours. The animal result behind the first reprogramming
therapy to be dosed in a person (Life Biosciences' announcement of
2026-06-09).
Yuancheng Lu, Benedikt Brommer, Xiao Tian, Anitha Krishnan, Margarita Meer, Chen Wang, Daniel L. Vera, Qiurui Zeng, Doudou Yu, Michael S. Bonkowski, Jae-Hyun Yang, Songlin Zhou, Emma M. Hoffmann, Margarete M. Karg, Michael B. Schultz, Alice E. Kane, Noah Davidsohn, Ekaterina Korobkina, Karolina Chwalek, Luis A. Rajman, George M. Church, Konrad Hochedlinger, Vadim N. Gladyshev, Steve Horvath, Morgan E. Levine, Meredith S. Gregory-Ksander, Bruce R. Ksander, Zhigang He, David A. Sinclair. Nature 588(7836), 124–129 (2020). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatments "Partially resetting cells reverses ageing in a living animal" (on the
branch for the cell's settings; shared with The Upgrade Tree) and "A person receives cell-resetting
genes in a registered trial", whose company trial uses the same three genes. The paper gives the
age reversal as a direction of change against controls in its figures, not as a single number of
years. Online 2020-12-02; the print issue is dated 2020-12-03.
The same five authors' update ten years on, raising the count from nine hallmarks to twelve by
adding the failure of the cell's recycling of its own worn parts (disabled macroautophagy),
low-grade inflammation that never switches off, and an unbalanced community of gut microbes
(dysbiosis). It restates the three tests a hallmark must pass: it shows up with age, making it worse
speeds ageing, and treating it slows, stops or reverses ageing.
Carlos López-Otín, Maria A. Blasco, Linda Partridge, Manuel Serrano, Guido Kroemer. Cell 186(2), 243–278 (2023). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Bears on every branch; the twelve hallmarks named here are the ones the site's eight branches
group, and the project's checking script refuses a grouping that drops or doubles one. Online
2023-01-03; the print issue is dated 2023-01-19.
A review that proposed nine "hallmarks" of ageing, the kinds of damage and malfunction that build
up with age in most animals: unstable DNA, shortening chromosome ends, drifting gene settings,
misfolded proteins, mis-set fuel sensing, failing power plants in the cell, worn-out cells that
will not die, exhausted stem cells, and garbled signalling between cells. It argued that each
should get worse with age, speed ageing when made worse, and slow ageing when treated. The
starting map for the field, and for this site's branches.
Carlos López-Otín, Maria A. Blasco, Linda Partridge, Manuel Serrano, Guido Kroemer. Cell 153(6), 1194–1217 (2013). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Bears on every branch: the eight branches group these hallmarks and the three added in 2023 (in
the update by the same authors). The project's documentation sets out which branch each hallmark
belongs to. Cell prints the title in capitals as given; the issue date is 2013-06-06 and no
earlier online date is recorded.
appeared 11 November 2023Read; moved nothingEnergy and fuel sensingSemaglutide and Cardiovascular Outcomes in Obesity without DiabetesLincoff and 16 others
The SELECT trial randomised 17,604 adults aged 45 and over with existing heart or blood-vessel
disease and a body mass index of 27 or more, but no diabetes, to a weekly injection of semaglutide
2.4 mg or placebo, and followed them for a mean of 39.8 months. Heart attack, stroke or death from
cardiovascular causes came to 6.5 percent on the drug against 8.0 percent on placebo, a hazard
ratio of 0.80 (95 percent confidence interval 0.72 to 0.90). The first large controlled trial to
show that a GLP-1 drug prevents hard outcomes in people without diabetes; it was not designed to
measure ageing, and 16.6 percent stopped the drug for side effects against 8.2 percent on
placebo.
A. Michael Lincoff, Kirstine Brown-Frandsen, Helen M. Colhoun, John Deanfield, Scott S. Emerson, Sille Esbjerg, Soren Hardt-Lindberg, G. Kees Hovingh, Steven E. Kahn, Robert F. Kushner, Ildiko Lingvay, Tugce K. Oral, Marie M. Michelsen, Jorge Plutzky, Christoffer W. Tornøe, Donna H. Ryan, for the SELECT Trial Investigators. New England Journal of Medicine 389(24), 2221–2232 (2023). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatment planned as a GLP-1 drug with an ageing endpoint (a trial judged on a
measure of ageing), on the energy and fuel sensing branch; this is the result that made such a
trial thinkable, not that trial. Sixteen named authors write for the SELECT Trial
Investigators, who are listed as a group. Funded by Novo Nordisk; registered as NCT03574597.
Online 2023-11-11; print issue 2023-12-14.
appeared 9 June 2026Settled a stageThe cell's settingsLife Biosciences Announces First Patient Dosed in Phase 1 Trial of ER-100 for Optic NeuropathiesLife Biosciences
The company says a first participant has been given ER-100, a one-time injection into one eye of a
gene therapy that switches on three of the four Yamanaka reprogramming genes (OCT4, SOX2 and KLF4)
for 56 days under the control of an oral antibiotic, in a phase 1 safety trial for open-angle
glaucoma and a sudden loss of blood supply to the optic nerve. The registry entry plans about 18
adults in sequential dose groups and measures safety to days 56 and 112. This is a first person
dosed, not a result: the release reports no measurement of any kind.
Life Biosciences, Inc.. Company press release, Boston, 2026-06-09; trial registered as NCT07290244. Read it.
Logged for the treatment "A person receives cell-resetting genes in a registered trial", on the
branch for the cell's settings. The animal result behind it is the 2020 optic nerve paper by Lu
and colleagues. The company's earlier release of 2026-01-28 announced the FDA's clearance to
start the trial and called ER-100 the first reprogramming therapy cleared for human trials. The
registry entry (last updated 2026-05-19) says the trial started on 2026-03-02 and gives the
doses; the release itself gives no site, dose or participant count.
appeared 3 May 2016Read; moved nothingEnergy and fuel sensingThe dog aging project: translational geroscience in companion animalsKaeberlein and 2 others
The paper that set out the Dog Aging Project: the case that pet dogs, which age ten times faster
than people, share our homes and get our diseases and our veterinary care, are the right animal
for testing whether a drug slows ageing within a human researcher's working life, and the plan for
a long-term study of tens of thousands of dogs with a rapamycin trial inside it. A rationale paper
with no results.
Matt Kaeberlein, Kate E. Creevy, Daniel E. L. Promislow. Mammalian Genome 27(7–8), 279–288 (2016). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatment "A drug makes people live longer in good health" (rapamycin), on the
energy and fuel sensing branch; the dog trial is the step between the 2009 study in mice by
Harrison and colleagues and any trial in people. The project's founding paper proper, with the
study's design and first enrolment, is the 2022 paper by the Dog Aging Project Consortium
(Creevy and colleagues). Online 2016-05-03; the print issue is August 2016.
appeared 5 January 2019Read; moved nothingWorn-out cellsSenolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot studyJustice and 10 others
Fourteen people with stable scarring of the lungs (idiopathic pulmonary fibrosis) at two centres
took dasatinib 100 mg and quercetin 1,250 mg a day for three days a week over three weeks, with no
placebo group. All fourteen stayed in; their six-minute walking distance, walking speed and
chair-stand time improved, while lung function, blood chemistry and frailty did not change, and
the effect on blood markers of worn-out cells was inconclusive. The first trial of a drug meant to
kill such cells in people, on physical function rather than on the cells themselves.
Jamie N. Justice, Anoop M. Nambiar, Tamar Tchkonia, Nathan K. LeBrasseur, Rodolfo Pascual, Shahrukh K. Hashmi, Larissa Prata, Michal M. Masternak, Stephen B. Kritchevsky, Nicolas Musi, James L. Kirkland. EBioMedicine 40, 554–563 (2019). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatment "A drug clears aged cells from a person", on the worn-out cells branch;
as the treatment's notes already say, this trial did not measure the cells, so the 2019 report by
Hickson and colleagues is the record that settles the treatment's stage and this is the first
human dosing. Online 2019-01-05; the print issue is February 2019. Registered as NCT02874989.
appeared 21 October 2013Read; moved nothingMeasuring ageingDNA methylation age of human tissues and cell typesHorvath
From about 8,000 samples across 51 healthy tissues and cell types, a predictor of a person's age
was built from the chemical methyl marks on 353 sites in their DNA. In samples it had not been
trained on it matched birth-certificate age with a correlation of 0.96 and a median error of 3.6
years, across tissues as different as blood, brain and skin; 20 kinds of cancer tissue read on
average 36 years older than the patient. The first multi-tissue "epigenetic clock", and the tool
every later claim of age reversal in people is measured with.
Steve Horvath. Genome Biology 14(10), R115 (2013). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatment planned as a clock validated to predict outcomes in a large cohort (a
large group of people followed over time), on the measuring ageing branch; this is the clock,
and the validation against outcomes came in later clocks (PhenoAge, GrimAge, DunedinPACE) and in
the criteria set out by Moqri and colleagues in 2023. The training-set error is 2.9 years; 3.6
years is the test-set figure. An erratum appeared in Genome Biology 16, 96 (2015) and was not
read here.
appeared 18 September 2019Settled a stageWorn-out cellsSenolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney diseaseHickson and 32 others
Nine people with diabetic kidney disease took a three-day course of two drugs that kill senescent
cells (dasatinib, a cancer drug, and quercetin, a plant compound). Eleven days later, samples of
their fat and skin held fewer such cells than before, and the blood carried less of the
inflammatory signal those cells give off. A first demonstration, in people, on a measurement; not
a clinical outcome, and with no control group.
LaTonya J. Hickson, Larissa G. P. Langhi Prata, Shane A. Bobart, Tamara K. Evans, Nino Giorgadze, Shahrukh K. Hashmi, Sandra M. Herrmann, Michael D. Jensen, Qingyi Jia, Kyra L. Jordan, Todd A. Kellogg, Sundeep Khosla, Daniel M. Koerber, Anthony B. Lagnado, Donna K. Lawson, Nathan K. LeBrasseur, Lilach O. Lerman, Kathleen M. McDonald, Travis J. McKenzie, João F. Passos, Robert J. Pignolo, Tamar Pirtskhalava, Ishran M. Saadiq, Kalli K. Schaefer, Stephen C. Textor, Stella G. Victorelli, Tammie L. Volkman, Ailing Xue, Mark A. Wentworth, Erin O. Wissler Gerdes, Yi Zhu, Tamara Tchkonia, James L. Kirkland. EBioMedicine 47, 446–456 (2019). Read it.
Checked against the open-access text on 2026-10-16: 33 authors as listed; nine people; dasatinib
100 mg and quercetin 1,000 mg daily for three days; fat and skin samples on study days 0 and 14,
so eleven days after the last dose. A corrigendum of 2020-01-23 (EBioMedicine 52, 102595,
https://doi.org/10.1016/j.ebiom.2019.12.004) re-analysed the raw data with five added statistical
authors and says some conclusions changed; the detail is in its appendix, not read here, so the
finding above should be read with that in mind.
appeared 8 July 2009Settled a stageEnergy and fuel sensingRapamycin fed late in life extends lifespan in genetically heterogeneous miceHarrison and 13 others
Mice of a deliberately mixed genetic background were fed rapamycin, a drug that damps the cell's
main fuel-sensing pathway, from 600 days of age, the equivalent of about sixty human years, at
three laboratories at once (The Jackson Laboratory, the University of Michigan and the University
of Texas Health Science Center). Across 1,901 mice the age by which nine in ten had died rose by
14 percent in females and 9 percent in males, and mean lifespan by 13 and 9 percent; the pattern
of diseases at death did not change. The first drug shown to lengthen life in a mammal when
started in old age, and the result the rapamycin trials in dogs and people grow from.
David E. Harrison, Randy Strong, Zelton Dave Sharp, James F. Nelson, Clinton M. Astle, Kevin Flurkey, Nancy L. Nadon, J. Erby Wilkinson, Krystyna Frenkel, Christy S. Carter, Marco Pahor, Martin A. Javors, Elizabeth Fernandez, Richard A. Miller. Nature 460(7253), 392–395 (2009). Read it.
Logged for the treatment "A drug makes people live longer in good health" (rapamycin), on the
energy and fuel sensing branch; this is its animal record. The paper attaches no percentage to
median lifespan: the 14 and 9 percent figures are for the age at 90 percent mortality, and the
13 and 9 percent for mean lifespan, so a line reading "median lifespan up 14 percent" would
mislabel the figure. Online 2009-07-08; the print issue is dated 2009-07-16.
appeared 22 June 2022Read; moved nothingReplacing lost cells and partsGenetically Modified Porcine-to-Human Cardiac XenotransplantationGriffith and 12 others
On 2022-01-07 a 57-year-old man with heart failure who could not get a human heart received the
heart of a pig carrying ten gene edits (four pig genes removed, six human genes added) at the
University of Maryland. The heart worked for seven weeks, then thickened and failed suddenly from
day 49; life support was withdrawn on day 60, and the damage did not look like ordinary rejection.
The first pig organ to keep a living person alive, for two months.
Bartley P. Griffith, Corbin E. Goerlich, Avneesh K. Singh, Martine Rothblatt, Christine L. Lau, Aakash Shah, Marc Lorber, Alison Grazioli, Kapil K. Saharia, Susie N. Hong, Susan M. Joseph, David Ayares, Muhammad M. Mohiuddin. New England Journal of Medicine 387(1), 35–44 (2022). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatment "An organ from a gene-edited pig keeps a person alive", on the branch for
replacing lost cells and parts; one of the five treatments shared with The Upgrade Tree. Online
2022-06-22; the print issue is dated 2022-07-07. Later pig kidney transplants into living people
(2024 onward) are for the treatment's entry to cite from their own reports.
David Gobel, co-founder of the Methuselah Foundation, opens the foreword by saying he coined the
phrase "longevity escape velocity" while working with Aubrey de Grey and Peter Diamandis on the
history of prizes. He gives no year, and no dated document from 2004 or earlier in which he uses
the phrase has been found; the earliest dated publication of the idea is de Grey's 2004 essay,
which uses the words "actuarial escape velocity" instead.
David Gobel. Let's Talk Longevity, Substack newsletter, 2022-05-12. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Bears on the headline question itself, so listed against all eight branches. Secondary sources
(Wikipedia; a 2018-09-05 Lifespan.io interview whose interviewer calls Gobel the first to put the
concept forward) repeat the attribution without a dated primary source. Kept so that the site can
say plainly who is credited with the phrase and on what evidence.
Ten healthy men aged 51 to 65 were recruited, and nine analysed, in a one-year trial (TRIIM) of
growth hormone with DHEA and metformin, aimed at regrowing the thymus, the gland that trains immune
cells and turns to fat with age. The thymus did regain working tissue on MRI in seven of nine men,
and four DNA-methylation clocks read about 1.5 years younger than at the start, which is about 2.5
years against the one year of ageing expected with no treatment. Nine men, no placebo group, and
the clocks were the outcome; the paper most often cited for age reversal in people, and the one
that shows how thin that claim is.
Gregory M. Fahy, Robert T. Brooke, James P. Watson, Zinaida Good, Shreyas S. Vasanawala, Holden Maecker, Michael D. Leipold, David T. S. Lin, Michael S. Kobor, Steve Horvath. Aging Cell 18(6), e13028 (2019). Read it.
Logged for the treatments planned as immune rejuvenation with a measured effect in people, on the
branch for inflammation and the body's messaging, and a clock as a trial measure, on the measuring
ageing branch. The 2.5-year figure often quoted is relative to expected ageing; the absolute
change from baseline is about 1.5 years. Why one of the ten recruited men is missing from the
analysis is not stated in the main text. Online 2019-09-08; the print issue is December 2019.
appeared 15 February 2017Settled a stageEnergy and fuel sensingAutologous mitochondrial transplantation for dysfunction after ischemia-reperfusion injuryEmani and 4 others
Five babies and young children at Boston Children's Hospital whose hearts had failed after surgery
and who were on a heart-lung machine had mitochondria, the cell's power plants, taken from a small
piece of their own abdominal muscle and injected straight into the heart muscle, about a hundred
million in ten small injections. Four of the five regained enough heart function to come off the
machine within three to six days; two of the five later died of other organ failure. The first
report of mitochondria moved from one tissue to another in people, in a handful of emergencies with
no comparison group.
Sitaram M. Emani, Breanna L. Piekarski, David Harrild, Pedro J. del Nido, James D. McCully. The Journal of Thoracic and Cardiovascular Surgery 154(1), 286–289 (2017). Read it.
Logged for the treatment "Fresh mitochondria are transplanted into a person's failing tissue",
on the energy and fuel sensing branch. The paper has no abstract; the figures are from its
text. Online 2017-02-15; the print issue is July 2017 and the journal gives no day.
An editorial welcoming the news that the TAME metformin trial's 75 million dollar budget had been
found: nearly half pledged through the American Federation for Aging Research by the
philanthropist Paul Glenn, the National Institute on Aging having twice turned down applications
for the rest, and the remainder, "very recently", from an anonymous donor. De Grey, no admirer of
metformin as a treatment, argues the trial is worth the money because it would establish ageing as
something a regulator lets a drug be tested against. Seven years on, the trial has not started
(the American Federation for Aging Research's
own page for the trial).
Aubrey D. N. J. de Grey. Rejuvenation Research 22(5), 375–376 (2019). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the entries planned as the TAME trial enrolling, on the energy and fuel sensing branch,
and a regulator accepting ageing as something a drug can be tested against, on the measuring ageing
branch. Kept because it is a dated, published statement that the money was in hand, against which
the later record (the American Federation for Aging Research's own page for the trial) can be read.
Checked 2026-10-17 against the editorial itself, which is free to read on the publisher's page (https://doi.org/10.1089/rej.2019.2274; first published online 2019-10-09, issue of October 2019, pages 375 to 376). It says that nearly half of the required 75 million dollars was pledged by Paul Glenn through the American Federation for Aging Research, that the National Institute on Aging twice rejected applications for the remaining money, and that the remaining support "materialized very recently, courtesy of an anonymous donor".
An essay arguing that once treatments cut the yearly risk of death at a given age fast enough, by
roughly a tenth a year in the age range where most people die, remaining life expectancy stops
falling with age and people pull away from death the way a rocket pulls away from the ground. De
Grey names that rate "actuarial escape velocity". The paper does not use the phrase "longevity
escape velocity"; that wording came later.
Aubrey D. N. J. de Grey. PLoS Biology 2(6), e187 (2004). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Bears on the headline question itself rather than any one branch, so it is listed against all
eight. Early PLoS Biology also carried print page numbers (723–726); the article number is the
publisher's citation. This site's log of claims holds de Grey's dated predictions; this record
is only the paper that framed the question.
appeared 2 February 2022Read; moved nothingEnergy and fuel sensingAn open science study of ageing in companion dogsThe Dog Aging Project Consortium
The Dog Aging Project's description of itself as of its first data release: more than 30,000 pet
dogs and their owners enrolled, more than 100 staff at more than 20 institutions, genome
sequencing planned for at least 10,000 dogs, a closely studied group of 1,000, and a
placebo-controlled trial of rapamycin in 350 middle-aged large dogs (TRIAD, the Test of Rapamycin
In Ageing Dogs) at seven US veterinary teaching hospitals, into which enrolment began in June
2021. The largest study of ageing in any animal that lives with people; the rapamycin result is
still to come.
The Dog Aging Project Consortium (Kate E. Creevy, Joshua M. Akey, Matt Kaeberlein, Daniel E. L. Promislow and members). Nature 602(7895), 51–57 (2022). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatment "A drug makes people live longer in good health" (rapamycin), on the
energy and fuel sensing branch. Nature prints the author as the consortium with a member list
that begins with the four names given; indexes list those four and the consortium. The enrolment
figures are as of December 2020. Online 2022-02-02; the print issue is February 2022.
appeared 17 February 2005Settled a stageInflammation and the body's messagingRejuvenation of aged progenitor cells by exposure to a young systemic environmentConboy and 5 others
Old and young mice were surgically joined so that they shared one bloodstream. The old mice's
muscle repair cells regained a young animal's ability to multiply and mend damage, their liver
cells divided more, and young serum alone did the same to old muscle cells in a dish. The paper
that showed something in young blood, or something missing from old blood, drives part of ageing
in tissue; the abstract gives no sample sizes or effect sizes.
Irina M. Conboy, Michael J. Conboy, Amy J. Wagers, Eric R. Girma, Irving L. Weissman, Thomas A. Rando. Nature 433(7027), 760–764 (2005). Read it.
Logged for the treatment planned as plasma exchange or dilution with a measured effect in
people, on the branch for inflammation and the body's messaging; this is the animal result the
field traces that treatment to. The later dilution paper (Mehdipour and colleagues, 2020) and
the young-plasma trial in Alzheimer's (Sha and colleagues, 2019) follow from it.
appeared 15 May 2012Settled a stageDamaged DNATelomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancerBernardes de Jesus and 6 others
Mice aged one year and two years were given a single injection of a gene-therapy virus (AAV9)
carrying the gene for telomerase, the enzyme that rebuilds the protective caps on chromosome ends.
Median lifespan rose by 24 percent in the one-year-old group and 13 percent in the two-year-old
group, with better insulin sensitivity, bone and coordination, and no more cancer than in untreated
littermates; an inactive version of the gene did nothing. The animal record for lengthening
chromosome ends in a living adult without a rise in cancer.
Bruno Bernardes de Jesus, Elsa Vera, Kerstin Schneeberger, Agueda M. Tejera, Eduard Ayuso, Fatima Bosch, Maria A. Blasco. EMBO Molecular Medicine 4(8), 691–704 (2012). Read it.
Logged for the treatment "A gene therapy lengthens the ends of chromosomes in an old animal, with
no rise in cancer", on the damaged DNA branch. The AAV9 serotype is given in the full text; the
abstract says only a wide-tropism AAV. Online 2012-05-15; the print issue is August 2012.
The design paper for the Targeting Aging with Metformin (TAME) trial: the authors plan to enrol
3,000 people aged 65 to 79 at about 14 US centres and measure the time to a first new occurrence
of any of heart attack and stroke, cancer, dementia or death, a composite chosen so that a trial
can test whether a drug slows ageing as a whole rather than one disease, with function and frailty
measured alongside. The paper reviews the observational and animal evidence for metformin and says
the trial has planning money from the American Federation for Aging Research. The template for how
an ageing trial could be run and judged; as of 2026-10-16 the trial has not been shown to have
started (see the American Federation for Aging Research's own page for the
trial).
Nir Barzilai, Jill P. Crandall, Stephen B. Kritchevsky, Mark A. Espeland. Cell Metabolism 23(6), 1060–1065 (2016). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the entries planned as the TAME trial enrolling and a drug makes people live longer in
good health (metformin), on the energy and fuel sensing branch, and a regulator accepting an
ageing marker or a composite as a trial endpoint (the outcome a trial is judged on), on the
measuring ageing branch. The paper does not give the six-year duration or describe the 2015
meeting with the FDA; those are from the American Federation for Aging Research's pages and news
reports, logged with the federation's own page for the trial.
appeared 31 July 2014Read; moved nothingEnergy and fuel sensingCan people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controlsBannister and 7 others
In UK general-practice records from 2000 onward, 78,241 people with type 2 diabetes who started on
metformin were matched to 90,463 people without diabetes. After adjustment, the people without
diabetes had a median survival 15 percent shorter than the metformin group (survival time ratio
0.85, 95 percent confidence interval 0.81 to 0.90), while 12,222 people started on a sulphonylurea
had a survival 38 percent shorter. An observational comparison, open to the objection that people
who start metformin are healthier than those who start the other drug; it is the result most often
cited as the reason to test metformin against ageing.
C. A. Bannister, S. E. Holden, S. Jenkins-Jones, C. Ll. Morgan, J. P. Halcox, G. Schernthaner, J. Mukherjee, C. J. Currie. Diabetes, Obesity and Metabolism 16(11), 1165–1173 (2014). Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the treatment planned as a drug makes people live longer in good health (metformin), on
the energy and fuel sensing branch. The paper prints the ratio with metformin as the reference, so
the figure is 0.85 for the people without diabetes, not a 15 percent gain for metformin users; the
gain is the same comparison read the other way and the paper does not print it. Online 2014-07-31;
the print issue is November 2014.
appeared 3 February 2016Settled a stageWorn-out cellsNaturally occurring p16Ink4a-positive cells shorten healthy lifespanBaker and 12 others
The same genetic switch as in the 2011 paper, this time in normally ageing mice of two genetic
backgrounds, with the cell-killing drug given twice a week from twelve months of age until death.
Median lifespan rose by 27 percent in the mixed-background mice and 24 percent in the inbred
strain, with increases of 17 to 35 percent by sex; kidney, heart and fat deteriorated more slowly,
cataracts came later, and tumours came later though not less often. The result that turned
clearing worn-out cells from a curiosity into a drug programme.
Darren J. Baker, Bennett G. Childs, Matej Durik, Melinde E. Wijers, Cynthia J. Sieben, Jian Zhong, Rachel A. Saltness, Karthik B. Jeganathan, Grace Casaclang Verzosa, Abdulmohammad Pezeshki, Khashayarsha Khazaie, Jordan D. Miller, Jan M. van Deursen. Nature 530(7589), 184–189 (2016). Read it.
Logged for the treatment planned as a drug clears aged cells from a person (the animal record for
lifespan, where the 2011 paper by Baker and colleagues is the record for healthy life). The
percentages are in the results text, not the abstract, which gives none. Online 2016-02-03; the
print issue is dated 2016-02-11.
appeared 2 November 2011Settled a stageWorn-out cellsClearance of p16Ink4a-positive senescent cells delays ageing-associated disordersBaker and 7 others
In mice bred to age fast (the BubR1 progeroid strain), a genetic switch was added that kills cells
carrying the senescence marker p16 whenever a drug is given. Clearing those cells throughout life
delayed the age-related decline of fat tissue, muscle and the eye, and clearing them late in life
slowed decline already under way. A gain in healthy life in a fast-ageing mouse, not in lifespan or
in a normally ageing animal; the first direct evidence that worn-out cells drive ageing rather
than merely mark it.
Darren J. Baker, Tobias Wijshake, Tamar Tchkonia, Nathan K. LeBrasseur, Bennett G. Childs, Bart van de Sluis, James L. Kirkland, Jan M. van Deursen. Nature 479(7372), 232–236 (2011). Read it.
Logged for the treatment "A drug clears aged cells from a person", as the evidence for its earlier
stage, shown in animals, which the treatment's record of its earlier stages already cites by this
paper's link. Online 2011-11-02; the print issue is November 2011 and its exact day was not
confirmed from the indexed records.
appeared 15 April 2006Settled a stageReplacing lost cells and partsTissue-engineered autologous bladders for patients needing cystoplastyAtala and 4 others
Seven children and young adults aged 4 to 19 with spina bifida and failing bladders had cells taken
from their own bladders, grown on a scaffold shaped like a bladder for about seven weeks, and
implanted to enlarge the organ. Over a mean follow-up of 46 months the best results came from the
composite scaffold wrapped in abdominal tissue: pressure at capacity fell by 56 percent, capacity
rose 1.58-fold and the bladder stretched 2.79 times better, with kidneys preserved and no stones.
The first organ-like tissue grown from a person's own cells to work in people for years.
Anthony Atala, Stuart B Bauer, Shay Soker, James J Yoo, Alan B Retik. The Lancet 367(9518), 1241–1246 (2006). Read it.
Logged for the treatment "A printed or lab-grown organ works in a person for a year", on the branch
for replacing lost cells and parts; one of the five treatments shared with The Upgrade Tree. A
bladder is the simplest organ to grow, and the approach has not reached a solid organ. Only the
issue date, 2006-04-15, is on record; no online-first date was confirmed.
appeared 4 July 2026Read; moved nothingEnergy and fuel sensingThe TAME Trial (Targeting Aging with Metformin)American Federation for Aging Research
Ten years after its design paper, the sponsor's own page still describes TAME in the future tense:
a six-year trial at 14 US institutions that "will engage" over 3,000 people aged 65 to 79, with Wake
Forest as coordinating centre, under the heading "Raising Funds to Launch" and a call for donors.
The published funding history runs: planning money from AFAR (2016); nearly half of a stated 75
million dollar budget pledged through AFAR by the philanthropist Paul Glenn, two refusals by the
National Institute on Aging, and a reported anonymous pledge for the remaining 40 million in
September 2019 that no later source confirms; a claim in April 2022 that the Hevolution Foundation
would fund a third, which the foundation did not confirm; about 5 million dollars set aside by the
National Institute on Aging and cost estimates of 45 to 70 million dollars in April 2024. No
primary source says enrolment has begun, and no registration for the trial was found on
ClinicalTrials.gov on 2026-10-16.
American Federation for Aging Research. AFAR's own trial page, afar.org/tame-trial, as archived on 2026-07-04. Read it.
What it moved: nothing. It was read against the treatments it bears on and no stage or estimate changed. Logging it anyway is how the record shows what has been considered.
Logged for the entry planned as the TAME trial enrolling, on the energy and fuel sensing branch.
This record exists so that the entry can say, with sources, that the field's flagship ageing trial
has been announced as imminent since 2015 and has not started. The weekly reading should check the
American Federation for Aging Research's (AFAR's) page and the trial registry; the day a
registration or a first-participant notice appears, that becomes a new record. AFAR's 2024 news
post gives the age range as 65 to 80; the trial page says 65 to 79.
Checked 2026-10-17. The page the finding describes was read in the web archive's copy of 2026-07-04 (the link now points to that exact capture; the earlier link, which asked the archive for any 2026 copy, now lands on a later "not found" copy). The archive holds the page as found until 2026-07-04 and as "not found" in its copies from 2026-10-01 on, and on 2026-10-17 AFAR's own site also answers "not found" at that address. The page is no longer on AFAR's site. No replacement page was found: AFAR's site map lists news posts and videos that mention the trial but no page for the trial itself, and a search of AFAR's site found none. The two refusals by the National Institute on Aging, the gift of nearly half the budget from Paul Glenn through AFAR and the later anonymous donor are all in Aubrey de Grey's editorial of 2019, which is free to read (also logged here; https://doi.org/10.1089/rej.2019.2274).
134 publications in the log so far. Know a paper that should be here? Say so, with the treatment it bears on.